KAT6 targeting compounds

Abstract

The present disclosure provides bifunctional compounds comprising a target protein binding moiety and a E3 ubiquitin ligase binding moiety, and associated methods of use.

Description

105807.005061 - PCT Application KAT6 TARGETING COMPOUNDSCROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U. S. Provisional Application Nos. 63 / 736,960 filed December 20, 2024, 63 / 822,904 filed June 13, 2025, and 63 / 922,437 filed November 21, 2025, the entireties of which are incorporated by reference herein.TECHNICAL FIELD

[0002] The description provides bifunctional compounds comprising a target protein binding moiety and a E3 ubiquitin ligase binding moiety, and associated methods of use. The bifunctional compounds are useful as modulators of targeted KAT6 proteins, which are degraded and / or otherwise inhibited by bifunctional compounds according to the present disclosure.BACKGROUND OF THE INVENTION

[0003] Epigenetic control of transcription via chromatin remodeling is a substantial regulatory mechanism that ultimately impacts the functional expression of many proteins. Aberrations to epigenetic regulators are contributors to human diseases and are considered major oncogenic drivers in many cancers. Regulation of histones plays an essential role in this process and epigenetic regulators modify histone proteins through assorted post -translational modifications such as acetylation and methylation to alter, for example, chromatin accessibility. Histone acetylation is catalyzed by histone acetyltransferases (HATs), and dysregulation of this class of epigenetic regulators is linked to transcriptional alterations and cancer (1, 2).

[0004] The MYST family of acetyltransferases have been linked to several types of cancer and contain a conserved catalytic domain (MYST domain). Lysine acetyltransferase 6a (KAT6A, MOZ, MYST3) is a member of this family, promotes histone acetylation, and is paralogous to lysine acetyltransferase 6b (KAT6B) (3, 4). KAT6A reportedly acetylates lysine 9 (H3K9ac), lysine 14 (H3K14ac)(4), and lysine 23 (H3K23ac) (5) of histone H3, although the functional dependency on these sites, and other potential substrates, remains poorly understood. In addition to histone proteins, KAT6A reportedly acetylates non-histone proteins such as p53 (6), but its role in regulating non-histone substrates is not clear. KAT6A can form a protein complex with inhibitor of growth family member 5 (ING5), bromodomain and PHD finger containing 1, 2 or 3 (BRPF1, BRPF2, BRPF3), and myst / Esal associated factor 6 (EAF6), which may enhance its gene regulatory capacity (4, 7). Mechanistically, KAT6A is linked to - 1 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application regulation of cellular processes such as senescence, cell cycle progression, and hematopoietic stem cell maintenance (4, 7, 8).

[0005] More recently, KAT6A was shown to epigenetically regulate estrogen receptor alpha (ER alpha) expression via its HAT domain in KAT6A amplified breast cancer cell lines. Loss of KAT6A was associated with reduced proliferation in vitro and tumor growth in vivo and its overexpression correlates with worse clinical outcome in estrogen receptor positive (ER+) breast cancers (9). Inhibitors of KAT6A reportedly show greater sensitivity in the ER+ luminal subtype (ER / PR+ / HER2-) (10). KAT6A is suggested to be an oncogenic in breast, brain, hematological, gynecological, and other cancers (5, 9, 11, 12).

[0006] KAT6A is frequently altered in many types of cancers, most often by copy number amplification or recurrent chromosomal translocations. Located within the recurrently amplified chromosomal 8pl 1-12 amplicon, KAT6A amplification is observed in numerous cancers including breast, lung, prostate, blood, bladder, uterine, endometrial, ovarian, esophageal, head and neck, stomach, colon, and other cancers (9, 13, 14). Especially in hematological cancers, recurrent rearrangements lead to several fusion proteins like KAT6A-CBP, KAT6A-p300, KAT6A-TIF2, KAT6A-NcoA3, and KAT6A-LEUTX (7). Recently, KAT6A has been implicated as important for the growth of MLL -rearranged AML (11).

[0007] To date, only one KAT6A targeted small molecule inhibitor is currently in clinical trials (PF-07248144, Phase 1, Pfizer) to study effects in locally advanced or metastatic ER+ / HER2- breast, castration-resistant prostate, and non-small cell lung cancer as a single agent or in combination with either fulvestrant or letrozole + palbociclib (NCT04606446) (15). It remains unclear whether traditional small molecule inhibitors of KAT6A can unlock the full potential of targeting these or other cancers in a selective manner. Therefore, exploring a targeted protein degradation (TPD) approach to develop potent and selective KAT6A degraders could enhance the therapeutic window in cancers dependent on KAT6A for growth, proliferation, or survival.

[0008] In light of the established role of KATs in diseases such as cancer, a need exists for new modulators of these proteins.

[0009] References:1. Nair SS, Kumar R. Chromatin remodeling in cancer: a gateway to regulate gene transcription. Mol Oncol. 2012;6(6):611-9.2. Farria A, Li W, Dent SY. KATs in cancer: functions and therapies. Oncogene.2015;34(38):4901-13.3. Avvakumov N, Cote J. The MYST family of histone acetyltransferases and their intimate links to cancer. Oncogene. 2007;26(37):5395-407.- 2 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application 4. Su J, Wang X, Bai Y, Sun M, Yao Y, Duan Y. The role of MOZ / KAT6A in hematological malignancies and advances in MOZ / KAT6A inhibitors. Pharmacol Res.2021;174:105930.5. Lv D, Jia F, Hou Y, Sang Y, Alvarez AA, Zhang W, et al. Histone Acetyltransferase KAT6A Upregulates PI3K / AKT Signaling through TRIM24 Binding. Cancer Res.2017;77(22):6190-201.6. Rokudai S, Laptenko O, Arnal SM, Taya Y, Kitabayashi I, Prives C. MOZ increases p53 acetylation and premature senescence through its complex formation with PML. Proc Natl Acad Sci U S A. 2013;110(10):3895-900.7. Huang F, Abmayr SM, Workman JL. Regulation of KAT6 Acetyltransferases and Their Roles in Cell Cycle Progression, Stem Cell Maintenance, and Human Disease. Mol Cell Biol. 2016;36(14): 1900-7.8. Sheikh BN, Phipson B, El-Saafin F, Vanyai HK, Downer NL, Bird MJ, et al. MOZ (MYST3, KAT6A) inhibits senescence via the INK4A-ARF pathway. Oncogene.2015;34(47):5807-20.9. Yu L, Liang Y, Cao X, Wang X, Gao H, Lin SY, et al. Identification of MYST3 as a novel epigenetic activator of ERa frequently amplified in breast cancer. Oncogene.2017;36(20):2910-8.10. Sharma S, Chung J, Uryu S, Rickard A, Nady N, Khan S, et al. Abstract 1130: First-in-class KAT6A / KAT6B inhibitor CTx-648 (PF-9363) demonstrates potent anti-tumor activity in ER+ breast cancer with KAT6A dysregulation. Cancer Research.2021; 81 ( 13_Supplement): 1130-.11. Yan F, Li J, Milosevic J, Petroni R, Liu S, Shi Z, et al. KAT6A and ENL Form an Epigenetic Transcriptional Control Module to Drive Critical Leukemogenic Gene-Expression Programs. Cancer Discov. 2022;12(3):792-811.12. Liu W, Zhan Z, Zhang M, Sun B, Shi Q, Luo F, et al. KAT6A, a novel regulator of P-catenin, promotes tumorigenicity and chemoresistance in ovarian cancer by acetylating COP1 Theranostics. 2021;l l(13):6278-92.13. Saglam O, Tang Z, Tang G, Medeiros LJ, Toruner GA. KAT6A amplifications are associated with shorter progression-free survival and overall survival in patients with endometrial serous carcinoma. PLoS One. 2020;15(9):e0238477.14. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The eBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401-4.- 3 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application 15. ClinicalTrials.gov. NCT04606446: Study of PF-07248144 in Advanced or Metastatic Solid Tumors (KAT6) Bethesda (MD): National Library of Medicine (US); 2020 [Available from: https: / / clinicaltrials.gov / ct2 / show / NCT04606446.SUMMARY OF THE INVENTION

[0010] The present disclosure is directed to compounds of Formula (I):ULM - Y - PTM(I)or a pharmaceutically acceptable salt or solvate thereof,wherein Y-PTM is a moiety of Formula IA:whereinY is a covalent bond, or chemical moiety that links PTM and ULM;* is a point of attachment to ULM;Ring A is a Ce-Cio membered aryl group or a 5-10 membered heteroaryl group;R1is H or 5-6 membered heteroaryl optionally substituted by methyl;R2is H, Ci-4alk-O-Ci-4alkyl, or -(C(R8)2)n-(5-9 membered heteroaryl) optionally substituted by halogen, C1-C3 alkyl, -CH2OH, or -OH;R3is H, halogen, C1-C4 alkyl, cyclopropyl, haloalkyl, C1-C4 alkoxy, or haloalkoxy;R4is H, halogen, C1-C4 alkyl, cyclopropyl, C1-C4 alkoxy, or -O-cyclopropyl; each R5is independently H, halogen, oxo, -OH, -CN, -NO2, -Ci-Cealkyl, -C2-Cealkenyl, -C2-Cealkynyl, Co-Cialk-aryl, Co-Cialk-heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, -ORa, -SRa, -NRcRd, -NRaRc, -C(O)Rb, -OC(O)Ra, -C(O)ORa, -C(0)NRcRd, -S(O)Rb, -S(O)2NRcRd, -S(O)(=NRb)Rb, -SF5, -P(O)RbRb, -P(O)(ORb)(ORb), -B(0Rd)(0Rc), or -S(O)2Rb;each Rais independently H, -C(O)Rb, -C(O)ORC, -C(0)NRcRd, -C(=NRb)NRbRc, -C(=N0Rb)NRbRc, -C(=NCN)NRbRc, -P(ORC)2, -P(O)RcRb, -P(O)ORcORb, -S(O)Rb, -S(O)NRcRd, -S(O)2Rb, -S(O)2NRcRd, SiRb3, -Ci-Cioalkyl, -C1-C10 haloalkyl, -C2-C10 alkenyl, -- 4 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application C2-C10 alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl;each Rbis independently H, -Ci-Ce alkyl, -Ci-Ce haloalkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl;each Rcor Rdis independently H, -C1-C10 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -OCi-Cealkyl, -O-cycloalkyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl; orRcand Rd, together with the atom to which they are both attached, form a monocyclic or multicyclic heterocycloalkyl, or a monocyclic or multicyclic heterocyclo-alkenyl group; each R8is independently H, halogen, or C1-C4 alkyl;m is 0, 1, 2, 3, or 4;n is 0 or 1; andULM is105807.005061\4896-4870-4897.1105807.005061 - PCT Application- 6 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application each X2 is independently N or CR15; andeach R15is independently H, D, halogen, oxo, -OH, -CN, -NO2, -Ci-Cealkyl, -Ci-Ce haloalkyl, -C2-Cealkenyl, -C2-Cealkynyl, Co-Cialk-aryl, Co-Cialk-heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, -ORa, -SRa, -NRcRd, -NRaRc, -C(O)Rb, -OC(O)Ra, -C(O)ORa, -C(O)NRcRd, -S(O)Rb, -S(O)2NRcRd, -S(O)(=NRb)Rb, -SF5, -P(O)RbRb, -P(O)(ORb)(ORb), -B(ORd)(ORc) or -S(O)2Rb;wherein any of the -Ci-Cealkyl, Ci-Cs alkoxide, -C2-Cealkenyl, -C2-Cealkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, spirocycloalkyl, spiroheterocycloalkyl and spiroheterocycloalkenyl groups in any of R1-R5, Rs, R15, and ring A is optionally substituted by 1-6 Rfgroups; andeach Rfis independently D, oxo, halogen, Ci-Cs alkoxy, Ci-Cs alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, -OH, -CN, -NO2, -C2-6 alkenyl, -C2-6 alkynyl, Ce-io aryl, C5-12 heteroaryl, C3-8 cycloalkyl, C3-8 cycloalkenyl, C3-8 heterocycloalkyl, C3-8 heterocycloalkenyl, -ORa, -SRa, -NRcRd, -NRaRc, -C(O)Rb, -OC(O)Rb, -C(O)ORb, -C(O)NRcRd, -S(O)Rb, -S(O)2NRcRd, -S(O)(=NRb)Rb, -SF5, -P(O)RbRb, -P(O)RcRd, -P(O)(ORb)(ORb), -B(ORc)(ORd), -S(O)2Rb, -C(O)NRbORb, -S(O)2ORb, -OS(O)2ORb, or -OPO(ORb)(ORb); wherein said Ci-C8alkyl is optionally substituted by 1-6 groups selected from D, halogen, -OH, -CN, -ORa, -SRa, -NRaRd, orNRcRd[OH] Stereoisomers of the compounds of Formula I, and the pharmaceutical salts and stereoisomers thereof, are also contemplated, described, and encompassed herein. Methods of using compounds of Formula I are described, as well as pharmaceutical compositions including the compounds of Formula I.DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

[0012] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. The terminology used in the description is for describing particular embodiments only and is not intended to be limiting of the disclosure.

[0013] Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise (such as in the case of a group containing a number of carbon atoms in which case each carbon atom number falling within the range is provided), between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges is also encompassed within the disclosure, subject to any specifically - 7 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding both of those included limits are also included in the disclosure.

[0014] The following terms are used to describe the present disclosure. In instances where a term is not specifically defined herein, that term is given an art -recognized meaning by those of ordinary skill applying that term in context to its use in describing the present disclosure.

[0015] The articles “a” and “an” as used herein and in the appended claims are used herein to refer to one or to more than one (e.g., to at least one) of the grammatical object of the article unless the context clearly indicates otherwise. By way of example, “an element” means one element or more than one element.

[0016] The terms “co-administration” and “co-administering” or “combination therapy” refer to both concurrent administration (administration of two or more therapeutic agents at the same time) and time varied administration (administration of one or more therapeutic agents at a time different from that of the administration of an additional therapeutic agent or agents), as long as the therapeutic agents are present in the patient to some extent, preferably at effective amounts, at the same time. In certain preferred aspects, one or more of the present compounds described herein, are co-administered in combination with at least one additional bioactive agent, especially including an anticancer agent. In particularly preferred aspects, the co-administration of compounds results in synergistic activity and / or therapy, including anti cancer activity.

[0017] The term “compound”, as used herein, unless otherwise indicated, refers to any specific chemical compound disclosed herein and includes tautomers, regioisomers, geometric isomers, and where applicable, stereoisomers, including optical isomers (enantiomers) and other stereoisomers (diastereomers) thereof, as well as pharmaceutically acceptable salts and derivatives, including prodrug and / or deuterated forms thereof where applicable, in context. Deuterated small molecules contemplated are those in which one or more of the hydrogen atoms contained in the drug molecule have been replaced by deuterium.

[0018] Within its use in context, the term compound generally refers to a single compound, but also may include other compounds such as stereoisomers, regioisomers and / or optical isomers (including racemic mixtures) as well as specific enantiomers or enantiomerically enriched mixtures of disclosed compounds. The term also refers, in context to prodrug forms of compounds which have been modified to facilitate the administration and delivery of compounds to a site of activity. It is noted that in describing the present compounds, numerous substituents and variables associated with same, among others, are described. It is understood by those of ordinary skill that molecules which are described herein are stable compounds as generally described hereunder.- 8 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0019] The term “ubiquitin ligase” refers to a family of proteins that facilitate the transfer of ubiquitin to a specific substrate protein, targeting the substrate protein for degradation. For example, an E3 ubiquitin ligase protein that alone or in combination with an E2 ubiquitin-conjugating enzyme causes the attachment of ubiquitin to a lysine on a target protein, and subsequently targets the specific protein substrates for degradation by the proteasome. Thus, E3 ubiquitin ligase alone or in complex with an E2 ubiquitin conjugating enzyme is responsible for the transfer of ubiquitin to targeted proteins. In general, the ubiquitin ligase is involved in polyubiquitination such that a second ubiquitin is attached to the first; a third is attached to the second, and so forth. Polyubiquitination marks proteins for degradation by the proteasome. However, there are some ubiquitination events that are limited to mono-ubiquitination, in which only a single ubiquitin is added by the ubiquitin ligase to a substrate molecule. Mono-ubiquitinated proteins are not targeted to the proteasome for degradation but may instead be altered in their cellular location or function, for example, via binding other proteins that have domains capable of binding ubiquitin. Further complicating matters, different lysines on ubiquitin can be targeted by an E3 to make chains. The most common lysine is Lys48 on the ubiquitin chain. This is the lysine used to make polyubiquitin, which is recognized by the proteasome.

[0020] As used herein, the term “alkyl”, by itself or as part of another substituent, means, unless otherwise stated, a straight or branched chain hydrocarbon radical having up to twelve carbon atoms. In some embodiments, the number of carbon atoms is designated (i.e., Ci-Cs means one to eight carbons). Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, iso-butyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. Alkyl groups may be optionally substituted as provided herein. In some embodiments, the alkyl group is a Ci-Ce alkyl; in some embodiments, it is a C1-C4 alkyl.

[0021] When a range of carbon atoms is used herein, for example, Ci-Ce, all ranges, as well as individual numbers of carbon atoms are encompassed. For example, “C1-C3” includes Ci-C3, C1-C2, C2-C3, Ci, C2, and C3.

[0022] The term “optionally substituted”, as used in combination with a substituent defined herein, means that the substituent may, but is not required to be, substituted with one or more suitable functional groups or other substituents as provided herein. For example, a substituent may be optionally substituted with one or more of: halo, cyano, C1-6 alkyl, C3-6 cycloalkyl, C2-6 alkenyl, C2-ealkynyl, halo(Ci-6)alkyl, C1-6 alkoxy, halo(C 1-6 alkoxy), C 1-6 alkylthio, C1-6 alkylamino, NH2, NH(CI-6 alkyl), N(CI-6 alkyl)2, NH(C 1-6 alkoxy), N(CI-6 alkoxy )2, — C(O)NHCI-6alkyl, — C(O)N(CI-6alkyl)2, — C(O)NH2, — C(O)Ci-6alkyl, — C(O)2Ci-6alkyl, —NHCO(CI-6alkyl), — N(CI-6alkyl)CO(Ci-6alkyl), — S(O)Ci-6alkyl, — S(O)2Ci-6alkyl, oxo,- 9 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application 6-12 membered aryl, benzyl, pyridinyl, pyrazolyl, thiazolyl, isothiazolyl, or other 5 to 12 membered heteroaryl groups. In some embodiments, each of the above optional substituents are themselves optionally substituted by one or two groups.

[0023] The term “cycloalkyl” as used herein refers to a 3-12 membered cyclic alkyl group, and includes bridged (e.g., adamantine) and spirocycles (e.g., spiro[3.5]nonane). Cycloalkyl groups may be fully saturated or partially unsaturated. The term “cycloalkyl” also includes multiple condensed ring systems (e.g., ring systems comprising 2, 3 or 4 rings) wherein a single cycloalkyl ring (as defined above) can be condensed with one or more groups selected from heterocycles, carbocycles, aryls, or heteroaryls to form the multiple condensed ring system. Such multiple condensed ring systems may be optionally substituted with one or more (e.g., 1, 2, 3 or 4) oxo groups on the carbocycle or heterocycle portions of the multiple condensed ring. The rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements. It is to be understood that the individual rings of the multiple condensed ring system may be connected in any order relative to one another. It is also to be understood that the point of attachment of a multiple condensed ring system (as defined above for a cycloalkyl) can be at any position of the cycloalkylic ring. Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cycloheptyl, cyclohexyl, cycloheptyl, cyclooctyl, indenyl, bicyclo[2.2.1]heptanyl, bicyclo[3.1.1]heptanyl, bicyclo[4.1.0]heptanyl, spiro[3.3]heptanyl, and spiro[3.4]octanyl. In some embodiments, the cycloalkyl group is a 3-7 membered cycloalkyl.

[0024] The term “akenyl” as used herein refers to C2-C12 alkyl group that contains at least one carbon-carbon double bond. In some embodiments, the alkenyl group is optionally substituted. In some embodiments, the alkenyl group is a C2-C6 alkenyl.

[0025] The term “akynyl” as used herein refers to C2-C12 alkyl group that contains at least one carbon-carbon triple bond. In some embodiments, the alkenyl group is optionally substituted. In some embodiments, the alkynyl group is a C2-Cealkynyl.

[0026] The terms “alkoxy,” “alkylamino” and “alkylthio”, are used in their conventional sense, and refer to those alkyl groups attached to the remainder of the molecule via an oxygen atom (“oxy”), an amino group (“amino”) or thio group. The term “alkylamino” includes mono- di-alkylamino groups, the alkyl portions can be the same or different.

[0027] The terms “halo” or “halogen”, by itself or as part of another substituent, means a fluorine, chlorine, bromine, or iodine atom.

[0028] The term “heteroalkyl” refers to an alkyl group in which one or more carbon atom has been replaced by a heteroatom selected from S, O, P and N. Exemplary heteroalkyls include alkyl ethers, secondary and tertiary alkyl amines, alkyl amides, alkyl sulfides, and the like.- 10 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application The group may be a terminal group or a bridging group. As used herein reference to the normal chain when used in the context of a bridging group refers to the direct chain of atoms linking the two terminal positions of the bridging group.

[0029] The term “aryl” as used herein refers to a single, all carbon aromatic ring or a multiple condensed all carbon ring system wherein at least one of the rings is aromatic. For example, in certain embodiments, an aryl group has 6 to 12 carbon atoms. Aryl includes a phenyl radical. Aryl also includes multiple condensed ring systems (e.g., ring systems comprising 2, 3 or 4 rings) having about 9 to 12 carbon atoms in which at least one ring is aromatic and wherein the other rings may be aromatic or not aromatic. Such multiple condensed ring systems are optionally substituted with one or more (e.g., 1, 2 or 3) oxo groups on any carbocycle portion of the multiple condensed ring system. The rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements. It is to be understood that the point of attachment of a multiple condensed ring system, as defined above, can be at any position of the aromatic ring. Non-limiting examples of aryl groups include, but are not limited to, phenyl, indenyl, naphthyl, 1, 2,3,4-tetrahydronaphthyl, and the like.

[0030] The term “heteroaryl” as used herein refers to a single aromatic ring that has at least one atom other than carbon in the ring, wherein the atoms are selected from the group consisting of oxygen, nitrogen and sulfur; “heteroaryl” also includes multiple condensed ring systems that have at least one such aromatic ring, which multiple condensed ring systems are further described below. Thus, “heteroaryl” includes single aromatic rings of from about 1 to 6 carbon atoms and about 1-4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur. The sulfur and nitrogen atoms may also be present in an oxidized form provided the ring is aromatic. Exemplary heteroaryl ring systems include but are not limited to pyridyl, pyrimidinyl, oxazolyl or furyl. “Heteroaryl” also includes multiple condensed ring systems (e.g., ring systems comprising 2, 3 or 4 rings) wherein a heteroaryl group, as defined above, is condensed with one or more rings selected from heteroaryls (to form for example a naphthyridinyl such as 1,8-naphthyridinyl), heterocycles, (to form for example a 1, 2, 3, 4-tetrahydronaphthyridinyl such as l,2,3,4-tetrahydro-l,8-naphthyridinyl), carbocycles (to form for example 5,6,7,8-tetrahydroquinolyl) and aryls (to form for example indazolyl) to form the multiple condensed ring system. Thus, a heteroaryl (a single aromatic ring or multiple condensed ring system) has about 1-20 carbon atoms and about 1-6 heteroatoms within the heteroaryl ring. A heteroaryl (a single aromatic ring or multiple condensed ring system) can also have about 5 to 12 or about 5 to 10 members within the heteroaryl ring. Multiple condensed ring systems may be optionally substituted with one or more (e.g., 1, 2, 3 or 4) oxo - 11 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application groups on the carbocycle or heterocycle portions of the condensed ring. The rings of a multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements. It is to be understood that the individual rings of the multiple condensed ring system may be connected in any order relative to one another. It is also to be understood that the point of attachment of a multiple condensed ring system (as defined above for a heteroaryl) can be at any position of the heteroaryl ring. It is also to be understood that the point of attachment for a heteroaryl or heteroaryl multiple condensed ring system can be at any suitable atom of the heteroaryl ring including a carbon atom and a heteroatom (e.g., a nitrogen). Exemplary heteroaryls include but are not limited to pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrazolyl, thienyl, indolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, furyl, oxadiazolyl, thiadiazolyl, quinolyl, isoquinolyl, benzothiazolyl, benzoxazolyl, indazolyl, quinoxalyl, quinazolyl, 5,6,7,8-tetrahydroisoquinolinyl benzofuranyl, benzimidazolyl, thianaphthenyl, pyrrolo[2,3-b]pyridinyl, quinazolinyl-4(3H)-one, triazolyl, 4,5,6,7-tetrahydro-lH-indazole and 3b,4,4a,5-tetrahydro-lH-cyclopropa[3,4]cyclo-penta[l,2-c]pyrazole. In one embodiment the term “heteroaryl” refers to a single aromatic ring containing at least one heteroatom. For example, the term includes 5-membered and 6-membered monocyclic aromatic rings that include one or more heteroatoms. Non-limiting examples of heteroaryl include but are not limited to pyridyl, furyl, thiazole, pyrimidine, oxazole, and thiadi azole.

[0031] The term “heterocyclyl” or “heterocycle” as used herein refers to a single saturated or partially unsaturated ring that has at least one atom other than carbon in the ring, wherein the atom is selected from the group consisting of oxygen, nitrogen and sulfur; the term also includes multiple condensed ring systems that have at least one such saturated or partially unsaturated ring, which multiple condensed ring systems are further described below. Thus, the term includes single saturated or partially unsaturated rings (e.g., 3, 4, 5, 6 or 7-membered rings) from about 1 to 6 carbon atoms and from about 1 to 3 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur in the ring. The ring may be substituted with one or more (e.g., 1, 2 or 3) oxo groups and the sulfur and nitrogen atoms may also be present in their oxidized forms. Exemplary heterocycles include but are not limited to azetidinyl, tetrahydrofuranyl and piperidinyl. The term “heterocycle” also includes multiple condensed ring systems (e.g., ring systems comprising 2, 3 or 4 rings) wherein a single heterocycle ring (as defined above) can be condensed with one or more groups selected from heterocycles (to form for example a 1,8-decahydronapthyridinyl), carbocycles (to form for example a decahydroquinolyl) and aryls to form the multiple condensed ring system. Thus, a heterocycle (a single saturated or single partially unsaturated ring or multiple condensed ring system) has - 12 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application about 2-20 carbon atoms and 1-6 heteroatoms within the heterocycle ring. Such multiple condensed ring systems may be optionally substituted with one or more (e.g., 1, 2, 3 or 4) oxo groups on the carbocycle or heterocycle portions of the multiple condensed ring. The rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements. It is to be understood that the individual rings of the multiple condensed ring system may be connected in any order relative to one another. Accordingly, a heterocycle (a single saturated or single partially unsaturated ring or multiple condensed ring system) has about 3-20 atoms including about 1-6 heteroatoms within the heterocycle ring system. It is also to be understood that the point of attachment of a multiple condensed ring system (as defined above for a heterocylyl) can be at any position of the heterocyclic ring. It is also to be understood that the point of attachment for a heterocycle or heterocycle multiple condensed ring system can be at any suitable atom of the heterocyclic ring including a carbon atom and a heteroatom (e.g., a nitrogen). In one embodiment the term heterocycle includes a C2-20 heterocycle. In one embodiment the term heterocycle includes a C2-7 heterocycle. In one embodiment the term heterocycle includes a C2-5 heterocycle. In one embodiment the term heterocycle includes a C2-4 heterocycle.Exemplary heterocycles include, but are not limited to aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, tetrahydrofuranyl, dihydrooxazolyl, tetrahydropyranyl, tetrahydrothiopyranyl, 1,2,3,4-tetrahydroquinolyl, benzoxazinyl, dihydrooxazolyl, chromanyl, 1,2-dihydropyridinyl, 2,3 -dihydrobenzofuranyl, 1,3-benzodioxolyl, 1,4-benzodioxanyl, spiro[cyclopropane-l,l'-isoindolinyl]-3'-one, isoindolinyl-l-one, 2-oxa-6-azaspiro[3.3]heptanyl, imidazolidin-2-one N-methylpiperidine, imidazolidine, pyrazolidine, butyrolactam, valerolactam, imidazolidinone, hydantoin, di oxolane, phthalimide, 1,4-di oxane, thiomorpholine, thiomorpholine-S-oxide, thiomorpholine-S, S-oxide, pyran, 3 -pyrroline, thiopyran, pyrone, tetrhydrothiophene, quinuclidine, tropane, 2-azaspiro[3.3]heptane, 2-azaspiro[3.5]nonane, 7-azaspiro[3.5]nonane, 2,7-diazaspiro[3.5]nonane, (lR,5S)-3-azabicyclo[3.2.1]octane, (ls,4s)-2-azabicyclo[2.2.2]octane, (lR,47?)-2-oxa-5-azabicyclo[2.2.2]octane and pyrrolidin-2-one. In one embodiment the term “heterocycle” refers to a monocyclic, saturated or partially unsaturated, 3-8 membered ring having at least one heteroatom. For example, the term includes a monocyclic, saturated or partially unsaturated, 4, 5, 6, or 7 membered ring having at least one heteroatom. Non-limiting examples of heterocycle include aziridine, azetidine, pyrrolidine, piperidine, piperidine, piperazine, oxirane, morpholine, and thiomorpholine. The term “9- or 10-membered heterobicycle” as used herein refers to a partially unsaturated or aromatic fused bicyclic ring system having at least one heteroatom. For example, the term 9- - 13 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application or 10-membered heterobicycle includes a bicyclic ring system having a benzo ring fused to a 5-membered or 6-membered saturated, partially unsaturated, or aromatic ring that contains one or more heteroatoms.

[0032] As used herein, the term “heteroatom” is meant to include oxygen (O), nitrogen (N), sulfur (S) and silicon (Si). The nitrogen and sulfur can be in an oxidized form when feasible.

[0033] As used herein, the term “chiral” refers to molecules which have the property of non-superimposability of the mirror image partner, while the term “achiral” refers to molecules which are superimposable on their mirror image partner.

[0034] As used herein, the term “stereoisomers” refers to compounds which have identical chemical constitution but differ with regard to the arrangement of the atoms or groups in space, e.g., enantiomers, diastereomers, tautomers.

[0035] The term “patient” or “subject” is used throughout the specification to describe an animal, preferably a human or a domesticated animal, to whom treatment, including prophylactic treatment, with the compositions according to the present disclosure is provided. For treatment of those infections, conditions or disease states which are specific for a specific animal such as a human patient, the term patient refers to that specific animal, including a domesticated animal such as a dog or cat or a farm animal such as a horse, cow, sheep, etc. In general, in the present disclosure, the term patient refers to a human patient unless otherwise stated or implied from the context of the use of the term.

[0036] The term “effective” is used to describe an amount of a compound, composition or component which, when used within the context of its intended use, effects an intended result. The term effective subsumes all other effective amount or effective concentration terms, which are otherwise described or used in the present application.

[0037] “Pharmaceutically acceptable” means approved or approvable by a regulatory agency of the Federal or a state government or the corresponding agency in countries other than the United States, or that is listed in the U. S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, e.g., in humans.

[0038] “Pharmaceutically acceptable salt” refers to a salt of a compound of the disclosure that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. In particular, such salts are non-toxic may be inorganic or organic acid addition salts and base addition salts. Specifically, such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, - 14 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-ene-l-carboxylic acid, glucoheptonic acid, 3 -phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like; or (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine and the like. Salts further include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkyl ammonium, and the like; and when the compound contains a basic functionality, salts of non-toxic organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the like.

[0039] A “pharmaceutically acceptable excipient” refers to a substance that is non-toxic, biologically tolerable, and otherwise biologically suitable for administration to a subject, such as an inert substance, added to a pharmacological composition or otherwise used as a vehicle, carrier, or diluent to facilitate administration of an agent and that is compatible therewith. Examples of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycols.

[0040] A “solvate” refers to a physical association of a compound of Formula I with one or more solvent molecules.

[0041] “Treating” or “treatment” of any disease or disorder refers, in one embodiment, to ameliorating the disease or disorder (e.g., arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In another embodiment “treating” or “treatment” refers to ameliorating at least one physical parameter, which may not be discernible by the subject. In yet another embodiment, “treating” or “treatment” refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both. In yet another embodiment, “treating” or “treatment” refers to delaying the onset of the disease or disorder.

[0042] In one embodiment, the disclosure is directed to a compound of Formula (I):ULM - Y - PTM(I)or a pharmaceutically acceptable salt or solvate thereof,wherein Y-PTM is a moiety of Formula IA:- 15 - 105807.005061\4896-4870-4897.1105807.005061 - PCT ApplicationwhereinY is a covalent bond, or chemical moiety that links PTM and ULM;* is a point of attachment to ULM;Ring A is a Ce-Cio membered aryl group or a 5-10 membered heteroaryl group;R1is H or 5-6 membered heteroaryl optionally substituted by methyl;R2is H, Ci-4alk-O-Ci-4alkyl, or -(C(R8)2)n-(5-9 membered heteroaryl) optionally substituted by halogen, C1-C3 alkyl, -CH2OH, or -OH;R3is H, halogen, C1-C4 alkyl, cyclopropyl, haloalkyl, C1-C4 alkoxy, or haloalkoxy;R4is H, halogen, C1-C4 alkyl, cyclopropyl, C1-C4 alkoxy, or -O-cyclopropyl; each R5is independently H, halogen, oxo, -OH, -CN, -NO2, -Ci-Cealkyl, -C2-Cealkenyl, -C2-C6alkynyl, Co-Cialk-aryl, Co-Cialk-heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, -ORa, -SRa, -NRcRd, -NRaRc, -C(O)Rb, -OC(O)Ra, -C(O)ORa, -C(O)NRcRd, -S(O)Rb, -S(O)2NRcRd, -S(O)(=NRb)Rb, -SF5, -P(O)RbRb, -P(O)(ORb)(ORb), -B(ORd)(ORc), or -S(O)2Rb;each Rais independently H, -C(O)Rb, -C(O)ORC, -C(O)NRcRd, -C(=NRb)NRbRc, -C(=NORb)NRbRc, -C(=NCN)NRbRc, -P(ORC)2, -P(O)RcRb, -P(O)ORcORb, -S(O)Rb, -S(O)NRcRd, -S(O)2Rb, -S(O)2NRcRd, SiRb3, -Ci-Cioalkyl, -C1-C10 haloalkyl, -C2-C10 alkenyl, -C2-C10 alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl;each Rbis independently H, -Ci-Ce alkyl, -Ci-Ce haloalkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl;each Rcor Rdis independently H, -C1-C10 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -OCi-Cealkyl, -O-cycloalkyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl; orRcand Rd, together with the atom to which they are both attached, form a monocyclic or multicyclic heterocycloalkyl, or a monocyclic or multicyclic heterocyclo-alkenyl group; each R8is independently H, halogen, or C1-C4 alkyl;- 16 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application m is 0, 1, 2, 3, or 4;n is 0 or 1; andULM is- 17 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application■r'jjis a point of attachment to Y;each X2 is independently N or CR15; andeach R15is independently H, D, halogen, oxo, -OH, -CN, -NO2, -Ci-Cealkyl, -Ci-Ce haloalkyl, -C2-Cealkenyl, -C2-Cealkynyl, Co-Cialk-aryl, Co-Cialk-heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, -ORa, -SRa, -NRcRd, -NRaRc, -C(O)Rb, -OC(O)Ra, -C(O)ORa, -C(O)NRcRd, -S(O)Rb, -S(O)2NRcRd, -S(O)(=NRb)Rb, -SF5, -P(O)RbRb, -P(O)(ORb)(ORb), -B(ORd)(ORc) or -S(O)2Rb;- 18 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application wherein any of the -Ci-Cealkyl, Ci-Cs alkoxide, -C2-Cealkenyl, -C2-Cealkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, spirocycloalkyl, spiroheterocycloalkyl and spiroheterocycloalkenyl groups in any of R1-R5, Rs, R15, and ring A is optionally substituted by 1-6 Rfgroups; andeach Rfis independently D, oxo, halogen, Ci-Cs alkoxy, Ci-Cs alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, -OH, -CN, -NO2, -C2-6 alkenyl, -C2-6 alkynyl, Ce-io aryl, C5-12 heteroaryl, C3-8 cycloalkyl, C3-8 cycloalkenyl, C3-8 heterocycloalkyl, C3-8 heterocycloalkenyl, -ORa, -SRa, -NRcRd, -NRaRc, -C(O)Rb, -OC(O)Rb, -C(O)ORb, -C(O)NRcRd, -S(O)Rb, -S(O)2NRcRd, -S(O)(=NRb)Rb, -SF5, -P(O)RbRb, -P(O)RcRd, -P(O)(ORb)(ORb), -B(ORc)(ORd), -S(O)2Rb, -C(O)NRbORb, -S(O)2ORb, -OS(O)2ORb, or -OPO(ORb)(ORb); wherein said Ci-C8alkyl is optionally substituted by 1-6 groups selected from D, halogen, -OH, -CN, -ORa, -SRa, -NRaRd, orNRcRd

[0043] In some embodiments, the compounds of Formula I include a protein targeting moiety (PTM). In some embodiments, the Y-PTM in the compounds of Formula I is a moiety of Formula I AR1

[0044] According to the disclosure, Y in Formula IA is a covalent bond, or chemical moiety that links PTM and ULM. In some embodiments, Y in Formula IA is a chemical moiety that links PTM and ULM. In other embodiments, Y in Formula IA is a covalent bond.

[0045] According to the disclosure, Ring A in Formula IA is a Ce-Cio membered aryl group or a 5-10 membered heteroaryl group. In some embodiments, Ring A in Formula IA is a Ce-C10 membered aryl group. In some embodiments, Ring A in Formula IA is a phenyl group. In other embodiments, Ring A in Formula IA is a 5-10 membered heteroaryl group.- 19 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0046] In some embodiments, Ring A in Formula IA is selected from#R5R5#,#and#; wherein is a point of attachment to the sulfonamide group and # is a point of attachment to Y.

[0047] In some embodiments, Ring A in Formula IAis #; whereinis a point of attachment to the sulfonamide group and # is a point of attachment to Y.R5

[0048] In some embodiments, Ring A in Formula IAis#; whereinis a point of attachment to the sulfonamide group and # is a point of attachment to Y.R5

[0049] In other embodiments, Ring A in Formula IAis#; whereinis a point of attachment to the sulfonamide group and # is a point of attachment to Y.

[0050] In yet other embodiments, Ring A in Formula IAis#; whereinis a point of attachment to the sulfonamide group and # is a point of attachment to Y.

[0051] In some embodiments, Ring A in Formula IA is selected from- 20 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application# wherein is a point of attachment to the sulfonamide group and # is a point of attachment to

[0052] In some embodiments, Ring A in Formula IAis#; whereinis a point of attachment to the sulfonamide group and # is a point of attachment to Y.

[0053] In some embodiments, Ring A in Formula IAis#; whereinis a point of attachment to the sulfonamide group and # is a point of attachment to Y.OMe

[0054] In some embodiments, Ring A in Formula IAis#; whereinis a point of attachment to the sulfonamide group and # is a point of attachment to Y.OMeOMe

[0055] In other embodiments, Ring A in Formula IAis#; whereinis a point of attachment to the sulfonamide group and # is a point of attachment to Y.OMeF OMe

[0056] In other embodiments, Ring A in Formula IAis#; whereinis a point of attachment to the sulfonamide group and # is a point of attachment to Y.

[0057] In yet other embodiments, Ring A in Formula IA is#; wherein is a point of attachment to the sulfonamide group and # is a point of attachment to Y.- 21 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0058] In yet other embodiments, Ring A in Formula IA is#OCF3; wherein is a point of attachment to the sulfonamide group and # is a point of attachment to Y.jQ

[0059] In yet other embodiments, Ring A in Formula IA is# Et; whereinis a point of attachment to the sulfonamide group and # is a point of attachment to Y.

[0060] According to the disclosure, R1in Formula IA is H, D, or 5-6 membered heteroaryl optionally substituted by methyl. In some embodiments, R1in Formula IA is H. In some embodiments, R1in Formula IA is D. In other embodiments, R1in Formula IA is 5-6 membered heteroaryl optionally substituted by methyl.

[0061] According to the disclosure, R2in Formula IA is H, D, Ci-4alk-O-Ci-4alkyl or -(C(R8)2)n-(5-9 membered heteroaryl) optionally substituted by halogen, C1-C3 alkyl, -CH2OH, or -OH. In some embodiments, R2in Formula IA is H. In some embodiments, R2in Formula IA is D. In other embodiments, R2in Formula IA is Ci-4alk-O-Ci-4alkyl. In other embodiments, R2in Formula IA is CH2-O-CH3.

[0062] In yet other embodiments, R2in Formula IA is -(C(R8)2)n-(5-9 membered heteroaryl) optionally substituted by halogen, C1-C3 alkyl, -CH2OH, or -OH. In yet other embodiments, R2in Formula IA is -(C(R8)2)n-(5-6 membered heteroaryl) optionally substituted by halogen, C1-C3 alkyl, -CH2OH, or -OH. In some embodiments, when R2in Formula IA is -(C(R8)2)n-(5-6 membered heteroaryl), the 5-6 membered heteroaryl is a pyrazole, a pyrrole, a pyridine or a pyridazine. In some embodiments, when R2in Formula IA is -(C(R8)2)n-(5-6 membered heteroaryl), the 5-6 membered heteroaryl is a pyrazole.

[0063] According to the disclosure, R8in Formula IA is H, D, halogen, or C1-C4 alkyl. In some embodiments, R8in Formula IA is H. In some embodiments, R8in Formula IA is D. In other embodiments, R8in Formula IA is halogen. In other embodiments, R8in Formula IA is C1-C4 alkyl.

[0064] According to the disclosure, n in Formula IA is 0 or 1. In some embodiments, n in Formula IA = 0. In other embodiments, n in Formula IA = 1.

[0065] According to the disclosure, R3in Formula IA is H, D, halogen, C1-C4 alkyl, cyclopropyl, haloalkyl, C1-C4 alkoxy, or haloalkoxy. In some embodiments, R3in Formula IA is H. In some embodiments, R3in Formula IA is D. In some embodiments, R3in Formula IA is halogen. In some embodiments, R3in Formula IA is C1-C4 alkyl. In other embodiments, R3in Formula IA is cyclopropyl. In other embodiments, R3in Formula IA is- 22 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application C1-C4 haloalkyl. In other embodiments, R3in Formula IA is C1-C4 alkoxy. In other embodiments, R3in Formula IA is haloalkoxy.

[0066] According to the disclosure, R4in Formula IA is H, D, halogen, C1-C4 alkyl, cyclopropyl, C1-C4 alkoxy, or -O-cyclopropyl. In some embodiments, R4in Formula IA is H. In some embodiments, R4in Formula IA is D. In some embodiments, R4in Formula IA is halogen. In some embodiments, R4in Formula IA is C1-C4 alkyl. In other embodiments, R4in Formula IA is cyclopropyl. In other embodiments, R4in Formula IA is C1-C4 alkoxy. In other embodiments, R4is -O-cyclopropyl. In other embodiments, R4in Formula IA is methoxy.

[0067] According to the disclosure, each R5in Formula IA is independently H, halogen, oxo, -OH, -CN, -NO2, -Ci-Cealkyl, -C2-C6alkenyl, -C2-C6alkynyl, Co-Cialk-aryl, Co-Cialk-heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, -ORa, -SRa, -NRcRd, -NRaRc, -C(O)Rb, -OC(O)Ra, -C(O)ORa, -C(O)NRcRd, -S(O)Rb, -S(O)2NRcRd, -S(O)(=NRb)Rb, -SF5, -P(O)RbRb, -P(O)(ORb)(ORb), -B(ORd)(ORc) or -S(O)2Rb.

[0068] In some embodiments, at least one R5in Formula IA is H. In some embodiments, each R5in Formula IA is D. In some embodiments, at least one R5in Formula IA is halogen. In some embodiments, each R5 in Formula IA is C1-C4 alkoxy. In some embodiments, at least one R5in Formula IA is C1-C4 alkoxy.

[0069] In other embodiments, at least one R5in Formula IA is F. In other embodiments, at least one R5in Formula IA is -CN. In other embodiments, at least one R5in Formula IA is C1-C4 alkyl. In other embodiments, at least one R5in Formula IA is haloalkyl. In other embodiments, at least one R5in Formula IA is cyclopropyl. In yet other embodiments, at least one R5in Formula IA is haloalkoxy. In yet other embodiments, at least one R5in Formula IA is -O-cyclopropyl. In yet other embodiments, at least one R5in Formula IA is -CH2-O-CH3. In yet other embodiments, at least one R5in Formula IA is -C(O)OCH3. In yet other embodiments, at least one R5in Formula IA is -C(O)N(H)CH3.

[0070] In some embodiments, at least one R5in Formula IA is halogen and at least one R5 is C1-C4 alkoxy. In some embodiments, one R5in Formula IA is halogen and two Rs are C1-C4 alkoxy. In some embodiments, one R5in Formula IA is F and two Rs are OCH3.

[0071] According to the disclosure, m in Formula IA is 0, 1, 2, 3, or 4. In some embodiments, m is 0. In some embodiments, m in Formula IA is 1. In other embodiments, m in Formula IA is 2. In other embodiments, m in Formula IA is 3. In other embodiments, m in Formula IA is 4.- 23 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0072] According to the disclosure, ULM is a small molecule E3 Ubiquitin Ligase binding moiety that binds a Cereblon E3 Ubiquitin Ligase. In some embodiments, ULM is a moiety as described herein.

[0073] In some embodiments, ULM is- 24 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application■r'jjis a point of attachment to Y;each X2 is independently N or CR15; andeach R15is independently H, D, halogen, oxo, -OH, -CN, -NO2, -Ci-Cealkyl, -Ci-Ce haloalkyl, -C2-Cealkenyl, -C2-Cealkynyl, Co-Cialk-aryl, Co-Cialk-heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, -ORa, -SRa, -NRcRd, -NRaRc, -C(O)Rb, -OC(O)Ra, -C(O)ORa, -C(O)NRcRd, -S(O)Rb, -S(O)2NRcRd, -S(O)(=NRb)Rb, -SF5, -P(O)RbRb, -P(O)(ORb)(ORb), -B(ORd)(ORc) or -S(O)2Rb.- 25 - 105807.005061\4896-4870-4897.1105807.005061 - PCT ApplicationH,x23Nox / rx2N

[0074] In some embodiments, ULM is; wherein -T’4'’ is a point of attachment to Y; and each X2 is independently N or CR15.Rb

[0075] In some embodiments, ULM is; whereinis a point of attachment to Y; and each X2 is independently N or CR15.Rb

[0076] In some embodiments, ULM is; whereinis a point of attachment to Y; and each X2 is independently N or CR15., X21X2' rxrX2O N O

[0077] In some embodiments, ULM is H; whereinis a point of attachment to Y; and each X2 is independently N or CR15.O x2^xN X2"2

[0078] In some embodiments, ULM is Rb; whereinis a point of attachment to Y; and each X2 is independently N or CR15.- 26 - 105807.005061\4896-4870-4897.1105807.005061 - PCT ApplicationHNN

[0079] In some embodiments, ULM is Rb; wherein-^ is a point of attachment to Y; and each X2 is independently N or CR15.O

[0080] In some embodiments, ULM is:2'-x2; wherein-^ is a point of attachment to Y; and each X2 is independently N or CR15.Rb /

[0081] In some embodiments, ULM is; whereinis a point of attachment to Y; and each X2 is independently N or CR15.RbNX2

[0082] In other embodiments, ULM is; whereinis a point of attachment to Y; and each X2 is independently N or CR15.

[0083] In other embodiments, ULM is; whereinis a point of attachment to Y; and each X2 is independently N or CR15.- 27 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application Rbx2X2

[0084] In other embodiments, ULM is; whereinis a point of attachment to Y; and each X2 is independently N or CR15.CLHNR15

[0085] In other embodiments, ULM is Rb; whereinis a point of attachment to Y; and each X2 is independently N or CR15.Rbx2 NXX?? 1 / >X2 \ O

[0086] In other embodiments, ULM is; whereinis a point of attachment to Y; and each X2 is independently N or CR15.HO / Rbx2X2~ y' _j

[0087] In other embodiments, ULM isA2; whereinj'r‘ is a point of attachment to Y; and each X2 is independently N or CR15.- 28 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application H

[0088] In other embodiments, ULM isx2 x2; whereinis a point of attachment to Y; and each X2 is independently N or CR15.

[0089] In other embodiments, ULM is; whereinis a point of attachment to Y; and each X2 is independently N or CR15.

[0090] In yet other embodiments, ULM is whereinis a point of attachment to Y; and each X2 is independently N or CR15.

[0091] In yet other embodiments, ULM is; whereinis a point of attachment to Y; and each X2 is independently N or CR15.

[0092] In yet other embodiments,ULM is; wherein is a point of attachment to Y; and each X2 is independently N or CR15.- 29 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0093] In yet other embodiments, ULM is; whereinis a point of attachment to Y; and each X2 is independently N or CR15.

[0094] In yet other embodiments,ULM is; whereinis a point of attachment to Y; and each X2 is independently N or CR15.o

[0095] In yet other embodiments,ULM is; whereinis a point of attachment to Y; and each X2 is independently N or CR15.

[0096] In some embodiments, each X2 of ULM is independently N or CR15. In some embodiments, at least one X2 of ULM is N. In some embodiments, at least one X2 of ULM is CRb. In some embodiments, each X2 of ULM is CR15.

[0097] According to the disclosure, each R15is independently H, D, halogen, oxo, -OH, -CN, -NO2, -Ci-Cealkyl, -Ci-Cehaloalkyl, -C2-Cealkenyl, -C2-Cealkynyl, Co-Cialk-aryl, Co-Cialk-heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, -ORa, -SRa, -NRcRd, -NRaRc, -C(O)Rb, -OC(O)Ra, -C(O)ORa, -C(O)NRcRd, -S(O)Rb, -S(O)2NRcRd, -S(O)(=NRb)Rb, -SF5, -P(O)RbRb, -P(O)(ORb)(ORb), -B(ORd)(ORc) or -S(O)2Rb.

[0098] In some embodiments, each R15is H. In some embodiments, at least one R15is H. In some embodiments, each R15is D. In some embodiments, at least one R15is D. In some embodiments, each R15is Ci-Cealkyl. In some embodiments, at least one R15is Ci-Cealkyl. In some embodiments, each R15is methyl or ethyl. In some embodiments, at least one R15is methyl or ethyl.- 30 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0099] In other embodiments, each R15is independently selected from halogen, oxo, -OH, -CN, -NO2, -Ci-Cehaloalkyl, -C2-Cealkenyl, -C2-Cealkynyl, Co-Cialk-aryl, Co-Cialk-heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, -ORa, -SRa, -NRcRd, -NRaRc, -C(O)Rb, -OC(O)Ra, -C(O)ORa, -C(O)NRcRd, -S(O)Rb, -S(O)2NRcRd, -S(O)(=NRb)Rb, -SF5, -P(O)RbRb, -P(O)(ORb)(ORb), -B(ORd)(ORc) or -S(O)2Rb.

[0100] In some embodiments, ULM is- 31 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Applicationattachment to Y.

[0101] In some embodiments, ULM is, whereinis a point of attachment to Y.- 32 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0102] In some embodiments, ULM is of attachment to Y.

[0103] In some embodiments, ULM is attachment to Y.attachment to Y.of attachment to Y.

[0106] In some embodiments, ULM is whereinis a point of attachment to Y.- 33 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application Iof attachment to Y.attachment to Y.

[0109] In some embodiments, ULM is, whereinis a point of attachment to Y.

[0110] In some embodiments, ULM is, whereinis a point of attachment to Y.[OHl] In other embodiments,ULM is, wherein is a point of attachment to Y.- 34 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0112] In other embodiments, ULM is attachment to Y.

[0113] In other embodiments, ULM is attachment to Y.

[0114] In other embodiments, ULM is attachment to Y.

[0115] In other embodiments, ULM is attachment to Y.

[0116] In other embodiments, ULM is attachment to Y.- 35 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0117] In other embodiments, ULM is attachment to Y.

[0118] In other embodiments, ULM is attachment to Y.

[0119] In yet other embodiments, ULM is D, whereinis a point of attachment to Y.is a point of attachment to Y.

[0121] In yet other embodiments, ULM is, whereinis a point of attachment to Y.- 36 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0122] In yet other embodiments, ULM is, whereinis a point of attachment to Y.

[0123] In yet other embodiments, ULM is, wherein •T’4'’ is a point of attachment to Y.

[0124] In yet other embodiments, ULM is, wherein-^ is a point of attachment to Y.of attachment to Y.

[0126] In yet other embodiments, ULM is, wherein-^ is a point of attachment to Y.

[0127] Chemical moieties that are used to link PTM and ULM moieties are known in the art. These moieties are sometimes referred to as “linkers” in the art. In some embodiments, Y in Formula IA is a chemical moiety that is used to link a PTM and ULM that is known in the- 37 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0128] In some embodiments, Y in Formula IA is a chemical moiety that is used to link a PTM and ULM as described in U. S. Patent Application Publication No. 2019 / 0300521, the entirety of which is incorporated by reference herein.

[0129] In other embodiments, Y in Formula IA is a chemical moiety that is used to link a PTM and ULM as described in U. S. Patent Application Publication No. 2019 / 0255066, the entirety of which is incorporated by reference herein.

[0130] In other embodiments, Y in Formula IA is a chemical moiety that is used to link a PTM and ULM as described in WO 2019 / 084030, the entirety of which is incorporated by reference herein.

[0131] In other embodiments, Y in Formula IA is a chemical moiety that is used to link a PTM and ULM as described in WO 2019 / 084026, the entirety of which is incorporated by reference herein.

[0132] In some embodiments, Y in Formula IA is a chemical structural unit represented by the formula:■(A)q-,wherein:q is an integer from 1 to 14;each A is independently selected from the group consisting of CRlaRlb, O, S, SO, SO2, NR1C, SO2NR1C, SONR1C, SO(=NR1C), SO(=NRlc)NRld, CONRlc, NRlcCONRld, NRlcC(O)O, NRlcSO2NRld, CO, CRla=CRlb, C=C, SiRlaRlb, P(O)Rla, P(O)ORla, (CRlaRlb)i-4, -(CRlaRlb)i-4O(CRlaRlb)i-4, -(CRlaRlb)i-4S(CRlaRlb)i-4, -(CRlaRlb)i-4NRlc(CRlaRlb)i-4, NRlcC(=NCN)NRldNRlcC(=NCN), NRlcC(=CNO2)NRld, 3-11 membered cycloalkyl, optionally substituted with 1-6 Rlaor Rlbgroups, 3-11 membered heteocyclyl optionally substituted with 1-6 Rlaor Rlbgroups, aryl optionally substituted with 1-6 Rlaor Rlbgroups, heteroaryl optionally substituted with 1-6 Rlaor Rlbgroups,and Rla, Rlb, Rlc, Rldand Rleare each independently, -H, D, -halo, -Ci-Csalkyl, -Ci-Cehaloalkyl, -O-Ci-Csalkyl, -S-Ci-Csalkyl, -NHCi-Csalkyl, -N(Ci-C8alkyl)2, 3-11 membered cycloalkyl, aryl, heteroaryl, 3-11 membered heterocyclyl, -O-(3-ll membered cycloalkyl), -S-(3-11 membered cycloalkyl), NH-(3-ll membered cycloalkyl), N(3-ll membered cycloalkyl)2, N-(3-ll membered cycloalkyl)(Ci-C8alkyl), -OH, -NH2, -SH, -SO2Ci-C8alkyl, -SO2-aryl, -SO2-heteroaryl, SO(NH)Ci-C8alkyl, P(O)(OCi-C8alkyl)(Ci-C8alkyl), -P(O)(OCi-C8alkyl)2, -C=C-Ci-C8alkyl, -C=CH, -CH=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=C(Ci-C8alkyl)2, -Si(OH)3, -Si(Ci-C8alkyl)3, -Si(OH)(Ci-C8alkyl)2, -C(O)Ci-C8alkyl, -C(O)OCi-C8alkyl, -CO2H, -CN, -CF3, -CHF2, -CH2F, -NO2, -SF5, -SO2NHCI-C8alkyl, -SO2N(Ci-C8alkyl)2, -SO(NH)NHCi-C8alkyl, -SO(NH)N(Ci-C8alkyl)2, -SONHCi- - 38 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application C8alkyl, -SON(Ci-C8alkyl)2, -CONHCi-C8alkyl, -CON(Ci-C8alkyl)2, -N(Ci-C8alkyl)CONH(Ci-C8alkyl), -N(Ci-C8alkyl)CON(Ci-C8alkyl)2, -NHCONH(Ci-C8alkyl), -NHCON(Ci-C8alkyl)2, -NHCONH2, -N(Ci-C8alkyl)SO2NH(Ci-C8alkyl), -N(Ci-C8alkyl)SO2N(Ci-C8alkyl)2, -NHSO2NH(Ci-C8alkyl), -NHSO2N(Ci-C8alkyl)2, or -NHSO2NH2;orwhere the context permits, Rlaor Rlb, are linked to other groups, or to each other, to form a cycloalkyl and / or a heterocyclyl moiety, optionally substituted with 0-4 Rlegroups.

[0133] In these embodiments, q represents the number of connected A groups. For example, when q = 1, -(A)q- is -Ai-; when q = 2, -(A)q- is -AI-A2-; when q = 3, -(A)q- is -Ai-A2-AS-; when q = 4, -(A)q- is -A1-A2-A3-A4-; when q = 5, -(A)q- is -AI-A2-A3-A4-AS-; when q = 6, -(A)q- is -AI-A2-A3-A4-AS-A6-; when q = 7, -(A)q- is -AI-A2-A3-A4-A5-A6-A?-; when q = 8, -(A)q- is -AI-A2-A3-A4-A5-A6-A?-A8-; when q = 9, -(A)q- is -AI-A2-A3-A4-A5-A6-A?-A8-A9-; when q = 10, -(A)q- is -Ai-A2-A3-A4-A5-Ae-A7-A8-A9-Aio-; when q = 11, -(A)q- is -Ai-A2-A3-A4-AS-A6-A7-A8-A9-AIO-AH-; when q = 12, -(A)q- is -AI-A2-A3-A4-AS-A6-A7-A8-A9-AIO-AH-AI2-; when q = 13, -(A)q- is -A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-; and when q = 14, -(A)q- is -A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-.

[0134] In some embodiments, q = 4 and Y in Formula IA is a chemical moiety represented by the formula: -A1-A2-A3-A4-, wherein each of A1-4 is independently selected from the group consisting of O, S, SO, SO2, NRlc, SO2NRlc, SONRlc, SO(=NRlc), SO(=NRlc)NRld, CONRlc, NRlcCONRld, NR1CC(O)O, NRlcSO2NRld, CO, CRla=CRlb, C=C, SiRlaRlb, P(O)Rla,P(O)ORla, (CRlaRlb)i-4, -(CRlaRlb)i-4O(CRlaRlb)i-4, -(CRlaRlb)i-4S(CRlaRlb)i-4, -(CRlaRlb)i-4NRlc(CRlaRlb)i-4, optionally substituted 3-11 membered cycloalkyl, 3-11 membered heterocyclyl, aryl, and heteroaryl;wherein Rlaand Rlbare each independently selected from the group consisting of -H, D, -halo, -Ci-C8alkyl, -O-Ci-C8alkyl, -Ci-C6haloalkyl, -S-Ci-C8alkyl,-NHCi-C8alkyl, -N(Ci-C8alkyl)2, 3-11 membered cycloalkyl, aryl, heteroaryl, 3-11 membered heterocyclyl, -O-(3-ll membered cycloalkyl), -S-(3-l 1 membered cycloalkyl), NH-(3-ll membered cycloalkyl), N(3-ll membered cycloalkyl)2, N-(3-ll membered cycloalkyl)(Ci-C8alkyl), -OH, -NH2, -SH, -SO2Ci-C8alkyl, -SO2-aryl, -SO2-heteroaryl, SO(NH)Ci-C8alkyl, P(O)(OCi-C8alkyl)(Ci-Csalkyl), -P(O)(OCi-C8alkyl)2, -C=C-Ci-C8alkyl, -C=CH, -CH=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=C(Ci-C8alkyl)2, -Si(OH)3, -Si(Ci-C8alkyl)3, -Si(OH)(Ci-C8alkyl)2, -C(O)Ci-C8alkyl, -C(O)OCi-C8alkyl, -CO2H, -CN, -NO2, -SF5, -SO2NHCi-C8alkyl, -SO2N(Ci-C8alkyl)2, -SO(NH)NHCi-C8alkyl, -SO(NH)N(Ci-C8alkyl)2, -SONHCi-C8alkyl, -SON(Ci-C8alkyl)2, -CONHCi-C8alkyl, -CON(Ci-C8alkyl)2, -N(Ci-C8alkyl)CONH(Ci-C8alkyl), -N(Ci-C8alkyl)CON(Ci-C8alkyl)2, -NHCONH(Ci-C8alkyl), - - 39 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application NHCON(Ci-C8alkyl)2, -NHCONH2, -N(Ci-C8alkyl)SO2NH(Ci-C8alkyl), -N(Ci-C8alkyl)SO2N(Ci-C8alkyl)2, -NHSO2NH(Ci-C8alkyl), -NHSO2N(Ci-C8alkyl)2, or -NHSO2NH2; andRlcand Rldare each independently selected from the group consisting of H, D, optionally substituted C1-4 alkyl, Cs-8cyclcoalkyl, Cs-8heterocyclcoalkyl, aryl, or heteroaryl.

[0135] In other embodiments, q = 3 and Y in Formula IA is a chemical moiety represented by the formula:-Ai-A2-A3-, wherein each of A1-3 is independently selected from the group consisting of O, S, SO, SO2, NRlc, SO2NRlc, SONRlc, SO(=NRlc), SO(=NRlc)NRld, CONRlc, NRlcCONRld, NR1CC(O)O, NRlcSO2NRld, CO, CRla=CRlb, C=C, SiRlaRlb, P(O)Rla,P(O)ORla, (CRlaRlb)i-4, -(CRlaRlb)i-4O(CRlaRlb)i-4, -(CRlaRlb)i-4S(CRlaRlb)i-4, -(CRlaRlb)i-4NRlc(CRlaRlb)i-4, optionally substituted 3-11 membered cycloalkyl, 3-11 membered heterocyclyl, aryl, and heteroaryl;wherein Rlaand Rlbare each independently selected from the group consisting of -H, D, -halo, -Ci-C8alkyl, -O-Ci-C8alkyl, -Ci-C6haloalkyl, -S-Ci-C8alkyl,-NHCi-C8alkyl, -N(Ci-C8alkyl)2, 3-11 membered cycloalkyl, aryl, heteroaryl, 3-11 membered heterocyclyl, -O-(3-ll membered cycloalkyl), -S-(3-l 1 membered cycloalkyl), NH-(3-ll membered cycloalkyl), N(3-ll membered cycloalkyl)2, N-(3-ll membered cycloalkyl)(Ci-C8alkyl), -OH, -NH2, -SH, -SO2Ci-C8alkyl, -SO2-aryl, -SO2-heteroaryl, SO(NH)Ci-C8alkyl, P(O)(OCi-C8alkyl)(Ci-C8alkyl), -P(O)(OCi-C8alkyl)2, -C=C-Ci-C8alkyl, -C=CH, -CH=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=C(Ci-C8alkyl)2, -Si(OH)3, -Si(Ci-C8alkyl)3, -Si(OH)(Ci-C8alkyl)2, -C(O)Ci-C8alkyl, -C(O)OCi-C8alkyl, -CO2H, -CN, -NO2, -SF5, -SO2NHCi-C8alkyl, -SO2N(Ci-C8alkyl)2, -SO(NH)NHCi-C8alkyl, -SO(NH)N(Ci-C8alkyl)2, -SONHCi-C8alkyl, -SON(Ci-C8alkyl)2, -CONHCi-C8alkyl, -CON(Ci-C8alkyl)2, -N(Ci-C8alkyl)CONH(Ci-C8alkyl), -N(Ci-C8alkyl)CON(Ci-C8alkyl)2, -NHCONH(Ci-C8alkyl), -NHCON(Ci-C8alkyl)2, -NHCONH2, -N(Ci-C8alkyl)SO2NH(Ci-C8alkyl), -N(Ci-C8alkyl)SO2N(Ci-C8alkyl)2, -NHSO2NH(Ci-C8alkyl), -NHSO2N(Ci-C8alkyl)2, or -NHSO2NH2; andRlcand Rldare each independently selected from the group consisting of H, D, optionally substituted C1-4 alkyl, Cs-8cyclcoalkyl, Cs-8heterocyclcoalkyl, aryl, or heteroaryl.

[0136] In other embodiments, q = 2 and Y in Formula IA is a chemical moiety represented by the formula:-Ai-A2-, wherein each of A1-2 is independently selected from the group consisting of O, S, SO, SO2, NRlc, SO2NRlc, SONRlc, SO(=NRlc), SO(=NRlc)NRld, CONRlc, NRlcCONRld, NR1CC(O)O, NRlcSO2NRld, CO, CRla=CRlb, C=C, SiRlaRlb, P(O)Rla,P(O)ORla, (CRlaRlb)i-4, -(CRlaRlb)i-4O(CRlaRlb)i-4, -(CRlaRlb)i-4S(CRlaRlb)i-4, -(CRlaRlb)i-- 40 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application 4NRlc(CRlaRlb)i-4, optionally substituted 3-11 membered cycloalkyl, 3-11 membered heterocyclyl, aryl, and heteroaryl;wherein Rlaand Rlbare each independently selected from the group consisting of -H, D, -halo, -Ci-C8alkyl, -O-Ci-C8alkyl, -Ci-C6haloalkyl, -S-Ci-C8alkyl,-NHCi-C8alkyl, -N(Ci-C8alkyl)2, 3-11 membered cycloalkyl, aryl, heteroaryl, 3-11 membered heterocyclyl, -O-(3-ll membered cycloalkyl), -S-(3-l 1 membered cycloalkyl), NH-(3-ll membered cycloalkyl), N(3-ll membered cycloalkyl)2, N-(3-ll membered cycloalkyl)(Ci-C8alkyl), -OH, -NH2, -SH, -SO2Ci-C8alkyl, -SO2-aryl, -SO2-heteroaryl, SO(NH)Ci-C8alkyl, P(O)(OCi-C8alkyl)(Ci-C8alkyl), -P(O)(OCi-C8alkyl)2, -C=C-Ci-C8alkyl, -C=CH, -CH=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=C(Ci-C8alkyl)2, -Si(OH)3, -Si(Ci-C8alkyl)3, -Si(OH)(Ci-C8alkyl)2, -C(O)Ci-C8alkyl, -C(O)OCi-C8alkyl, -CO2H, -CN, -NO2, -SF5, -SO2NHCi-C8alkyl, -SO2N(Ci-C8alkyl)2, -SO(NH)NHCi-C8alkyl, -SO(NH)N(Ci-C8alkyl)2, -SONHCi-Csalkyl, -SON(Ci-C8alkyl)2, -CONHCi-C8alkyl, -CON(Ci-C8alkyl)2, -N(Ci-C8alkyl)CONH(Ci-C8alkyl), -N(Ci-C8alkyl)CON(Ci-C8alkyl)2, -NHCONH(Ci-C8alkyl), -NHCON(Ci-C8alkyl)2, -NHCONH2, -N(Ci-C8alkyl)SO2NH(Ci-C8alkyl), -N(Ci-C8alkyl)SO2N(Ci-C8alkyl)2, -NHSO2NH(Ci-C8alkyl), -NHSO2N(Ci-C8alkyl)2, or -NHSO2NH2; andRlcand Rldare each independently selected from the group consisting of H, D, optionally substituted C1-4 alkyl, C3.8cyclcoalkyl, C3.8heterocyclcoalkyl, aryl, or heteroaryl.

[0137] In other embodiments, q = 1 and Y in Formula IA is a chemical moiety represented by the formula:-Ai-, wherein Ai is selected from the group consisting of O, S, SO, SO2, NRlc, SO2NR1C, SONR1C, SO(=NR1C), SO(=NRlc)NRld, CONRlc, NRlcCONRld, NRlcC(O)O, NRlcSO2NRld, CO, CRla=CRlb, C=C, SiRlaRlb, P(O)Rla, P(O)ORla, (CRlaRlb)i-4, -(CRlaRlb)i-4O(CRlaRlb)i-4, -(CRlaRlb)i-4S(CRlaRlb)i-4, -(CRlaRlb)i-4NRlc(CRlaRlb)i-4, optionally substituted 3-11 membered cycloalkyl, 3-11 membered heterocyclyl, aryl, and heteroaryl; wherein Rlaand Rlbare each independently selected from the group consisting of -H, D, -halo, -Ci-C8alkyl, -O-Ci-C8alkyl, -Ci-C6haloalkyl, -S-Ci-C8alkyl,-NHCi-C8alkyl, -N(Ci-C8alkyl)2, 3-11 membered cycloalkyl, aryl, heteroaryl, 3-11 membered heterocyclyl, -O-(3-ll membered cycloalkyl), -S-(3-l 1 membered cycloalkyl), NH-(3-ll membered cycloalkyl), N(3-ll membered cycloalkyl)2, N-(3-ll membered cycloalkyl)(Ci-C8alkyl), -OH, -NH2, -SH, -SO2Ci-C8alkyl, -SO2-aryl, SO(NH)Ci-C8alkyl, P(O)(OCi-C8alkyl)(Ci-C8alkyl), -P(O)(OCi-C8alkyl)2, -C=C-Ci-C8alkyl, -C=CH, -CH=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=C(Ci-C8alkyl)2, -Si(OH)3, -Si(Ci-C8alkyl)3, -Si(OH)(Ci-C8alkyl)2, -C(O)Ci-C8alkyl, -C(O)OCi-C8alkyl, -CO2H, -CN, -NO2, -SF5, -SO2NHCi-C8alkyl, -SO2N(CI-C8alkyl)2, -SO(NH)NHCi-C8alkyl, -SO(NH)N(Ci-C8alkyl)2, -SONHCi-C8alkyl, -SON(Ci- - 41 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application C8alkyl)2, -CONHCi-Csalkyl, -CON(Ci-C8alkyl)2, -N(Ci-C8alkyl)CONH(Ci-C8alkyl), -N(Ci-C8alkyl)CON(Ci-C8alkyl)2, -NHCONH(Ci-C8alkyl), -NHCON(Ci-C8alkyl)2, -NHCONH2, -N(Ci-C8alkyl)SO2NH(Ci-C8alkyl), -N(Ci-C8alkyl)SO2N(Ci-C8alkyl)2, -NHSO2NH(CI-C8alkyl), -NHSO2N(Ci-C8alkyl)2, or -NHSO2NH2; andRlcand Rldare each independently selected from the group consisting of H, D, optionally substituted C1-4 alkyl, Cs-8cyclcoalkyl, Cs-8heterocyclcoalkyl, aryl, or heteroaryl.

[0138] In some embodiments, Y in Formula IA is a covalent bond, 3-11 membered cycloalkyl optionally substituted with 1-6 Rlaor Rlbgroups, 3-11 membered heterocyclyl optionally substituted with 1-6 Rlaor Rlbgroups, -(CRlaRlb)i-5, -(CRla=CRlb)-, -(CRlaRlb)i-5-A- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-A-(CRlaRlb)i-5- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-A-(CRlaRlb)i-5-A- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-(CRla=CRlb)-(CRlaRlb)i-5-, -(CRlaRlb)i-5-( CRla=CRlb)-(CRlaRlb)i-5-A- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-(C=C)-(CRlaRlb)i-5-, -(CRlaRlb)i-5-(C=C)-(CRlaRlb)i-5-A- wherein A is O, S, or NR1C, -(C=C)-(CRlaRlb)i-5-A-(CRlaRlb)i-5- wherein A is O, S, or NRlc, -(C=C)-(CRlaRlb)i-5, -(CRlaRlb)i-5-(3-l 1 membered cycloalkyl optionally substituted with 1-6 Rlaor Rlbgroups)-, -(CRlaRlb)i-5-(3-l 1 membered heterocyclyl optionally substituted with 1-6 Rlaor Rlbgroups)-, -(3-11 membered cycloalkyl optionally substituted with 1-6 Rlaor Rlbgroups)-(CRlaRlb)i-s-, -(3-11 membered heterocyclyl optionally substituted with 1-6 Rlaor Rlbgroups) -(CRlaRlb)i-5-, -(CRlaRlb)i-5-(3-l 1 membered cycloalkyl optionally substituted with 1-6 Rlaor Rlbgroups)-A-, -(CRlaRlb)i-5-(3-ll membered heterocyclyl optionally substituted with 1-6 Rlaor Rlbgroups)-A-, -(CRlaRlb)i-5-(3-ll membered cycloalkyl optionally substituted with 1-6 Rlaor Rlbgroups)-(CRlaRlb)i-5, -(CRlaRlb)i-5-(3-l 1 membered cycloalkyl optionally substituted with 1-6 Rlaor Rlbgroups)-A- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-(3-l 1 membered cycloalkyl optionally substituted with 1-6 Rlaor Rlbgroups)-(CRlaRlb)i-5-A- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-A-(3-ll membered cycloalkyl optionally substituted with 1-6 Rlaor Rlbgroups)- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-(3-l 1 membered heterocyclyl optionally substituted with 1-6 RlaorRlbgroups)-(CRlaRlb)i-s, -(CRlaRlb)i-5-(3-l 1 membered heterocyclyl optionally substituted with 1-6 Rlaor Rlbgroups)-(CRlaRlb)i-s-A- wherein A is O, S, orNRlc, -(CRlaRlb)i-5-(3-ll membered heterocyclyl optionally substituted with 1-6 Rlaor Rlbgroups)-A- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-A-(3-l 1 membered heterocyclyl optionally substituted with 1-6 Rlaor Rlbgroups)- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-(3-11 membered cycloalkyl optionally substituted with 1-6 Rlaor Rlbgroups)-(CRlaRlb)i-s-A-wherein A is O, S, or NRlc, -(CRlaRlb)i-5-A-(3-l 1 membered cycloalkyl optionally substituted with 1-6 Rlaor Rlbgroups)- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-A-(3-l 1 membered cycloalkyl optionally substituted with 1-6 Rlaor Rlbgroups)-(CRlaRlb)i-5-A- wherein each A - 42 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application is independently O, S, or NRlc, -(CRlaRlb)i-5-A-(3-l 1 membered heterocyclyl optionally substituted with 1-6 Rlaor Rlbgroups)-(CRlaRlb)i-s-A- wherein each A is independently O, S, or NRlc, -(CRlaRlb)i-5-A-(CRlaRlb)i-5-A- wherein A is O, S, orNRlc, -(CRlaRlb)i-5-A-(CRlaRlb)i-5-A-(CRlaRlb)i-5-A-(CRlaRlb)i-5-A- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-A-(CO) wherein A is O, S, or NRlc, -(CRlaRlb)i-5-( CRla=CRlb)-(CRlaRlb)i-5-A-(CO)- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-(C=C)-(CRlaRlb)i-5-A-(CO)- wherein A is O, S, orNRlc, -(CRlaRlb)i-5-(3-l 1 membered cycloalkyl optionally substituted with 1-6 Rlaor Rlbgroups)-(CRlaRlb)i-5-A-(CO)- wherein A is O, S, orNRlc, -(CRlaRlb)i-5-A-(CO)-(3-l 1 membered cycloalkyl optionally substituted with 1-6 Rlaor Rlbgroups)- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-(3-l 1 membered heterocyclyl optionally substituted with 1-6 Rlaor Rlbgroups)-(CRlaRlb)i-5-A-(CO)- wherein A is O, S, orNRlc, -(CRlaRlb)i-5-A-(CO)-(3-l 1 membered heterocyclyl optionally substituted with 1-6 Rlaor Rlbgroups)- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-A-(3-l 1 membered cycloalkyl optionally substituted with 1-6 Rlaor Rlbgroups)-A-(CO)- wherein each A is independently O, S, orNRlc, -(3-11 membered cycloalkyl optionally substituted with 1-6 Rlaor Rlbgroups)-CO-(CRlaRlb)i-s-A- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-(3-ll membered cycloalkyl optionally substituted with 1-6 Rlaor Rlbgroups)-(CRlaRlb)i-5-A-(CO)- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-(3-l 1 membered heterocyclyl optionally substituted with 1-6 Rlaor Rlbgroups)-(CRlaRlb)i-s-A-(CO)- wherein A is O, S, or NRlc, -(3-11 membered cycloalkyl optionally substituted with 1-6 Rlaor Rlbgroups)-(CRlaRlb)i-5-, or -(3-11 membered heterocyclyl optionally substituted with 1-6 Rlaor Rlbgroups)-(CRlaRlb)i-5-

[0139] In some embodiments, Y in Formula IA is -CRla=CRlb-, such as, for example, -CH=CH-.

[0140] In some embodiments, Y in Formula IA is -(CRlaRlb)i-5, for example -(CH2)I-5-, -CH2-, -CH2CH2CH2- and the like.

[0141] In some embodiments, Y in Formula IA is -(CRlaRlb)i-5-A- wherein A is O, S, or NR1C, such as for example, -(CH2)I-5-O-, -(CH2)I-5-S-, -(CH2)I-5-NH-, or -(CH2)O-2-(C(CH3)2)-(CH2)o-2-0-.

[0142] In other embodiments, Y in Formula IA is -(CRlaRlb)i-5-A-(CRlaRlb)i-5- wherein A is O, S, orNRlc, such as, for example, -(CH2)I-5-O-(CH2)I-5-, -(CH2)I-5-S-(CH2)I-5-, -(CH2)I-5-NH-(CH2)I-5-.

[0143] In some embodiments, Y in Formula IA is -(C=C)-(CRlaRlb)i-5, such as, for example, -(C=C)-(CH2)2-, and the like.

[0144] In some embodiments, Y in Formula IA is -(CRlaRlb)i-5-(3-l 1 membered cycloalkyl optionally substituted with 1-6 Rlaor Rlbgroups)-, such as, for example, -CH2-cyclobutyl-.- 43 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0145] In some embodiments, Y in Formula IA is -(CRlaRlb)i-5-(3-l 1 membered cycloalkyl optionally substituted with 1-6 Rlaor Rlbgroups)-(CRlaRlb)i-s, such as, for example, -CH2-cyclobutyl-CH2- and the like.

[0146] In some embodiments, Y in Formula IA is -(CRlaRlb)i-5-(3-l 1 membered heterocyclyl optionally substituted with 1-6 Rlaor Rlbgroups)-(CRlaRlb)i-s, such as, for example, -CFF-azetidinyl-CFF-.

[0147] In some embodiments, Y in Formula IA is -(CRlaRlb)i-5-(3-l 1 membered heterocyclyl optionally substituted with 1-6 Rlaor Rlbgroups)-, such as, for example, -CH2-azetidinyl-.

[0148] In some embodiments, Y in Formula IA is -(3-11 membered heterocyclyl optionally substituted with 1-6 Rlaor Rlbgroups) -(CRlaRlb)i-5-, such as, for example, -azetidinyl-CFF-, -pyrolidnyl-CFF-, -piperidinyl-CFF-, and the like.

[0149] In some embodiments, Y in Formula IA is -(CRlaRlb)i-5-(3-l 1 membered cycloalkyl optionally substituted with 1-6 Rlaor Rlbgroups)-(CRlaRlb)i-s-A- wherein A is O, S, or NRlc, such as, for example, -CH2-cyclopropyl-CH2-O-, and the like.

[0150] In some embodiments, Y in Formula IA is -(CRlaRlb)i-5-(3-l 1 membered heterocyclyl optionally substituted with 1-6 Rlaor Rlbgroups)-(CRlaRlb)i-s-A- wherein A is O, S, or NRlc, such as, for example, -CFF-piperidinyl-CFFCFF-O-, and the like.

[0151] In some embodiments, Y in Formula IA is -(CRlaRlb)i-5-(3-l 1 membered heterocyclyl optionally substituted with 1-6 Rlaor Rlbgroups)-A- wherein A is O, S, or NRlc, such as, for example, -CFF-azetidinyl-O-, and the like.

[0152] In some embodiments, Y in Formula IA is -(CRlaRlb)i-5-A-(3-l 1 membered heterocyclyl optionally substituted with 1-6 Rlaor Rlbgroups)- wherein A is O, S, or NRlc, such as, for example, -CFF-O-azetidinyl-, -CFh-NH-azetidinyl-, and the like.

[0153] In other embodiments, Y in Formula IA is -(CRlaRlb)i-5-A-(3-l 1 membered cycloalkyl optionally substituted with 1-6 Rlaor Rlbgroups)- wherein A is O, S, or NRlc, such as -CH2-O-cyclobutylene-, -CH2-NH-cyclobutylene-, and the like.

[0154] In some embodiments, Y in Formula IA is -(CRlaRlb)i-5-A-(CRlaRlb)i-5-A- wherein A is O, S, or NRlc, such as, for example, -CH2-O-CH2CH2-O-.

[0155] In some embodiments, Y in Formula IA is1 1-2 1-3whereinis a point of attachment to PTM;- 44 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application Li, L2, and L3 are each independently a bond, CRlaRlb, O, S, SO, SO2, NRlc, SO2NR1C, SONR1C, SO(=NR1C), SO(=NRlc)NRld, CONRlc, NRlcCONRld, NRlcC(O)O, NRlcSO2NRld, CO, CRla=CRlb, C=C, SiRlaRlb, P(O)Rla, P(O)ORla, (CRlaRlb)i-4, -(CRlaRlb)i-4O(CRlaRlb)i-4, -(CRlaRlb)i-4S(CRlaRlb)i-4, -(CRlaRlb)i-4NRlc(CRlaRlb)i-4, NRlcC(=NCN)NRld, NRlcC(=NCN), NRlcC(=CNO2)NRld;ring Ai and ring A2 are each independently 3-12 membered cycloalkyl, optionally substituted with 1-6 Rlaor Rlbgroups, 3-12 membered heterocyclyl optionally substituted with 1-6 Rlaor Rlbgroups, aryl optionally substituted with 1-6 Rlaor Rlbgroups, or heteroaryl optionally substituted with 1-6 Rlaor Rlbgroups,wherein Rla, Rlb, Rlc, Rldand Rleare each independently, -H, D, -halo, -Ci-Csalkyl, -O-Ci-C8alkyl, -Ci-C6haloalkyl, -S-Ci-C8alkyl,-NHCi-C8alkyl, -N(Ci-C8alkyl)2, 3-11 membered cycloalkyl, aryl, heteroaryl, 3-11 membered heterocyclyl, -O-(3-ll membered cycloalkyl), -S-(3-l 1 membered cycloalkyl), NH-(3-ll membered cycloalkyl), N(3-ll membered cycloalkyl)2, N-(3-ll membered cycloalkyl)(Ci-C8alkyl), -OH, -NH2, -SH, -SO2Ci-C8alkyl, -SO2-aryl, -SO2-heteroaryl, SO(NH)Ci-C8alkyl, P(O)(OCi-C8alkyl)(Ci-C8alkyl), -P(O)(OCi-C8alkyl)2, -C=C-Ci-C8alkyl, -C=CH, -CH=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=C(Ci-C8alkyl)2, -Si(OH)3, -Si(Ci-C8alkyl)3, -Si(OH)(Ci-C8alkyl)2, -C(O)Ci-C8alkyl, -C(O)OCi-C8alkyl, -CO2H, -CN, -CF3, -CHF2, -CH2F, -NO2, -SF5, -SO2NHC1-C8alkyl, -SO2N(Ci-C8alkyl)2, -SO(NH)NHCi-C8alkyl, -SO(NH)N(Ci-C8alkyl)2, -SONHCi-Csalkyl, -SON(Ci-C8alkyl)2, -CONHCi-C8alkyl, -CON(Ci-C8alkyl)2, -N(Ci-C8alkyl)CONH(Ci-C8alkyl), -N(Ci-C8alkyl)CON(Ci-C8alkyl)2, -NHCONH(Ci-C8alkyl), -NHCON(Ci-C8alkyl)2, -NHCONH2, -N(Ci-C8alkyl)SO2NH(Ci-C8alkyl), -N(Ci-C8alkyl)SO2N(Ci-C8alkyl)2, -NHSO2NH(Ci-C8alkyl), -NHSO2N(Ci-C8alkyl)2, or -NHSO2NH2; and where Rlaor Rlb, each independently may be optionally linked to other groups to form cycloalkyl and / or heterocyclyl moiety, optionally substituted with 0-4 Rlegroups.

[0156] In some embodiments, Y in Formula IA isx"***■1 l~2L3 wherein** is a point of attachment to PTM;Li is a bond, (C(R10)2)Por CO;L2 is a bond, (C(R10)2)Por CO;L3is a bond, (C(R10)2)Por CO;each p is independently 1, 2, 3, or 4;- 45 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application each R10is independently H, D, or C1-C4 alkyl;ring Ai is a 3-7 membered cycloalkyl group, a 4-10-membered heterocycloalkyl group, an aryl group, or a heteroaryl group; andring A2 is a 3-7 membered cycloalkyl group, a 4-12-membered heterocycloalkyl group, an aryl group, or a heteroaryl group.

[0157] According to the disclosure, Li is a bond, (C(R10)2)Por CO. In some embodiments, Li is a bond. In some embodiments, Li is (C(R10)2)P. In other embodiments, Li is CO.

[0158] According to the disclosure, L2 is a bond, (C(R10)2)Por CO. In some embodiments, L2 is a bond. In some embodiments, L2 is (C(R10)2)P. In other embodiments, L2 is CO.

[0159] According to the disclosure, L3 is a bond, (C(R10)2)Por CO. In some embodiments, L3 is a bond. In some embodiments, L3 is (C(R10)2)P. In other embodiments, L3 is CO.

[0160] According to the disclosure, each p is independently 1, 2, 3, or 4. In some embodiments, each p is 1. In some embodiments, at least one p is 1. In some embodiments, each p is 2. In some embodiments, at least one p is 2. In other embodiments, each p is 3. In other embodiments, at least one p is 3. In other embodiments, each p is 4. In other embodiments, at least one p is 4.

[0161] According to the disclosure, each R10is independently H, D, or C1-C4 alkyl. In some embodiments, each R10is H. In some embodiments, at least one R10is H. In some embodiments, each R10is D. In some embodiments, at least one R10is D. In other embodiments, each R10is C1-C4 alkyl. In other embodiments, at least one R10is C1-C4 alkyl. In other embodiments, each R10is methyl or ethyl. In other embodiments, at least one R10is methyl or ethyl.

[0162] According to the disclosure, ring Ai is a 3-7 membered cycloalkyl group, a 4-10-membered heterocycloalkyl group, an aryl group, or a heteroaryl group. In some embodiments, ring Ai is a 3-7 membered cycloalkyl group. In some embodiments, ring Ai is a 4-10-membered heterocycloalkyl group. In other embodiments, ring Ai is an aryl group. In other embodiments, ring Ai is a heteroaryl group.

[0163] In some embodiments, ring Ai is a piperazine group, a morpholine group, a piperidine group, a pyrrolidine group, an azetidine group or an azabicyclo-alkyl group. In some embodiments, ring Ai is a piperazine group. In some embodiments, ring Ai is a morpholine group. In other embodiments, ring Ai is a piperidine group. In other embodiments, ring Ai is a pyrrolidine group. In yet other embodiments, ring Ai is an azetidine group. In yet other embodiments, ring Ai is an azabicyclo-alkyl group.

[0164] In other embodiments, ring Ai is a piperidine or pyrrolidine group.- 46 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0165] According to the disclosure, ring A2 is a 3-7 membered cycloalkyl group, a 4-12-membered heterocycloalkyl group, an aryl group, or a heteroaryl group. In some embodiments, ring A2 is a 3-7 membered cycloalkyl group. In some embodiments, ring A2 is a 4-12-membered heterocycloalkyl group. In other embodiments, ring A2 is an aryl group. In other embodiments, ring A2 is a heteroaryl group.

[0166] In some embodiments, ring A2 is a piperazine group, a piperidine group, a pyrrolidine group, an azaspiroalkyl group, a diazaspiroalkyl group or an azabicycloalkyl group. In some embodiments, ring A2 is a piperazine group. In some embodiments, ring A2 is a piperidine group. In other embodiments, ring A2 is a pyrrolidine group. In other embodiments, ring A2 is an azaspiroalkyl group. In yet other embodiments, ring A2 is a diazaspiroalkyl group. In yet other embodiments, ring A2 is an azabicycloalkyl group.

[0167] In other embodiments, ring A2 is a piperazine group, an azaspiroalkyl group or a diazaspiroalkyl group.

[0168] In other embodiments, ring A2 is aryl optionally substituted with 1-6 Rlaor Rlbgroups.

[0169] In some embodiments, Y in Formula IA isA11 / WL2wherein* is a point of attachment to ULM;** is a point of attachment to PTM;W is CRn orN;U is CRn orN;R11 is H, D, F, Ci-ealkyl, or Ci-ealkoxide; andeach g, h, j and k is independently 0, 1 or 2.

[0170] According to the disclosure, W is CRn or N. In some embodiments, W is N. In other embodiments, W is CRn.

[0171] According to the disclosure, U is CRn or N. In some embodiments, U is N. In other embodiments, U is CRn.

[0172] In some embodiments, W and U are N. In other embodiments, W is CRn and U are N. In yet other embodiments, W is N and U is CRn.

[0173] According to the disclosure, Rn is H, D, F, Ci-ealkyl, or Ci-ealkoxide. In some embodiments, Rn is H. In other embodiments, Rn is D. In other embodiments, Rn is F. In other embodiments, Rn is Ci-ealkyl. In other embodiments, Rn is Ci-ealkoxide.- 47 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0174] According to the disclosure, g is 0, 1 or 2. In some embodiments, g is 0. In other embodiments, g is 1. In yet other embodiments, g is 2.

[0175] According to the disclosure, h is 0, 1 or 2. In some embodiments, h is 0. In other embodiments, h is 1. In yet other embodiments, h is 2.

[0176] According to the disclosure, j is 0, 1 or 2. In some embodiments, j is 0. In other embodiments, j is 1. In yet other embodiments, j is 2.

[0177] According to the disclosure, k is 0, 1 or 2. In some embodiments, k is 0. In other embodiments, k is 1. In yet other embodiments, k is 2.

[0178] In some embodiments, j and g are each 2. In some embodiments, k and h are each 1. In other embodiments, j and g are each 1. In yet other embodiments, k and h are each 2.

[0179] In some embodiments, Y in Formula IA iswherein is a point of attachment to ULM;* is a point of attachment to PTM;each E is independently CRn or N;Rn is H, F, Ci-ealkyl, or Ci-ealkoxide; andt is 0, 1, 2 or 3.

[0180] According to the disclosure, each E is independently CRn or N. In some embodiments, each E is N. In other embodiments, one E is CRn and the other E is N. In yet other embodiments, each E is CRn.

[0181] According to the disclosure, t is 0, 1, 2 or 3. In some embodiments, t is 0. In some embodiments, t is 1. In other embodiments, t is 2. In other embodiments, t is 3.

[0182] According to the disclosure, Rn is H, D, F, Ci-ealkyl, or Ci-ealkoxide. In some embodiments, Rn is H. In other embodiments, Rn is D. In other embodiments, Rn is F. In other embodiments, Rn is Ci-ealkyl. In other embodiments, Rn is Ci-ealkoxide.

[0183] In some embodiments, Y in Formula IA isR1aR1aR1aNR1aNN- 48 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Applicationwherein * is a point of attachment to ULM and ** is a point of attachment to PTM.

[0184] In some embodiments, Y in Formula IA iswherein * is a point of attachment to ULM and ** is a point of attachment to PTM.*

[0185] In some embodiments, Y in Formula IAis wherein * is a point of attachment to ULM and ** is a point of attachment to PTM.

[0186] In other embodiments, Y in Formula IA isis a point of attachment to ULM and ** is a point of attachment to PTM.*

[0187] In other embodiments, Y in Formula IAis wherein * is a point of attachment to ULM and ** is a point of attachment to PTM.

[0188] In other embodiments,Y; wherein * is a point of attachment to ULM and ** is a point of attachment to PTM.- 49 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0189] In yet other embodiments, Y in Formula IAis wherein is a point of attachment to ULM and ** is a point of attachment to PTM.

[0190] In yet other embodiments, Y in Formula IAis wherein * is a point of attachment to ULM and ** is a point of attachment to PTM.

[0191] According to the disclosure, Y-PTM is a compound of formula IA-1(IA-1)or a pharmaceutically acceptable salt thereof; wherein R2, R3, R4, R5and Y are as defined herein.

[0192] According to the disclosure, Y-PTM is a compound of formula IA-2or a pharmaceutically acceptable salt thereof; wherein R2, R3, R4, R5, L2, ring Ai and ring A2 are as defined herein.

[0193] According to the disclosure, ring Ai is selected from:; wherein is a point of attachment to L2 and * is a point of attachment to ULM.- 50 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0194] In some embodiments, ring Ai is* whereinis a point of attachment to L2 and * is a point of attachment to ULM.

[0195] In some embodiments, ring Ai is* whereinis a point of attachment to L2 and * is a point of attachment to ULM.

[0196] In some embodiments, ring Ai is; whereinis a point of attachment to L2 and * is a point of attachment to ULM.

[0197] In other embodiments, ring Ai is; whereinis a point of attachment to L2 and * is a point of attachment to ULM.

[0198] In other embodiments, ring Ai is; whereinis a point of attachment to L2 and * is a point of attachment to ULM.

[0199] In other embodiments, ring Ai is; whereinis a point of attachment to L2 and * is a point of attachment to ULM.

[0200] In yet other embodiments, ring Ai is *; whereinis a point of attachment to L2 and * is a point of attachment to ULM.N

[0201] In yet other embodiments, ring Ai is *; whereinis a point of attachment to L2 and * is a point of attachment to ULM.

[0202] According to the disclosure, ring A2 is selected from:- 51 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application- 52 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0203] In some embodiments, ring A2 is \ whereinis a point of attachment to PLM and * is a point of attachment to L2.

[0204] In some embodiments, ring A2 is; whereinis a point of attachment to PLM and * is a point of attachment to L2.

[0205] In some embodiments, ring A2 is; whereinis a point of attachment to PLM and * is a point of attachment to L2.

[0206] In some embodiments, ring A2 is *; whereinis a point of attachment to PLM and * is a point of attachment to L2.

[0207] In some embodiments, ring A2 is*; whereinis a point of attachment to PLM and * is a point of attachment to L2.

[0208] In some embodiments, ring A2 is*; whereinis a point of attachment to PLM and * is a point of attachment to L2.- 53 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0209] In some embodiments, ring A H2 is; whereinis a point of attachment to PLM and * is a point of attachment to L2.

[0210] In some embodiments, ring A2 is*H; whereinis a point of attachment to PLM and * is a point of attachment to L2.

[0211] In some embodiments, ring A2 is whereinis a point of attachment to PLM and * is a point of attachment to L2.

[0212] In some embodiments, ring A2 is*; whereinis a point of attachment to PLM and * is a point of attachment to L2.

[0213] In some embodiments, ring A2 is; whereinis a point of attachment to PLM and * is a point of attachment to L2.

[0214] In some embodiments, ring A2 is; wherein ■r'JJis a point of attachment to PLM and * is a point of attachment to L2.

[0215] In other embodiments, ring A2 is; whereinis a point of attachment to PLM and * is a point of attachment to L2.- 54 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0216] In other embodiments, ring A2 is*; whereinis a point of attachment to PLM and * is a point of attachment to L2.

[0217] In other embodiments, ring A2 is \ whereinis a point of attachment to PLM and * is a point of attachment to L2.

[0218] In other embodiments, ring A2 is; whereinis a point of attachment to PLM and * is a point of attachment to L2.

[0219] In other embodiments, ring A2 is * \ whereinis a point of attachment to PLM and * is a point of attachment to L2.

[0220] In other embodiments, ring A2 is; whereinis a point of attachment to PLM and * is a point of attachment to L2.

[0221] In other embodiments, ring A2 is; whereinis a point of attachment to PLM and * is a point of attachment to L2.

[0222] In other embodiments, ring A2 is; whereinis a point of attachment to PLM and * is a point of attachment to L2.- 55 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0223] In other embodiments, ring A2 is \ whereinis a point of attachment to PLM and * is a point of attachment to L2.

[0224] In other embodiments, ring A2 is whereinis a point of attachment to PLM and * is a point of attachment to L2.

[0225] In other embodiments, ring A2 is whereinis a point of attachment to PLM and * is a point of attachment to L2.

[0226] In other embodiments, ring A2 is whereinis a point of attachment to PLM and * is a point of attachment to L2.CN

[0227] In other embodiments, ring A2 is*; whereinis a point of attachment to PLM and * is a point of attachment to L2.CF3

[0228] In other embodiments, ring A2 is*; whereinis a point of attachment to PLM and * is a point of attachment to L2.

[0229] In yet other embodiments, ring A2 isCF3; whereinis a point of attachment to PLM and * is a point of attachment to L2.- 56 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Applicationz0

[0230] In yet other embodiments, ring A2 isF3C; whereinis a point of attachment to PLM and * is a point of attachment to L2.

[0231] In yet other embodiments, ring A2 is *; wherein •T’4'’ is a point of attachment to PLM and * is a point of attachment to L2.

[0232] In yet other embodiments, ring A2 is *; whereinis a point of attachment to PLM and * is a point of attachment to L2.

[0233] In yet other embodiments, ring A2 is; whereinis a point of attachment to PLM and * is a point of attachment to L2.

[0234] In yet other embodiments, ring A2 is; whereinis a point of attachment to PLM and * is a point of attachment to L2.

[0235] In yet other embodiments, ring A2 is * \ whereinis a point of attachment to PLM and * is a point of attachment to L2.

[0236] In yet other embodiments, ring A2 is * \ whereinis a point of attachment to PLM and * is a point of attachment to L2.- 57 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0237] In yet other embodiments, ring A2 is \ whereinis a point of attachment to PLM and * is a point of attachment to L2.

[0238] In yet other embodiments, ring A2 is0; whereinis a point of attachment to PLM and * is a point of attachment to L2.

[0239] According to the disclosure, Y-PTM is a compound of formula IA-3R2(IA-3);

[0240] or a pharmaceutically acceptable salt thereof; wherein R2, R3, R4, R5, R11, L2, ring Ai, W, U, j, k, g and h are as defined herein.

[0241] According to the disclosure, Y-PTM is a compound of formula IA-4R5R2(IA-4) or a pharmaceutically acceptable salt thereof; wherein R2, R3, R4, R5, R11, L2, ring Ai, W and U are as defined herein.

[0242] According to the disclosure, Y-PTM is a compound of formula IA-5R5(IA-5) or a pharmaceutically acceptable salt thereof; wherein R2, R3, R4, R5, R11, L2, ring Ai, W and U are as defined herein.- 58 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0243] According to the disclosure, Y-PTM is a compound of formula IA-6R5(IA-6); or a pharmaceutically acceptable salt thereof; wherein R2, R3, R4, R5, R11, W and U are as defined herein; and whereineach E is independently CRn or N; andt is 0, 1, 2 or 3.

[0244] According to the disclosure, each E is independently CRn or N. In some embodiments, each E is N. In other embodiments, one E is CRn and the other E is N. In yet other embodiments, each E is CRn.

[0245] According to the disclosure, t is 0, 1, 2 or 3. In some embodiments, t is 0. In some embodiments, t is 1. In other embodiments, t is 2. In other embodiments, t is 3.

[0246] According to the disclosure, Rn is H, D, F, Ci-ealkyl, or Ci-ealkoxide. In some embodiments, Rn is H. In other embodiments, Rn is D. In other embodiments, Rn is F. In other embodiments, Rn is Ci-ealkyl. In other embodiments, Rn is Ci-ealkoxide.

[0247] According to the disclosure, Y-PTM is a compound of formula IA-7(IA-7); or a pharmaceutically acceptable salt thereof; wherein R2, R3, R4, R5, R11, W, U, E and t are as defined herein.

[0248] According to the disclosure, Y-PTM is a compound of formula IA-8(IA-8);or a pharmaceutically acceptable salt thereof; wherein R2, R3, R4, R5, R11, L2, ring A2, E and t are as defined herein.- 59 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0249] According to the disclosure, Y-PTM is a compound of formula IA-9or a pharmaceutically acceptable salt thereof; wherein R2, R3, R4, R5, R11, ring A2 and E are as defined herein.

[0250] According to the disclosure, any of the -Ci-Cealkyl, Ci-Cs alkoxide, -C2-Cealkenyl, -C2-Cealkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, spirocycloalkyl, spiroheterocycloalkyl and spiroheterocycloalkenyl groups in any of R1-R15 and ring A is optionally substituted by 1-6 Rfgroups.

[0251] In some embodiments, each Rfin Formula I is independently D, oxo, halogen, Ci-Cs alkoxy, Ci-Cs alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, -OH, -CN, -NO2, -C2-C6 alkenyl, -C2-C6 alkynyl, Ce-io aryl, C5-12 heteroaryl, C3-8 cycloalkyl, C3-8 cycloalkenyl, C3-8 heterocycloalkyl, C3-8 heterocycloalkenyl, -ORa, -SRa, -NRcRd, -NRaRc, -C(O)Rb, -OC(O)Rb, -C(O)ORb, -C(O)NRcRd, -S(O)Rb, -S(O)2NRcRd, -S(O)(=NRb)Rb, -SF5, -P(O)RbRb, -P(O)RcRd, -P(O)(ORb)(ORb), -B(ORc)(ORd), -S(O)2Rb, -C(O)NRbORb, -S(O)2ORb, -OS(O)2ORb, or -OPO(ORb)(ORb); wherein said Ci-Cs alkyl is optionally substituted by 1-6 groups selected from D, halogen, -OH, -CN, -ORa, -SRa, -NRaRd, or NRcRd.

[0252] In some embodiments, at least one Rfin Formula I is D. In some embodiments, at least one Rfin Formula I is oxo. In some embodiments, at least one Rfin Formula I is halogen. In some embodiments, at least one Rfin Formula I is Ci-Cs alkoxy. In some embodiments, at least one Rfin Formula I is Ci-Cs alkyl. In some embodiments, the Ci-Cs alkyl is optionally substituted by 1-6 groups selected from D, halogen, -OH, -CN, -ORa, -SRa, -NRaRd, or NRcRd. In some embodiments, at least one Rfin Formula I is haloalkyl. In some embodiments, at least one Rfin Formula I is -OH. In some embodiments, Rfin Formula I is -CN. In some embodiments, at least one Rfin Formula I is -NO2. In some embodiments, at least one Rfin Formula I is -C2-C6 alkenyl. In some embodiments, at least one Rfin Formula I is -C2-C6 alkynyl. In some embodiments, at least one Rfin Formula I is Ce-io aryl. In some embodiments, at least one Rfin Formula I is C5-12 heteroaryl. In some embodiments, at least one Rfin Formula I is C3-8 cycloalkyl. In other embodiments, at least one Rfin Formula I is C3-8 cycloalkenyl. In other embodiments, at least one Rfin Formula I is C3-8 heterocycloalkyl. In other embodiments, at least one Rfin Formula I is C3-8 heterocycloalkenyl. In other- 60 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application embodiments, at least one Rfin Formula I is -ORa. In other embodiments, at least one Rfin Formula I is -SRa. In other embodiments, at least one Rfin Formula I is -NRcRd. In other embodiments, at least one Rfin Formula I is -NRaRc. In other embodiments, at least one Rfin Formula I is -C(O)Rb. In other embodiments, at least one Rfin Formula I is -OC(O)Rb. In other embodiments, at least one Rfin Formula I is -C(O)ORb. In other embodiments, at least one Rfin Formula I is -C(O)NRcRd. In yet other embodiments, at least one Rfin Formula I is -S(O)Rb. In yet other embodiments, at least one Rfin Formula I is -S(O)2NRcRd. In yet other embodiments, at least one Rfin Formula I is -S(O)(=NRb)Rb. In yet other embodiments, at least one Rfin Formula I is -SF5. In yet other embodiments, at least one Rfin Formula I is -P(O)RbRb. In yet other embodiments, at least one Rfin Formula I is -P(O)(ORb)(ORb). In yet other embodiments, at least one Rfin Formula I is -B(ORc)(ORd). In yet other embodiments, at least one Rfin Formula I is -S(O)2Rb. In yet other embodiments, at least one Rfin Formula I is -C(O)NRbORb. In yet other embodiments, at least one Rfin Formula I is -S(O)2ORb. In yet other embodiments, at least one Rfin Formula I is -OS(O)2ORb. In yet other embodiments, at least one Rfin Formula I is -OPO(ORb)(ORb).

[0253] In some embodiments, each Rain Formula I is independently H, D, -C(O)Rb, -C(O)ORC, -C(O)NRcRd, -C(=NRb)NRbRc, -C(=NORb)NRbRc, -C(=NCN)NRbRc, -P(ORC)2, -P(O)RcRb, -P(O)ORcORb, -S(O)Rb, -S(O)NRcRd, -S(O)2Rb, -S(O)2NRcRd, SiR\ -Ci-Cioalkyl, -Ci-Ciohaloalkyl, -C2-C10 alkenyl, -C2-C10 alkynyl, Ce-io aryl, C3-8 cycloalkyl, C3-8 cycloalkenyl, C5-12 heteroaryl, C3-8 heterocycloalkyl, or C3-8 heterocycloalkenyl.

[0254] In some embodiments, at least one Rain Formula I is H. In some embodiments, at least one Rain Formula I is D. In some embodiments, at least one Rain Formula I is -C(O)Rb. In some embodiments, at least one Rain Formula I is -C(O)ORC. In some embodiments, at least one Rain Formula I is -C(O)NRcRd. In some embodiments, at least one Rain Formula I is -C(=NRb)NRbRc. In some embodiments, at least one Rain Formula I is C(=NORb)NRbRc. In some embodiments, at least one Rain Formula I is -C(=NCN)NRbRc.

[0255] In other embodiments, at least one Rain Formula I is -P(ORC)2, -P(O)RcRb, -P(O)ORcORb, -S(O)Rb, -S(O)NRcRd, -S(O)2Rb, -S(O)2NRcRd, SiRb3, and the like. In yet other embodiments, at least one Rain Formula I is -Ci-Cioalkyl, -Ci-Ciohaloalkyl, -C2-C10 alkenyl, -C2-C10 alkynyl, Ce-io aryl, C3-8 cycloalkyl, C3-8 cycloalkenyl, C5-12 heteroaryl, C3-8 heterocycloalkyl, C3-8 heterocycloalkenyl, and the like.

[0256] In some embodiments, each Rbin Formula I is independently H, D, -Ci-Ce alkyl, -Ci-Cehaloalkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, Ce-io aryl, C3-8 cycloalkyl, C3-8 cycloalkenyl, C5-12 heteroaryl, C3-8 heterocycloalkyl, or C3-8 heterocycloalkenyl.- 61 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0257] In some embodiments, at least one Rbin Formula I is H. In some embodiments, at least one Rbin Formula I is D. In some embodiments, at least one Rbin Formula I is -Ci-Ce alkyl. In some embodiments, at least one Rbin Formula I is -Ci-Ce haloalkyl. In some embodiments, at least one Rbin Formula I is -C2-C6 alkenyl. In some embodiments, at least one Rbin Formula I is -C2-C6 alkynyl. In other embodiments, at least one Rbin Formula I is Ce-io aryl. In other embodiments, at least one Rbin Formula I is C3-8 cycloalkyl. In other embodiments, at least one Rbin Formula I is C3-8 cycloalkenyl. In other embodiments, at least one Rbin Formula I is C5-12 heteroaryl. In other embodiments, at least one Rbin Formula I is C3-8 heterocycloalkyl. In other embodiments, at least one Rbin Formula I is C3-8 heterocycloalkenyl.

[0258] In some embodiments, each Rcor Rdin Formula I is independently H, D, -Ci-Ce alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, Ce-io aryl, C3-8 cycloalkyl, C3-8 cycloalkenyl, C5-12 heteroaryl, C3-8 heterocycloalkyl, or C3-8 heterocycloalkenyl.

[0259] In some embodiments, Rcor Rdin Formula I is H. In some embodiments, Rcor Rdin Formula I is D. In some embodiments, Rcor Rdin Formula I is -C1-C10 alkyl. In some embodiments, Rcor Rdin Formula I is -C2-C6 alkenyl. In some embodiments, Rcor Rdin Formula I is -C2-C6 alkynyl. In other embodiments, Rcor Rdin Formula I is -OCi-Cealkyl. In other embodiments, Rcor Rdin Formula I is -O-cycloalkyl. In other embodiments, Rcor Rdin Formula I is Ce-io aryl. In other embodiments, Rcor Rdin Formula I is C3-8 cycloalkyl. In other embodiments, Rcor Rdin Formula I is C3-8 cycloalkenyl. In other embodiments, Rcor Rdin Formula I is C5-12 heteroaryl. In other embodiments, Rcor Rdin Formula I is C3-8 heterocycloalkyl. In other embodiments, Rcor Rdin Formula I is C3-8 heterocycloalkenyl. In yet other embodiments, Rcand Rdin Formula I, together with the atom to which they are both attached, form a monocyclic or multicyclic heterocycloalkyl, or a monocyclic or multi cyclic heterocycloalkenyl group. In yet other embodiments, Rcand Rdin Formula I form a monocyclic heterocycloalkyl. In yet other embodiments, Rcand Rdin Formula I form a multicyclic heterocycloalkyl. In yet other embodiments, Rcand Rdin Formula I form a monocyclic heterocycloalkenyl group. In yet other embodiments, Rcand Rdin Formula I form a multicyclic heterocycloalkenyl group.

[0260] In some embodiments, the compounds disclosed herein are7V-(6-((l / 7-Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(7-(((3S)-l-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-l / 7-indazol-5-yl)pyrrolidin-3-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)benzenesulfonamide;- 62 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application 7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(7-((l-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-17 / -benzo[J]imidazol-5-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)benzenesulfonamide;7V-(6-((177-Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(7-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)pyrrolidin-3-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)benzenesulfonamide;7V-(6-((177-Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-l7 / -pyrrolo[3,2-c]pyridin-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)benzenesulfonamide;7V-(6-((177-Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(7-((l-(2-(2,6-dioxopiperidin-3-yl)-l-oxo-l,2-dihydroisoquinolin-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-methoxybenzenesulfonamide;7V-(6-((177-Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(7-((l-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-IT / -indazol-5-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-methoxybenzenesulfonamide;7V-(6-((177-Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-IT / -indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-methoxybenzenesulfonamide;7V-(6-((177-Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(7-((l-(6-(2,6-dioxopiperidin-3-yl)-l-methyl-IT / -indazol-3-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-methoxybenzenesulfonamide;7V-(6-((177-Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-l7 / -pyrrolo[2,3- / i]pyridin-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-methoxybenzenesulfonamide;7V-(6-((177-Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(7-((l-(3-(2,4-dioxotetrahydropyrimidin- 1 (27 / )-yl)- 1 -methyl-lJ7-indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2,4-dimethoxybenzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lJH-indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2,6-dimethoxybenzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-4-(7-((l-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-lJH-indazol-5-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)benzenesulfonamide;- 63 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application 7V-(6-((lJ7-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-4-(7-((l-(2-(2,6-dioxopiperidin-3-yl)-l-oxo-l,2-dihydroisoquinolin-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)benzenesulfonamide;7V-(6-((177-Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-4-(7-((l-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-IT / -indazol-5-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-methoxybenzenesulfonamide;7V-(6-((177-Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-4-(7-((l-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-17 / -benzo[J]imidazol-5-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-methoxybenzenesulfonamide;7V-(6-((177-Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-4-(4-((l-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-17 / -benzo[J]imidazol-5-yl)piperidin-4-yl)methyl)-3,3-dimethylpiperazin-l-yl)benzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-4-((3a5',6a5)-5-((l-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-17 -benzo[ ]imidazol-5-yl)piperidin-4-yl)methyl)hexahydropyrrolo[3,4-c]pyrrol-2(177)-yl)benzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-4-((3a7?,6a5)-5-((l-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-17 -benzo[ ]imidazol-5-yl)piperidin-4-yl)methyl)hexahydropyrrolo[3,4-c]pyrrol-2(177)-yl)-2-methoxybenzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(9-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)-3,9-diazaspiro[5.5]undecan-3-yl)benzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(9-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-IT / -indazol-6-yl)piperidin-4-yl)methyl)-3,9-diazaspiro[5.5]undecan-3-yl)benzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lJH-indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-(2,2,2-trifluoroethoxy)benzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-2-chloro-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lJH-indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)benzenesulfonamide;N-(6-((177-Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lJH-indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2-methoxybenzenesulfonamide;- 64 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application 7V-(6-((lJ7-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-5-chloro-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-IT / -indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-methoxybenzenesulfonamide;7V-(6-((177-Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-IT / -indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-methoxy-5-methylbenzenesulfonamide;7V-(6-((l#-pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-IT / -indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-(trifluoromethyl)benzenesulfonamide;7V-(6-((l -pyrazol-l-yl)methyl)-4-methoxybenzo|7 / / isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-IT / -indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-fluorobenzenesulfonamide;7V-(6-((177-Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-IT / -indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;7V-(6-((177-Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-5-(7-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-methylbenzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(7-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-methylbenzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-4-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-IT / -indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-methylbenzenesulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-4-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-ethylbenzenesulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-4-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-(trifluoromethoxy)benzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-l#-indazol-6-yl)piperidin-4-yl)methyl)-7-azaspiro[3.5]nonan-2-yl)benzenesulfonamide;- 65 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application 7V-(6-((177-Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(2-((4-(3-(2,4-dioxotetrahydropyrimidin- 1 (27 / )-yl )- 1 -methyl- l / 7-indazol-6-yl)piperi din- 1 -yl)methyl)-7-azaspiro[3.5]nonan-7-yl)benzenesulfonamide;7V-(6-((lJ7-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(2-((4-(3-(2,6-di oxopiperi din-3 -yl)- 1 -methyl- l / 7-indazol-6-yl)piperidin- 1 -yl)methyl)-7-azaspiro[3.5]nonan-7-yl)benzenesulfonamide;7V-(6-((lJ7-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(2-((4-((l-(2,6-di oxopiperi din-3-yl)-3-methyl-2-oxo-2,3-dihydro-l / / -benzo[ ]imidazol -4-yl)ethynyl)piperidin-l-yl)methyl)-7-azaspiro[3.5]nonan-7-yl)benzenesulfonamide;7V-(6-((l / 7-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-4'-((4-(3-(2,4-dioxotetrahydropyrimidin-l(2J7)-yl)-l-methyl-l / 7-indazol-6-yl)piperidin-l-yl)methyl)-2,4-dimethoxy-[ 1, 1 '-biphenyl]-3 -sulfonamide;or a pharmaceutically acceptable salt thereof.

[0261] In some embodiments, the compounds disclosed herein are3-(7-((l-(3-(2,6-Dioxopiperidin-3-yl)-l-methyl-l / 7-indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxy-7V-(4-methoxy-6-(methoxymethyl)-benzo[t / ]isoxazol-3-yl)benzenesulfonamide;3-(7-((l-(3-(2,4-Dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)-piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxy-N-(4-methoxy-6-(methoxymethyl)benzo[d]isoxazol-3-yl)benzenesulfonamide;3-(7-((l-(3-(2,6-Dioxopiperidin-3-yl)-l-methyl-lH-pyrrolo[2,3-b]pyridin-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxy-N-(4-methoxy-6-(methoxy-methyl)benzo[d]isoxazol-3-yl)benzenesulfonamide;3-(2-((l -(3-(2, 6-Dioxopiperi din-3 -yl)-l-methyl-lH-indazol-6-yl)piperi din-4-yl)methyl)-l,2,3,4-tetrahydroisoquinolin-6-yl)-5-fluoro-2,6-dimethoxy-N-(4-methoxy-6-(methoxymethyl)-benzo[d]isoxazol-3-yl)benzenesulfonamide;3-(2-((l-(3-(2,4-Dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)-piperidin-4-yl)methyl)-l,2,3,4-tetrahydroisoquinolin-6-yl)-5-fluoro-2,6-dimethoxy-N-(4-methoxy-6-(methoxymethyl)benzo[d]isoxazol-3-yl)benzenesulfonamide;4'-((4-(3-(2, 6-Dioxopiperi din-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-l-yl)methyl)-5-fluoro-2,4-dimethoxy-N-(4-methoxy-6-(methoxymethyl)benzo[d]isoxazol-3-yl)-3'-methyl-[1,1 '-biphenyl]-3 -sulfonamide;4'-((4-(3-(2,4-Dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperidin-l-yl)methyl)-5-fluoro-2,4-dimethoxy-N-(4-methoxy-6-(methoxymethyl)benzo-[d]isoxazol-3-yl)-3'-methyl-[l,l'-biphenyl]-3-sulfonamide;- 66 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application N-(6-(( IH-Pyrazol- 1 -yl)methyl)-4-methoxybenzo[d]isoxazol-3 -y l)-3 -(7 -(( 1 -(3 -(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;rac-3 -((ci s)-3 -(( 1 -(3 -(2,4-Dioxotetrahy dropyrimidin- 1 (2H)-yl)- 1 -methyl- 1 H-indazol -6-yl)piperidin-4-yl)methyl)-3,7-diazabicyclo[4.2.0]octan-7-yl)-5-fluoro-2,6-dimethoxy-N-(4-methoxy-6-(methoxymethyl)benzo[d]isoxazol-3-yl)benzenesulfonamide;3-((l-(3-(2,6-Dioxopiperidin-3-yl)-l-methyl-lH-pyrrolo[2,3-b]pyridin-6-yl)piperidin-4-yl)methyl)-3,7-diazabicyclo[4.2.0]octan-7-yl)-5-fluoro-2,6-dimethoxy-N-(4-methoxy-6-(methoxymethyl)benzo[d]isoxazol-3-yl)benzenesulfonamide;rac-3 -((ci s)-3 -(( 1 -(3 -(2,4-Dioxotetrahy dropyrimidin- 1 (2H)-yl)- 1 -methyl- 1 H-indazol -6-yl)piperidin-4-yl)methyl)-3,7-diazabicyclo[4.2.0]octan-7-yl)-2 -methoxy -N-(4-methoxy-6-(methoxymethyl)benzo[d]isoxazol-3-yl)-5-(trifluoromethyl)benzenesulfonamide;3-((l-(3-(2,6-Dioxopiperidin-3-yl)-l-methyl-lH-pyrrolo[2,3-b]pyridin-6-yl)piperidin-4-yl)methyl)-3,7-diazabicyclo[4.2.0]octan-7-yl)-2-methoxy-N-(4-methoxy-6-(methoxymethyl)-benzo[d]isoxazol-3-yl)-5-(trifluoromethyl)benzenesulfonamide;7V-(6-((l / 7-pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(6-((l-(3-(2,4-dioxotetrahydropyrimidin-l(2J7)-yl)-l-methyl-l / 7-indazol-6-yl)piperidin-4-yl)methyl)-5,6,7,8-tetrahydro-l,6-naphthyridin-2-yl)-5-fluoro-2,6-dimethoxybenzene-sulfonamide;N-(6-(( 1 H-pyrazol - 1 -yl)methyl)-4-methoxybenzo[d]i soxazol -3 -y 1 ) -3 -(7 -(( 1 -(4-(2, 6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;rac-3-(cis)-N-(6-((lH-pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-((l-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)-piperidin-4-yl)methyl)-3,7-diazabicyclo[4.2.0]octan-7-yl)-5-fluoro-2,6-dimethoxy -benzenesulfonamide;or a pharmaceutically acceptable salt thereof.

[0262] In some embodiments, the compounds disclosed herein are7V-(6-((l / 7-Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(7-((4-(3-(2,4-dioxotetrahydropyrimidin-l(2J7)-yl)-l-methyl-l / 7-indazol-6-yl)piperazin-l-yl)methyl)-2-azaspiro[3.5]nonan-2-yl)benzenesulfonamide;7V-(6-((l / 7-Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(7-((4-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-l-yl)methyl)-2-azaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;N-(6-(( 1 H-Pyrazol- 1 -yl)methyl)-4-m ethoxyb enzo[d]i soxazol -3 -y 1 ) -3 -(7 -(( 1 -(3 -(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)benzenesulfonamide;- 67 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application N-(6-(( IH-Pyrazol- 1 -yl)methyl)-4-methoxybenzo[d]isoxazol-3 -y l)-3 -(7 -(( 1 -(3 -(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-pyrazolo[3,4-b]pyridin-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2,6-dimethoxybenzenesulfonamide;N-(6-(( 1 H-Pyrazol- 1 -yl)methyl)-4-m ethoxyb enzo[d]i soxazol -3 -y 1 ) -3 -(7 -(( 1 -(3 -(2,6-dioxopiperidin-3-yl)-l-methyl-lH-pyrazolo[3,4-b]pyridin-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;N-(6-(( IH-Pyrazol- 1 -yl)methyl)-4-methoxybenzo[d]isoxazol-3 -y l)-3 -(7 -(( 1 -(3 -(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-7-fluoro-l-methyl-lH-indazol-6-yl)piperi din-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(4-((7-(3-(2,4-dioxotetrahy dropyrimidin- 1 (2H)-yl)- 1 -methyl - 1 H-indazol -6-yl) -7 -azaspiro[3.5 ]nonan-2-yl)methyl)piperazin-l-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(6-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)-5,6,7,8-tetrahydro-l,6-naphthyridin-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-4'-((4-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperidin-l-yl)methyl)-2,4-dimethoxy-3'-methyl-[l,l'-biphenyl]-3-sulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-4'-((4-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperidin-l-yl)methyl)-2,2',4-trimethoxy-[ 1, 1 '-biphenyl]-3 -sulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-4'-((4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-pyrrolo[2,3-b]pyridin-6-yl)piperidin-l-yl)methyl)-2,3',4-trimethoxy-[ 1, 1 '-biphenyl]-3 -sulfonamide;N-(6-(( 1 H-Pyrazol- 1 -yl)methyl)-4-m ethoxybenzo [d]i soxazol -3 -y 1 ) -4 ' -((4-(3 -(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-l-yl)methyl)-2,4-dimethoxy-3'-(trifluoromethoxy)-[ 1, 1 '-biphenyl]-3 -sulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-4'-((4-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperidin-l-yl)methyl)-2'-fluoro-2,4-dimethoxy-[ 1, 1 '-biphenyl]-3 -sulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-4'-((4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-l-yl)methyl)-3'-fluoro-2,4-dimethoxy-[ 1, 1 '-biphenyl]-3 -sulfonamide;- 68 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-4'-((4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-l-yl)methyl)-2',5'-difluoro-2,4-dimethoxy-[ 1, 1 '-biphenyl]-3 -sulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-4'-((4-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperidin-l-yl)methyl)-2,4-dimethoxy-3'-(trifluoromethyl)-[l,r-biphenyl]-3-sulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-4'-((4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-l-yl)methyl)-2,4-dimethoxy-2'-(trifluoromethyl)-[ 1, 1 '-biphenyl]-3 -sulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-2'-cyano-4'-((4-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperidin-l-yl)methyl)- 2.4-dimethoxy-[ 1, 1 '-biphenyl]-3 -sulfonamide;N-(6-(( 1 H-Pyrazol- 1 -yl)methyl)-4-m ethoxyb enzo[d]i soxazol -3 -y 1 ) -3 -(5 -((4-(3 -(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-l-yl)methyl)thiophen-3-yl)-2,6-dimethoxybenzenesulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(2-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)-l,2,3,4-tetrahydro-isoquinolin-6-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(2-((l-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)-isoindolin-5-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(2-((l-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)- 1.2.3.4-tetrahydroisoquinolin-6-yl)-6-fluoro-2 -methoxybenzenesulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(2-((l-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)- 1.2.3.4-tetrahydroisoquinolin-7-yl)-2-methoxy-5-(trifluoromethyl)benzenesulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-5-(tert-butyl)-3-(6-((l-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)-5,6,7,8-tetrahydro-l,6-naphthyridin-2-yl)-2-methoxybenzenesulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(2-((4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-l-yl)methyl)pyrimidin-5-yl)-2,6-dimethoxybenzenesulfonamide;- 69 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(6-((4-(3-(2,6-dioxopiperi din-3-yl)-l -methyl-lH-indazol-6-yl)piperidin-l-yl)methyl)-2-methylpyri din-3 -yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-4'-(4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidine-l-carbonyl)-2,4-dimethoxy-[l,r-biphenyl]-3-sulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(l-((l-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)-piperidin-4-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(4-((4-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperidin-l-yl)methyl)cyclo-hexyl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;7V-(6-((lJ7-Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(3-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lJH-indazol-6-yl)piperidin-4-yl)methyl)-3-azaspiro[5.5]-undecan-9-yl)-2,6-dimethoxybenzenesulfonamide;7V-(6-((lJ7-Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-((l-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lJH-pyrrolo[2,3- ’]pyridin-6-yl)piperidin-4-yl)methyl)piperidin-4-yl)methyl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-4'-((4-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperidin-l-yl)methyl)-2,4-dimethoxy-[ 1, 1 '-biphenyl]-3 -sulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-4'-((4-(3-(2,4-dioxotetrahy dropyrimidin- 1 (2J7)-yl)- 1 -methyl - 1 / 7-indazol -6-yl)piperazin- 1 -yl)methyl)-5 -fluoro-2,4-dimethoxy-2'-(trifluoromethyl)-[l,r-biphenyl] -3 -sulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-4'-((3-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-IT / -indazol-6-yl)pyrrolidin-l-yl)methyl)-5-fluoro-2,4-dimethoxy -2'-(trifluoromethyl)-[ 1, 1 '-biphenyl]-3 -sulfonamide;rac-N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-((3a,7a)-5-((l-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)octahydro-2H-pyrrolo[3,4-c]pyridin-2-yl)-5-fluoro-2,6-dimethoxy-benzenesulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-((4aR,8aR)-6-((l-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)octahydro-2,6-naphthyridin-2(lH)-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;- 70 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-((3aR,6aR)-5-((l-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-ethyl-lH-indazol-6-yl)piperidin-4-yl)methyl)hexahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)-2,6-dimethoxybenzenesulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(ll-((l-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)-3,l 1-diazadispiro[5.1.58.16]tetradecan-3-yl)-2,6-dimethoxybenzenesulfonamide;N-(6-(( IH-Pyrazol- 1 -yl)methyl)-4-methoxybenzo[d]isoxazol-3 -y l)-3 -(7 -(( 1 -(3 -(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-ethyl-lH-indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;N-(6-(( 1 H-Pyrazol- 1 -yl)methyl)-4-m ethoxyb enzo[d]i soxazol -3 -y 1 ) -3 -(7 -(( 1 -(4-(2, 6-dioxopiperidin-3-yl)-2-methylphenyl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;N-(6-(( 1 H-Pyrazol- 1 -yl)methyl)-4-m ethoxyb enzo[d]i soxazol -3 -y 1 ) -3 -(7 -(( 1 -(4-(2, 6-dioxopiperidin-3-yl)-3-fluorophenyl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-methoxybenzenesulfonamide;N-(6-(( 1 H-Pyrazol- 1 -yl)methyl)-4-m ethoxyb enzo[d]i soxazol -3 -y 1 ) -3 -(7 -(( 1 -(4-(2, 6-dioxopiperidin-3-yl)-3,5-difluorophenyl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2 -methoxybenzenesulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(7-(2-(l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)ethyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;N-(6-(( 1 H-Pyrazol- 1 -yl)methyl)-4-m ethoxyb enzo[d]i soxazol -3 -y 1 ) -3 -(7 -(((3 S ) - 1 -( 1 -(2,6-dioxopiperidin-3-yl)-3-methyl-lH-indazol-5-yl)pyrrolidin-3-yl)methyl)-2,7-diazaspiro-[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(7-(((3S)-l-(4-(2,6-dioxopiperidin-3-yl)phenyl)pyrrolidin-3-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(7-(((3R,4S)-l-(4-(2,6-dioxopiperidin-3-yl)phenyl)-3-fluoropiperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;N-(6-(( IH-Pyrazol- 1 -yl)methyl)-4-methoxybenzo[d]isoxazol-3 -y l)-3 -(7 -(( 1 -(3 -(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-pyrrolo[2,3-b]pyridin-6-yl)-4-fluoro-piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-methoxybenzenesulfonamide;- 71 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application 3-[7-[[4-[4-(2,6-Dioxopiperidin-3-yl)phenyl]piperazin-l-yl]methyl]-2-azaspiro-[3.5]nonan-2-yl]-5-fluoro-2 -methoxy -N-[4-methoxy-6-(pyrazol-l -ylmethyl)-l, 2-benzoxazol-3-yl]benzenesulfonamide;7V-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-((lS,6S)-3-((l-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)-3,7-diazabicyclo[4.2.0]octan-7-yl)-2-methoxy-6-methylbenzenesulfonamide;7V-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-5-fluoro-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;7V-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-((3R)-3-((4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-l-yl)methyl)piperidin-l-yl)-2,6-dimethoxybenzenesulfonamide;3-[6-[[4-[3-(2,6-Dioxopiperidin-3-yl)-l-methylindazol-6-yl]piperidin-l-yl]methyl]-2-pyridinyl]-2,6-dimethoxy-N-[4-methoxy-6-(pyrazol-l-ylmethyl)-l,2-benzoxazol-3-yl]benzenesulfonamide;N-(6-((lZ7-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(4-((4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-l7 / -indazol-6-yl)piperidin-l-yl)methyl)pyridin-2-yl)-2,6-dimethoxybenzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(8-((l-(3-(2,4-dioxotetrahydropyrimidin-l(2J7)-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)-8-azabicyclo[3.2.1]octan-3-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(7-((l-(2-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-pyrrolo[2,3-b]pyridin-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2 -methoxybenzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(7-((l-(2-(2,6-dioxopiperidin-3-yl)-l-methyl-lJH-pyrrolo[2,3-b]pyridin-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(7-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;4-(4-((2-(3-(N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)sulfamoyl)-5-fluoro-2,4-dimethoxyphenyl)-2,7-diazaspiro[3.5]nonan-7-yl)methyl)-piperidin-l-yl)-N-(2,6-dioxopiperidin-3-yl)benzamide;- 72 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application (R)-N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(7-((l-(4-(2,6-dioxopiperidin-3-yl-3,4,4,5,5-d5)phenyl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]-nonan-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;( / )- / ' / -(6-((lf / -Pyrazol-l -yl (methyl )-4-methoxybenzo[t / ]isoxazol-3-yl)-3-(7-((l -(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;fS')-IV-(6-((l7 / -Pyrazol-l-yl)methyl)-4-methoxybenzo[t / ]isoxazol-3-yl)-3-(7-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;7V-(6-((lJ7-Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(6-((l-(3-(2,6-dioxopiperidin-3-yl)-l-(methyl-d3)-1 7-pyrrolo[2,3-&]pyridin-6-yl)piperidin-4-yl)methyl)- 5.6.7.8-tetrahydro-l,6-naphthyridin-2-yl)-5-fluoro-2,6-dimethoxybenzene-sulfonamide;7V-(6-((lJ7-Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(6-((l-(3-(2,4-dioxotetrahydropyrimidin-l(27 / )-yl)-l-(methyl-t / ?)-l7 / -indazol-6-yl)piperidin-4-yl)methyl)- 5.6.7.8-tetrahydro-l,6-naphthyridin-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;7V-(6-((lJ7-Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-(2,2,2-trifluoroethyl)-l7 / -indazol-6-yl)piperidin-4-yl)rnethyl)-2,7-diazaspiro[3.5] / 7<7 / 76 / / 7-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide; / ' / -(6-((l7 / -Pyrazol-l-yl)methyl)-4-methoxybenzo[t / ]isoxazol-3-yl)-3-(2-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-l7 / -indazol-6-yl)piperidin-4-yl)methyl)-2,8-diazaspiro[4.5]-decan-8-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide; / ' / -(6-((l7 / -Pyrazol-l-yl)methyl)-4-methoxybenzo[t / ]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-IT / -indazol-6-yl)piperidin-4-yl)methyl)-5,6,7,8-tetrahydro-imidazo[l,2-a]pyrazin-3-yl)-2,6-dimethoxybenzenesulfonamide;A-(6-((IT / -Pyrazol-l-yl)rnethyl)-4-rnethoxybenzo[t / ]isoxazol-3-yl)-3-(7-(3-(2,6-dioxo-piperidin-3-yl)-l -methyl- 1 / 7-indazol -6-yl)-2,7-diazaspiro[3.5]nonan-2-yl)-2 -methoxybenzenesulfonamide;or a pharmaceutically acceptable salt thereof.

[0263] It will be apparent that the compounds of the invention, including all subgenera described herein, may have multiple stereogenic centers. As a result, there exist multiple stereoisomers (enantiomers and diastereomers) of the compounds (and subgenera described herein). The present disclosure contemplates and encompasses each stereoisomer of any compound of encompassed by the disclosure as well as mixtures of said stereoisomers.

[0264] Pharmaceutically acceptable salts and solvates of the compounds of the disclosure (including all subgenera described herein) are also within the scope of the disclosure.- 73 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0265] Isotopic variants of the compounds of the disclosure (including all subgenera described herein) are also contemplated by the present disclosure. Isotopes include those atoms have the same atomic number but different mass numbers. For example, isotopes of hydrogen are tritium and deuterium.Pharmaceutical compositions and methods of administration

[0266] The subject pharmaceutical compositions are typically formulated to provide a therapeutically effective amount of a compound of the present disclosure as the active ingredient, or a pharmaceutically acceptable salt, ester, prodrug, solvate, hydrate or derivative thereof. Where desired, the pharmaceutical compositions contain pharmaceutically acceptable salt and / or coordination complex thereof, and one or more pharmaceutically acceptable excipients, carriers, including inert solid diluents and fillers, diluents, including sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants.

[0267] The subject pharmaceutical compositions can be administered alone or in combination with one or more other agents, which are also typically administered in the form of pharmaceutical compositions. Where desired, the one or more compounds of the invention and other agent(s) may be mixed into a preparation or both components may be formulated into separate preparations to use them in combination separately or at the same time.In some embodiments, the concentration of one or more compounds provided in the pharmaceutical compositions of the present invention is less than 100%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%, 0.0002%, or 0.0001% (or a number in the range defined by and including any two numbers above) w / w, w / v or v / v.

[0268] In some embodiments, the concentration of one or more compounds of the invention is greater than 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19.75%, 19.50%, 19.25%, 19%, 18.75%, 18.50%, 18.25% 18%, 17.75%, 17.50%, 17.25% 17%, 16.75%, 16.50%, 16.25%, 16%, 15.75%, 15.50%, 15.25% 15%, 14.75%, 14.50%, 14.25% 14%, 13.75%, 13.50%, 13.25%, 13%, 12.75%, 12.50%, 12.25%, 12%, 11.75%, 11.50%, 11.25% 11%, 10.75%, 10.50%, 10.25% 10%, 9.75%, 9.50%, 9.25%, 9%, 8.75%, 8.50%, 8.25% 8%, 7.75%, 7.50%, 7.25%, 7%, 6.75%, 6.50%, 6.25%, 6%, 5.75%, 5.50%, 5.25%, 5%, 4.75%, 4.50%, 4.25%, 4%, 3.75%, 3.50%, 3.25%, 3%, 2.75%, 2.50%, 2.25%, 2%, 1.75%, 1.50%, 1.25%, 1%, 0.9%,- 74 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%, 0.0002%, or 0.0001% (or a number in the range defined by and including any two numbers above) w / w, w / v, or v / v.

[0269] In some embodiments, the concentration of one or more compounds of the invention is in the range from approximately 0.0001% to approximately 50%, approximately 0.001% to approximately 40%, approximately 0.01% to approximately 30%, approximately 0.02% to approximately 29%, approximately 0.03% to approximately 28%, approximately 0.04% to approximately 27%, approximately 0.05% to approximately 26%, approximately 0.06% to approximately 25%, approximately 0.07% to approximately 24%, approximately 0.08% to approximately 23%, approximately 0.09% to approximately 22%, approximately 0.1% to approximately 21%, approximately 0.2% to approximately 20%, approximately 0.3% to approximately 19%, approximately 0.4% to approximately 18%, approximately 0.5% to approximately 17%, approximately 0.6% to approximately 16%, approximately 0.7% to approximately 15%, approximately 0.8% to approximately 14%, approximately 0.9% to approximately 12%, approximately 1% to approximately 10% w / w, w / v or v / v.

[0270] In some embodiments, the concentration of one or more compounds of the invention is in the range from approximately 0.001% to approximately 10%, approximately 0.01% to approximately 5%, approximately 0.02% to approximately 4.5%, approximately 0.03% to approximately 4%, approximately 0.04% to approximately 3.5%, approximately 0.05% to approximately 3%, approximately 0.06% to approximately 2.5%, approximately 0.07% to approximately 2%, approximately 0.08% to approximately 1.5%, approximately 0.09% to approximately 1%, approximately 0.1% to approximately 0.9% w / w, w / v or v / v.

[0271] In some embodiments, the amount of one or more compounds of the invention is equal to or less than 10 g, 9.5 g, 9.0 g, 8.5 g, 8.0 g, 7.5 g, 7.0 g, 6.5 g, 6.0 g, 5.5 g, 5.0 g, 4.5 g, 4.0 g, 3.5 g, 3.0 g, 2.5 g, 2.0 g, 1.5 g, 1.0 g, 0.95 g, 0.9 g, 0.85 g, 0.8 g, 0.75 g, 0.7 g, 0.65 g, 0.6 g, 0.55 g, 0.5 g, 0.45 g, 0.4 g, 0.35 g, 0.3 g, 0.25 g, 0.2 g, 0.15 g, 0.1 g, 0.09 g, 0.08 g, 0.07 g, 0.06 g, 0.05 g, 0.04 g, 0.03 g, 0.02 g, 0.01 g, 0.009 g, 0.008 g, 0.007 g, 0.006 g, 0.005 g, 0.004 g, 0.003 g, 0.002 g, 0.001 g, 0.0009 g, 0.0008 g, 0.0007 g, 0.0006 g, 0.0005 g, 0.0004 g, 0.0003 g, 0.0002 g, or 0.0001 g (or a number in the range defined by and including any two numbers above).

[0272] In some embodiments, the amount of one or more compounds of the invention is more than 0.0001 g, 0.0002 g, 0.0003 g, 0.0004 g, 0.0005 g, 0.0006 g, 0.0007 g, 0.0008 g, 0.0009 g, 0.001 g, 0.0015 g, 0.002 g, 0.0025 g, 0.003 g, 0.0035 g, 0.004 g, 0.0045 g, 0.005 g,- 75 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application 0.0055 g, 0.006 g, 0.0065 g, 0.007 g, 0.0075 g, 0.008 g, 0.0085 g, 0.009 g, 0.0095 g, 0.01 g, 0.015 g, 0.02 g, 0.025 g, 0.03 g, 0.035 g, 0.04 g, 0.045 g, 0.05 g, 0.055 g, 0.06 g, 0.065 g, 0.07 g, 0.075 g, 0.08 g, 0.085 g, 0.09 g, 0.095 g, 0.1 g,, 0.15 g, 0.2 g,, 0.25 g, 0.3 g,, 0.35 g, 0.4 g,, 0.45 g, 0.5 g, 0.55 g, 0.6 g,, 0.65 g, 0.7 g, 0.75 g, 0.8 g, 0.85 g, 0.9 g, 0.95 g, 1 g, 1.5 g, 2 g, 2.5, 3 g, 3.5, 4 g, 4.5 g, 5 g, 5.5 g, 6 g, 6.5g, 7 g, 7.5g, 8 g, 8.5 g, 9 g, 9.5 g, or 10 g (or a number in the range defined by and including any two numbers above).

[0273] In some embodiments, the amount of one or more compounds of the invention is in the range of 0.0001-10 g, 0.0005-9 g, 0.001-8 g, 0.005-7 g, 0.01-6 g, 0.05-5 g, 0.1-4 g, 0.5-4 g, or 1-3 g.

[0274] The compounds according to the invention are effective over a wide dosage range. For example, in the treatment of adult humans, dosages from 0.01 to 1000 mg, from 0.5 to 100 mg, from 1 to 50 mg per day, and from 5 to 40 mg per day are examples of dosages that may be used. An exemplary dosage is 10 to 30 mg per day. The exact dosage will depend upon the route of administration, the form in which the compound is administered, the subject to be treated, the body weight of the subject to be treated, and the preference and experience of the attending physician.

[0275] A pharmaceutical composition of the invention typically contains an active ingredient (e.g., a compound of the disclosure) of the present invention or a pharmaceutically acceptable salt and / or coordination complex thereof, and one or more pharmaceutically acceptable excipients, carriers, including but not limited to inert solid diluents and fillers, diluents, sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants.

[0276] Described below are non- limiting exemplary pharmaceutical compositions and methods for preparing the same.Pharmaceutical compositions for oral administration.

[0277] In some embodiments, the invention provides a pharmaceutical composition for oral administration containing a compound of the invention, and a pharmaceutical excipient suitable for oral administration.

[0278] In some embodiments, the invention provides a solid pharmaceutical composition for oral administration containing: (i) an effective amount of a compound of the invention; optionally (ii) an effective amount of a second agent; and (iii) a pharmaceutical excipient suitable for oral administration. In some embodiments, the composition further contains: (iv) an effective amount of a third agent.- 76 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0279] In some embodiments, the pharmaceutical composition may be a liquid pharmaceutical composition suitable for oral consumption. Pharmaceutical compositions of the invention suitable for oral administration can be presented as discrete dosage forms, such as capsules, cachets, or tablets, or liquids or aerosol sprays each containing a predetermined amount of an active ingredient as a powder or in granules, a solution, or a suspension in an aqueous or non-aqueous liquid, an oil-in- water emulsion, or a water-in-oil liquid emulsion. Such dosage forms can be prepared by any of the methods of pharmacy, but all methods include the step of bringing the active ingredient into association with the carrier, which constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation. For example, a tablet can be prepared by compression or molding, optionally with one or more accessory ingredients. Compressed tablets can be prepared by compressing in a suitable machine the active ingredient in a free- flowing form such as powder or granules, optionally mixed with an excipient such as, but not limited to, a binder, a lubricant, an inert diluent, and / or a surface active or dispersing agent. Molded tablets can be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.

[0280] This invention further encompasses anhydrous pharmaceutical compositions and dosage forms comprising an active ingredient, since water can facilitate the degradation of some compounds. For example, water may be added (e.g., 5%) in the pharmaceutical arts as a means of simulating long-term storage in order to determine characteristics such as shelf- life or the stability of formulations over time. Anhydrous pharmaceutical compositions and dosage forms of the invention can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions. Pharmaceutical compositions and dosage forms of the invention which contain lactose can be made anhydrous if substantial contact with moisture and / or humidity during manufacturing, packaging, and / or storage is expected. An anhydrous pharmaceutical composition may be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions may be packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastic or the like, unit dose containers, blister packs, and strip packs.

[0281] An active ingredient can be combined in an intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier can take a wide variety of forms depending on the form of preparation desired for administration. In preparing the compositions for an oral dosage form, any of the usual - 77 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application pharmaceutical media can be employed as carriers, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like in the case of oral liquid preparations (such as suspensions, solutions, and elixirs) or aerosols; or carriers such as starches, sugars, micro-crystalline cellulose, diluents, granulating agents, lubricants, binders, and disintegrating agents can be used in the case of oral solid preparations, in some embodiments without employing the use of lactose. For example, suitable carriers include powders, capsules, and tablets, with the solid oral preparations. If desired, tablets can be coated by standard aqueous or nonaqueous techniques.

[0282] Binders suitable for use in pharmaceutical compositions and dosage forms include, but are not limited to, corn starch, potato starch, or other starches, gelatin, natural and synthetic gums such as acacia, sodium alginate, alginic acid, other alginates, powdered tragacanth, guar gum, cellulose and its derivatives (e.g., ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose), polyvinyl pyrrolidone, methyl cellulose, pre-gelatinized starch, hydroxypropyl methyl cellulose, microcrystalline cellulose, and mixtures thereof.

[0283] Examples of suitable fillers for use in the pharmaceutical compositions and dosage forms disclosed herein include, but are not limited to, talc, calcium carbonate (e.g., granules or powder), microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and mixtures thereof.

[0284] Disintegrants may be used in the compositions of the invention to provide tablets that disintegrate when exposed to an aqueous environment. Too much of a disintegrant may produce tablets which may disintegrate in the bottle. Too little may be insufficient for disintegration to occur and may thus alter the rate and extent of release of the active ingredient(s) from the dosage form. Thus, a sufficient amount of disintegrant that is neither too little nor too much to detrimentally alter the release of the active ingredients) may be used to form the dosage forms of the compounds disclosed herein. The amount of disintegrant used may vary based upon the type of formulation and mode of administration, and may be readily discernible to those of ordinary skill in the art. About 0.5 to about 15 weight percent of disintegrant, or about 1 to about 5 weight percent of disintegrant, may be used in the pharmaceutical composition. Disintegrants that can be used to form pharmaceutical compositions and dosage forms of the invention include, but are not limited to, agar-agar, alginic acid, calcium carbonate, microcrystalline cellulose, croscarmellose sodium, crospovidone, polacrilin potassium, sodium starch glycolate, potato or tapioca starch, other starches, pre-gelatinized starch, other starches, clays, other algins, other celluloses, gums or mixtures thereof.- 78 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0285] Lubricants which can be used to form pharmaceutical compositions and dosage forms of the invention include, but are not limited to, calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oil (e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil), zinc stearate, ethyl oleate, ethyl laureate, agar, or mixtures thereof. Additional lubricants include, for example, a syloid silica gel, a coagulated aerosol of synthetic silica, or mixtures thereof. A lubricant can optionally be added, in an amount of less than about 1 weight percent of the pharmaceutical composition.

[0286] When aqueous suspensions and / or elixirs are desired for oral administration, the active ingredient therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if so desired, emulsifying and / or suspending agents, together with such diluents as water, ethanol, propylene glycol, glycerin and various combinations thereof.

[0287] The tablets can be uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate can be employed. Formulations for oral use can also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.

[0288] Surfactant which can be used to form pharmaceutical compositions and dosage forms of the invention include, but are not limited to, hydrophilic surfactants, lipophilic surfactants, and mixtures thereof. That is, a mixture of hydrophilic surfactants may be employed, a mixture of lipophilic surfactants may be employed, or a mixture of at least one hydrophilic surfactant and at least one lipophilic surfactant may be employed.

[0289] A suitable hydrophilic surfactant may generally have an HLB value of at least 10, while suitable lipophilic surfactants may generally have an HLB value of or less than about 10. An empirical parameter used to characterize the relative hydrophilicity and hydrophobicity of non-ionic amphiphilic compounds is the hydrophilic-lipophilic balance (" HLB" value). Surfactants with lower HLB values are more lipophilic or hydrophobic, and have greater solubility in oils, while surfactants with higher HLB values are more hydrophilic, and have greater solubility in aqueous solutions.

[0290] Hydrophilic surfactants are generally considered to be those compounds having an HLB value greater than about 10, as well as anionic, cationic, or zwitterionic compounds for - 79 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application which the HLB scale is not generally applicable. Similarly, lipophilic (e.g., hydrophobic) surfactants are compounds having an HLB value equal to or less than about 10. However, HLB value of a surfactant is merely a rough guide generally used to enable formulation of industrial, pharmaceutical and cosmetic emulsions.

[0291] Hydrophilic surfactants may be either ionic or non-ionic. Suitable ionic surfactants include, but are not limited to, alkylammonium salts; fusidic acid salts; fatty acid derivatives of amino acids, oligopeptides, and polypeptides; glyceride derivatives of amino acids, oligopeptides, and polypeptides; lecithins and hydrogenated lecithins; lysolecithins and hydrogenated lysolecithins; phospholipids and derivatives thereof; lysophospholipids and derivatives thereof; carnitine fatty acid ester salts; salts of alkyl sulfates; fatty acid salts; sodium docusate; acyl lactylates; mono- and di-acetylated tartaric acid esters of mono- and diglycerides; succinylated mono- and di-glycerides; citric acid esters of mono- and diglycerides; and mixtures thereof.

[0292] Within the aforementioned group, ionic surfactants include, by way of example: lecithins, lysolecithin, phospholipids, lysophospholipids and derivatives thereof; carnitine fatty acid ester salts; salts of alkylsulfates; fatty acid salts; sodium docusate; acylactylates; mono- and di-acetylated tartaric acid esters of mono- and di -glycerides; succinylated mono-and di-glycerides; citric acid esters of mono- and di-glycerides; and mixtures thereof.

[0293] Ionic surfactants may be the ionized forms of lecithin, lysolecithin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid, phosphatidyl -serine, lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylglycerol, lysophosphatidic acid, lysophosphatidylserine, PEG-phosphatidylethanolamine, PVP -phosphatidylethanolamine, lactylic esters of fatty acids, stearoyl -2 -lactyl ate, stearoyl lactylate, succinylated monoglycerides, mono / diacetylated tartaric acid esters of mono / diglycerides, citric acid esters of mono / diglycerides, cholyl sarcosine, caproate, caprylate, caprate, laurate, myristate, palmitate, oleate, ricinoleate, linoleate, linolenate, stearate, lauryl sulfate, teracecyl sulfate, docusate, lauroyl carnitines, palmitoyl carnitines, myristoyl carnitines, and salts and mixtures thereof.

[0294] Hydrophilic non-ionic surfactants may include, but are not limited to, alkylglucosides; alkylmaltosides; alkylthioglucosides; lauryl macrogolglycerides; polyoxyalkylene alkyl ethers such as polyethylene glycol alkyl ethers; polyoxyalkylene alkylphenols such as polyethylene glycol alkyl phenols; polyoxyalkylene alkyl phenol fatty acid esters such as polyethylene glycol fatty acids monoesters and polyethylene glycol fatty acids diesters; polyethylene glycol glycerol fatty acid esters; polyglycerol fatty acid esters; polyoxyalkylene sorbitan fatty acid esters such as polyethylene glycol sorbitan fatty acid - 80 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application esters; hydrophilic transesterification products of a polyol with at least one member of the group consisting of glycerides, vegetable oils, hydrogenated vegetable oils, fatty acids, and sterols; polyoxyethylene sterols, derivatives, and analogues thereof; polyoxyethylated vitamins and derivatives thereof; polyoxyethylene-polyoxypropylene block copolymers; and mixtures thereof; polyethylene glycol sorbitan fatty acid esters and hydrophilic transesterification products of a polyol with at least one member of the group consisting of triglycerides, vegetable oils, and hydrogenated vegetable oils. The polyol may be glycerol, ethylene glycol, polyethylene glycol, sorbitol, propylene glycol, pentaerythritol, or a saccharide.

[0295] Other hydrophilic-non-ionic surfactants include, without limitation, PEG- 10 laurate, PEG- 12 laurate, PEG-20 laurate, PEG-32 laurate, PEG-32 dilaurate, PEG- 12 oleate, PEG-15 oleate, PEG-20 oleate, PEG-20 di oleate, PEG-32 oleate, PEG-200 oleate, PEG-400 oleate, PEG- 15 stearate, PEG-32 distearate, PEG-40 stearate, PEG- 100 stearate, PEG-20 dilaurate, PEG-25 glyceryl trioleate, PEG-32 dioleate, PEG-20 glyceryl laurate, PEG-30 glyceryl laurate, PEG-20 glyceryl stearate, PEG-20 glyceryl oleate, PEG-30 glyceryl oleate, PEG-30 glyceryl laurate, PEG-40 glyceryl laurate, PEG-40 palm kernel oil, PEG-50 hydrogenated castor oil, PEG-40 castor oil, PEG-35 castor oil, PEG-60 castor oil, PEG-40 hydrogenated castor oil, PEG-60 hydrogenated castor oil, PEG-60 corn oil, PEG-6 caprate / caprylate glycerides, PEG-8 caprate / caprylate glycerides, polyglyceryl- 10 laurate, PEG-30 cholesterol, PEG-25 phyto sterol, PEG-30 soya sterol, PEG-20 trioleate, PEG-40 sorbitan oleate, PEG-80 sorbitan laurate, polysorbate 20, polysorbate 80, POE-9 lauryl ether, POE -23 lauryl ether, POE- 10 oleyl ether, POE-20 oleyl ether, POE-20 stearyl ether, tocopheryl PEG- 100 succinate, PEG-24 cholesterol, polyglyceryl-10 oleate, Tween 40, Tween 60, sucrose monostearate, sucrose mono laurate, sucrose monopalmitate, PEG 10-100 nonyl phenol series, PEG 15-100 octyl phenol series, and poloxamers.

[0296] Suitable lipophilic surfactants include, by way of example only: fatty alcohols; glycerol fatty acid esters; acetylated glycerol fatty acid esters; lower alcohol fatty acids esters; propylene glycol fatty acid esters; sorbitan fatty acid esters; polyethylene glycol sorbitan fatty acid esters; sterols and sterol derivatives; polyoxyethylated sterols and sterol derivatives; polyethylene glycol alkyl ethers; sugar esters; sugar ethers; lactic acid derivatives of mono-and di-glycerides; hydrophobic transesterification products of a polyol with at least one member of the group consisting of glycerides, vegetable oils, hydrogenated vegetable oils, fatty acids and sterols; oil-soluble vitamins / vitamin derivatives; and mixtures thereof. Within this group, preferred lipophilic surfactants include glycerol fatty acid esters, propylene glycol fatty acid esters, and mixtures thereof, or are hydrophobic transesterification products of a - 81 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application polyol with at least one member of the group consisting of vegetable oils, hydrogenated vegetable oils, and triglycerides.

[0297] In one embodiment, the composition may include a solubilizer to ensure good solubilization and / or dissolution of the compound of the present invention and to minimize precipitation of the compound of the present invention. This can be especially important for compositions for non-oral use, e.g., compositions for injection. A solubilizer may also be added to increase the solubility of the hydrophilic drug and / or other components, such as surfactants, or to maintain the composition as a stable or homogeneous solution or dispersion.

[0298] Examples of suitable solubilizers include, but are not limited to, the following: alcohols and polyols, such as ethanol, isopropanol, butanol, benzyl alcohol, ethylene glycol, propylene glycol, butanediols and isomers thereof, glycerol, pentaerythritol, sorbitol, mannitol, transcutol, dimethyl isosorbide, polyethylene glycol, polypropylene glycol, polyvinylalcohol, hydroxypropyl methylcellulose and other cellulose derivatives, cyclodextrins and cyclodextrin derivatives; ethers of polyethylene glycols having an average molecular weight of about 200 to about 6000, such as tetrahydrofurfuryl alcohol PEG ether (glycofurol) or methoxy PEG; amides and other nitrogen-containing compounds such as 2-pyrrolidone, 2-piperidone, s-caprolactam, N-alkylpyrrolidone, N-hydroxyalkylpyrrolidone, N-alkylpiperidone, N-alkylcaprolactam, dimethylacetamide and polyvinylpyrrolidone; esters such as ethyl propionate, tributyl citrate, acetyl tri ethyl citrate, acetyl tributyl citrate, tri ethyl citrate, ethyl oleate, ethyl caprylate, ethyl butyrate, triacetin, propylene glycol monoacetate, propylene glycol diacetate, s-caprolactone and isomers thereof, 6 -valerolactone and isomers thereof, P-butyrolactone and isomers thereof; and other solubilizers known in the art, such as dimethyl acetamide, dimethyl isosorbide, N-methyl pyrrolidones, monooctanoin, diethylene glycol monoethyl ether, and water.

[0299] Mixtures of solubilizers may also be used. Examples include, but not limited to, triacetin, tri ethyl citrate, ethyl oleate, ethyl caprylate, dimethylacetamide, N-methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, hydroxypropyl methylcellulose, hydroxypropyl cyclodextrins, ethanol, polyethylene glycol 200-100, glycofurol, transcutol, propylene glycol, and dimethyl isosorbide. Particularly preferred solubilizers include sorbitol, glycerol, triacetin, ethyl alcohol, PEG-400, glycofurol and propylene glycol.

[0300] The amount of solubilizer that can be included is not particularly limited. The amount of a given solubilizer may be limited to a bioacceptable amount, which may be readily determined by one of skill in the art. In some circumstances, it may be advantageous to include amounts of solubilizers far in excess of bioacceptable amounts, for example to- 82 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application maximize the concentration of the drug, with excess solubilizer removed prior to providing the composition to a subject using conventional techniques, such as distillation or evaporation. Thus, if present, the solubilizer can be in a weight ratio of 10%, 25%o, 50%), 100%o, or up to about 200%> by weight, based on the combined weight of the drug, and other excipients. If desired, very small amounts of solubilizer may also be used, such as 5%>, 2%>, 1%) or even less. Typically, the solubilizer may be present in an amount of about 1%> to about 100%, more typically about 5%> to about 25%> by weight.

[0301] The composition can further include one or more pharmaceutically acceptable additives and excipients. Such additives and excipients include, without limitation, detackifiers, anti-foaming agents, buffering agents, polymers, antioxidants, preservatives, chelating agents, viscomodulators, tonicifiers, flavorants, colorants, odorants, opacifiers, suspending agents, binders, fillers, plasticizers, lubricants, and mixtures thereof.

[0302] In addition, an acid or a base may be incorporated into the composition to facilitate processing, to enhance stability, or for other reasons. Examples of pharmaceutically acceptable bases include amino acids, amino acid esters, ammonium hydroxide, potassium hydroxide, sodium hydroxide, sodium hydrogen carbonate, aluminum hydroxide, calcium carbonate, magnesium hydroxide, magnesium aluminum silicate, synthetic aluminum silicate, synthetic hydrocalcite, magnesium aluminum hydroxide, diisopropylethylamine, ethanolamine, ethylenediamine, triethanolamine, triethylamine, triisopropanolamine, trimethylamine, tris(hydroxymethyl)aminomethane (TRIS) and the like. Also suitable are bases that are salts of a pharmaceutically acceptable acid, such as acetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acid, amino acids, ascorbic acid, benzoic acid, boric acid, butyric acid, carbonic acid, citric acid, fatty acids, formic acid, fumaric acid, gluconic acid, hydroquinosulfonic acid, isoascorbic acid, lactic acid, maleic acid, oxalic acid, parabromophenylsulfonic acid, propionic acid, p-toluenesulfonic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, thioglycolic acid, toluenesulfonic acid, uric acid, and the like. Salts of polyprotic acids, such as sodium phosphate, disodium hydrogen phosphate, and sodium dihydrogen phosphate can also be used. When the base is a salt, the cation can be any convenient and pharmaceutically acceptable cation, such as ammonium, alkali metals, alkaline earth metals, and the like. Example may include, but not limited to, sodium, potassium, lithium, magnesium, calcium and ammonium.

[0303] Suitable acids are pharmaceutically acceptable organic or inorganic acids. Examples of suitable inorganic acids include hydrochloric acid, hydrobromic acid, hydriodic acid, sulfuric acid, nitric acid, boric acid, phosphoric acid, and the like. Examples of suitable organic acids include acetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acids,- 83 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application amino acids, ascorbic acid, benzoic acid, boric acid, butyric acid, carbonic acid, citric acid, fatty acids, formic acid, fumaric acid, gluconic acid, hydroquinosulfonic acid, isoascorbic acid, lactic acid, maleic acid, methanesulfonic acid, oxalic acid, para-bromophenylsulfonic acid, propionic acid, p-toluenesulfonic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, thioglycolic acid, toluenesulfonic acid, uric acid and the like.Pharmaceutical compositions for injection.

[0304] In some embodiments, the invention provides a pharmaceutical composition for injection containing a compound of the present invention and a pharmaceutical excipient suitable for injection. Components and amounts of agents in the compositions are as described herein.

[0305] The forms in which the novel compositions of the present invention may be incorporated for administration by injection include aqueous or oil suspensions, or emulsions, with sesame oil, corn oil, cottonseed oil, or peanut oil, as well as elixirs, mannitol, dextrose, or a sterile aqueous solution, and similar pharmaceutical vehicles.

[0306] Aqueous solutions in saline are also conventionally used for injection. Ethanol, glycerol, propylene glycol, liquid polyethylene glycol, and the like (and suitable mixtures thereof), cyclodextrin derivatives, and vegetable oils may also be employed. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, for the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.

[0307] Sterile injectable solutions are prepared by incorporating the compound of the present invention in the required amount in the appropriate solvent with various other ingredients as enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, certain desirable methods of preparation are vacuum -drying and freeze- drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.Pharmaceutical compositions for topical (e.g„ transdermal) delivery.- 84 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0308] In some embodiments, the invention provides a pharmaceutical composition for transdermal delivery containing a compound of the present invention and a pharmaceutical excipient suitable for transdermal delivery.

[0309] Compositions of the present invention can be formulated into preparations in solid, semisolid, or liquid forms suitable for local or topical administration, such as gels, water soluble jellies, creams, lotions, suspensions, foams, powders, slurries, ointments, solutions, oils, pastes, suppositories, sprays, emulsions, saline solutions, dimethylsulfoxide (DMSO)-based solutions. In general, carriers with higher densities are capable of providing an area with a prolonged exposure to the active ingredients. In contrast, a solution formulation may provide more immediate exposure of the active ingredient to the chosen area.

[0310] The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients, which are compounds that allow increased penetration of, or assist in the delivery of, therapeutic molecules across the stratum corneum permeability barrier of the skin. There are many of these penetration- enhancing molecules known to those trained in the art of topical formulation.

[0311] Examples of such carriers and excipients include, but are not limited to, humectants (e.g., urea), glycols (e.g., propylene glycol), alcohols (e.g., ethanol), fatty acids (e.g., oleic acid), surfactants (e.g., isopropyl myristate and sodium lauryl sulfate), pyrrolidones, glycerol monolaurate, sulfoxides, terpenes (e.g., menthol), amines, amides, alkanes, alkanols, water, calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.

[0312] Another exemplary formulation for use in the methods of the present invention employs transdermal delivery devices ("patches"). Such transdermal patches may be used to provide continuous or discontinuous infusion of a compound of the present invention in controlled amounts, either with or without another agent.

[0313] The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g., U. S. Pat. Nos. 5,023,252, 4,992,445 and 5,001,139. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.Pharmaceutical compositions for inhalation.

[0314] Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. Preferably the compositions are administered by the oral or nasal- 85 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application respiratory route for local or systemic effect. Compositions in preferably pharmaceutically acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be inhaled directly from the nebulizing device or the nebulizing device may be attached to a face mask tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions may be administered, preferably orally or nasally, from devices that deliver the formulation in an appropriate manner.Other pharmaceutical compositions.

[0315] Pharmaceutical compositions may also be prepared from compositions described herein and one or more pharmaceutically acceptable excipients suitable for sublingual, buccal, rectal, intraosseous, intraocular, intranasal, epidural, or intraspinal administration.Preparations for such pharmaceutical compositions are well-known in the art. See, e.g., Anderson, Philip O.; Knoben, James E.; Troutman, William G, eds., Handbook of Clinical Drug Data, Tenth Edition, McGraw-Hill, 2002; Pratt and Taylor, eds., Principles of Drug Action, Third Edition, Churchill Livingston, New York, 1990; Katzung, ed., Basic and Clinical Pharmacology, Ninth Edition, McGraw Hill, 20037ybg; Goodman and Gilman, eds., The Pharmacological Basis of Therapeutics, Tenth Edition, McGraw Hill, 2001; Remingtons Pharmaceutical Sciences, 20th Ed., Lippincott Williams & Wilkins., 2000; Martindale, The Extra Pharmacopoeia, Thirty-Second Edition (The Pharmaceutical Press, London, 1999); all of which are incorporated by reference herein in their entirety.

[0316] Administration of the compounds or pharmaceutical composition of the present invention can be effected by any method that enables delivery of the compounds to the site of action. These methods include oral routes, intraduodenal routes, parenteral injection (including intravenous, intraarterial, subcutaneous, intramuscular, intravascular, intraperitoneal or infusion), topical (e.g. transdermal application), rectal administration, via local delivery by catheter or stent or through inhalation. Compounds can also be administered intraadiposally or intrathecally.

[0317] In some embodiments, the compounds or pharmaceutical composition of the present invention are administered by intravenous injection.

[0318] The amount of the compound administered will be dependent on the subject being treated, the severity of the disorder or condition, the rate of administration, the disposition of the compound and the discretion of the prescribing physician. However, an effective dosage is in the range of about 0.001 to about 100 mg per kg body weight per day, preferably about 1 to about 35 mg / kg / day, in single or divided doses. For a 70 kg human, this would amount to about 0.05 to 7 g / day, preferably about 0.05 to about 2.5 g / day. In some instances, dosage - 86 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, e.g. by dividing such larger doses into several small doses for administration throughout the day.

[0319] In some embodiments, a compound of the invention is administered in a single dose. Typically, such administration will be by injection, e.g., intravenous injection, in order to introduce the agent quickly. However, other routes may be used as appropriate. A single dose of a compound of the invention may also be used for treatment of an acute condition.

[0320] In some embodiments, a compound of the invention is administered in multiple doses. Dosing may be about once, twice, three times, four times, five times, six times, or more than six times per day. Dosing may be about once a month, once every two weeks, once a week, or once every other day. In another embodiment a compound of the invention and another agent are administered together about once per day to about 6 times per day. In another embodiment the administration of a compound of the invention and an agent continues for less than about 7 days. In yet another embodiment the administration continues for more than about 6, 10, 14, 28 days, two months, six months, or one year. In some cases, continuous dosing is achieved and maintained as long as necessary.

[0321] Administration of the compounds of the invention may continue as long as necessary. In some embodiments, a compound of the invention is administered for more than 1, 2, 3, 4, 5, 6, 7, 14, or 28 days. In some embodiments, a compound of the invention is administered for less than 28, 14, 7, 6, 5, 4, 3, 2, or 1 day. In some embodiments, a compound of the invention is administered chronically on an ongoing basis, e.g., for the treatment of chronic effects.

[0322] An effective amount of a compound of the invention may be administered in either single or multiple doses by any of the accepted modes of administration of agents having similar utilities, including rectal, buccal, intranasal and transdermal routes, by intra-arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, or as an inhalant.

[0323] The compositions of the invention may also be delivered via an impregnated or coated device such as a stent, for example, or an artery-inserted cylindrical polymer. Such a method of administration may, for example, aid in the prevention or amelioration of restenosis following procedures such as balloon angioplasty. Without being bound by theory, compounds of the invention may slow or inhibit the migration and proliferation of smooth muscle cells in the arterial wall which contribute to restenosis. A compound of the invention may be administered, for example, by local delivery from the struts of a stent, from a stent graft, from grafts, or from the cover or sheath of a stent. In some embodiments, a compound - 87 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application of the invention is admixed with a matrix. Such a matrix may be a polymeric matrix, and may serve to bond the compound to the stent. Polymeric matrices suitable for such use, include, for example, lactone-based polyesters or copolyesters such as polylactide, polycaprolactonglycolide, polyorthoesters, polyanhydrides, polyaminoacids, polysaccharides, polyphosphazenes, poly (ether-ester) copolymers (e.g. PEO-PLLA); polydimethylsiloxane, poly(ethylene-vinylacetate), acrylate-based polymers or copolymers (e.g. polyhydroxyethyl methylmethacrylate, polyvinyl pyrrolidinone), fluorinated polymers such as polytetrafluoroethylene and cellulose esters. Suitable matrices may be nondegrading or may degrade with time, releasing the compound or compounds. Compounds of the invention may be applied to the surface of the stent by various methods such as dip / spin coating, spray coating, dip-coating, and / or brush-coating. The compounds may be applied in a solvent and the solvent may be allowed to evaporate, thus forming a layer of compound onto the stent. Alternatively, the compound may be located in the body of the stent or graft, for example in microchannels or micropores. When implanted, the compound diffuses out of the body of the stent to contact the arterial wall. Such stents may be prepared by dipping a stent manufactured to contain such micropores or microchannels into a solution of the compound of the invention in a suitable solvent, followed by evaporation of the solvent. Excess drug on the surface of the stent may be removed via an additional brief solvent wash. In yet other embodiments, compounds of the invention may be covalently linked to a stent or graft. To link compounds of the invention to the stent or graft, a covalent linker may be used which degrades in vivo, leading to the release of the compound from the stent. Any bio-labile linkage may be used for such a purpose, such as ester, amide or anhydride linkages. Compounds of the invention may additionally be administered intravascularly from a balloon used during angioplasty.Extravascular administration of the compounds via the pericard or via advential application of formulations of the invention may also be performed to decrease restenosis.

[0324] A variety of stent devices which may be used as described are disclosed, for example, in the following references, all of which are hereby incorporated by reference: U. S. Pat. No. 5451233; U. S. Pat. No. 5040548; U. S. Pat. No. 5061273; U. S. Pat. No. 5496346; U. S. Pat. No. 5292331; U. S. Pat. No. 5674278; U. S. Pat. No. 3657744; U. S. Pat. No.4739762; U. S. Pat. No. 5195984; U. S. Pat. No. 5292331; U. S. Pat. No. 5674278; U. S. Pat. No. 5879382; U. S. Pat. No. 6344053.

[0325] The compounds of the invention may be administered in dosages. It is known in the art that due to intersubject variability in compound pharmacokinetics, individualization of dosing regimen is necessary for optimal therapy. Dosing for a compound of the invention may be found by routine experimentation in light of the instant disclosure.- 88 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0326] When a compound of the invention is administered in a composition that comprises one or more agents, and the agent has a shorter half- life than the compound of the invention unit dose forms of the agent and the compound of the invention may be adjusted accordingly. The subject pharmaceutical composition may, for example, be in a form suitable for oral administration as a tablet, capsule, pill, powder, sustained release formulations, solution, suspension, for parenteral injection as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository. The pharmaceutical composition may be in unit dosage forms suitable for single administration of precise dosages. The pharmaceutical composition will include a conventional pharmaceutical carrier or excipient and a compound according to the invention as an active ingredient. In addition, it may include other medicinal or pharmaceutical agents, carriers, adjuvants, etc. Exemplary parenteral administration forms include solutions or suspensions of active compound in sterile aqueous solutions, for example, aqueous propylene glycol or dextrose solutions. Such dosage forms can be suitably buffered, if desired.Methods of Use

[0327] The method typically comprises administering to a subject a therapeutically effective amount of a compound of the invention. The therapeutically effective amount of the subject combination of compounds may vary depending upon the intended application (in vitro or in vivo), or the subject and disease condition being treated, e.g., the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art. The term also applies to a dose that will induce a particular response in target cells, e.g., reduction of proliferation or downregulation of activity of a target protein. The specific dose will vary depending on the particular compounds chosen, the dosing regimen to be followed, whether it is administered in combination with other compounds, timing of administration, the tissue to which it is administered, and the physical delivery system in which it is carried.

[0328] In certain embodiment, the present invention provides a pharmaceutical composition comprising a compound of bispecific formula, or pharmaceutically acceptable salt thereof.

[0329] In certain embodiment, the present invention provides a pharmaceutical composition comprising a compound of bispecific formula for use in degrading a target protein in a cell.

[0330] In certain embodiment, a method of degrading a target protein comprising administering to a cell therapeutically effective amount of a bispecific compound, or pharmaceutically acceptable salt, wherein the compound is effective for degrading the target protein.- 89 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0331] “Abnormal cell growth” or “cancer” as used herein, unless otherwise indicated, refers to cell growth that is independent of normal regulatory mechanisms (e.g., loss of contact inhibition). This includes the abnormal growth of: (1) tumor cells (tumors) that proliferate by expressing a mutated tyrosine kinase or overexpression of a receptor tyrosine kinase; (2) benign and malignant cells of other proliferative diseases in which aberrant tyrosine kinase activation occurs; (3) any tumors that proliferate by receptor tyrosine kinases; (4) any tumors that proliferate by aberrant serine / threonine kinase activation; (5) benign and malignant cells of other proliferative diseases in which aberrant serine / threonine kinase activation occurs; (6) any tumors that proliferate by aberrant signaling, metabolic, epigenetic and transcriptional mechanism; and (7) benign and malignant cells of other proliferative diseases in which aberrant signaling, metabolic, epigenetic and transcriptional mechanism.

[0332] For convenience, certain well-known abbreviations, may be used herein, including: estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-), non-small cell lung cancer (NSCLC) and castration resistant prostate cancer (CRPC).

[0333] Further embodiments relate to methods of treating abnormal cell growth in a patient. Additional embodiments relate to a method of treating abnormal cell growth in a patient comprising administering to the patient an amount of a compound described herein that is effective in treating abnormal cell growth.

[0334] In other embodiments, the abnormal cell growth is cancer.

[0335] In some embodiments, the cancer is selected from the group consisting of lung cancer, mesothelioma, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, hepatic carcinoma, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin’s disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, hematology malignancy, chronic or acute leukemia, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system (CNS), primary CNS lymphoma, spinal axis tumors, glioblastoma, brain stem glioma, pituitary adenoma, or a combination of two or more of the foregoing cancers.

[0336] Additional embodiments relate to methods of treating solid tumors in a patient. Some embodiments relate to the treatment of solid tumors in a patient comprising administering to- 90 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application the patient an amount of a compound described herein that is effective in treating the solid tumor.

[0337] In one embodiment, the solid tumor is breast, lung, colon, brain, prostate, stomach, pancreatic, ovarian, melanoma, endocrine, uterine, testicular, or bladder.

[0338] In one embodiment, the solid tumor is breast, lung, prostate, pancreatic, or ovarian.

[0339] In one embodiment, the cancer is breast cancer.

[0340] In one embodiment, the breast cancer is ER+ breast cancer.

[0341] In one embodiment, the breast cancer is ER+ HER2- breast cancer.

[0342] In one embodiment, the breast cancer is locally advanced or metastatic ER+ HER2-breast cancer.

[0343] In one embodiment, the lung cancer is non-small cell lung cancer.

[0344] In one embodiment, the lung cancer is locally advanced or metastatic non-small cell lung cancer.

[0345] In one embodiment, the prostate cancer is castration resistant prostate cancer. In one embodiment, the prostate cancer is locally advanced or metastatic castration resistant prostate cancer.

[0346] Additional embodiments relate to methods of treating hematologic tumors in a patient. Some embodiments relate to the treatment of hematologic tumors in a patient comprising administering to the patient an amount of a compound described herein that is effective in treating the hematologic tumor.

[0347] In one embodiment, the hematologic tumor is leukemia, lymphoma or multiple myeloma.

[0348] In one embodiment, the hematologic tumor is leukemia or lymphoma.

[0349] Additional embodiments relate to methods of treating cancer in a patient comprising administering to the patient an amount of a compound described herein that is effective in treating cancer. In one embodiment, the cancer is breast, lung, colon, brain, prostate, stomach, pancreatic, ovarian, melanoma, endocrine, uterine, testicular, bladder, or hematologic.

[0350] In one embodiment, the cancer is breast, lung, prostate, pancreatic, ovarian, or hematologic.

[0351] In one embodiment, the cancer is breast, lung, prostate, pancreatic, or ovarian. In one embodiment, the cancer is breast cancer.

[0352] In one embodiment, the breast cancer is ER+ breast cancer.

[0353] In one embodiment, the breast cancer is ER+ HER2- breast cancer.

[0354] In one embodiment, the breast cancer is locally advanced or metastatic ER+ HER2-breast cancer.- 91 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0355] In one embodiment, the lung cancer is non-small cell lung cancer.

[0356] In one embodiment, the lung cancer is locally advanced or metastatic non-small cell lung cancer.

[0357] In one embodiment, the prostate cancer is castration resistant prostate cancer. In one embodiment, the prostate cancer is locally advanced or metastatic castration resistant prostate cancer.

[0358] In one embodiment, the cancer is hematologic.

[0359] In one embodiment, the hematologic tumor is leukemia or lymphoma.

[0360] Further embodiments relate to methods of treating cancer in a patient which comprises administering to the patient an amount of a compound described herein that is effective in treating cancer in combination with an anti-tumor agent selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, radiation, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, antibodies, cytotoxics, anti- hormones, and anti -androgens.

[0361] More embodiments relate to pharmaceutical compositions for treating cancer in a patient comprising an amount of a compound described herein that is effective in treating cancer, and a pharmaceutically acceptable carrier.

[0362] Additional embodiments relate to a method of treating cancer in a patient, and in particular a human, comprising administering to the patient an amount of a compound described herein, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, that is effective in treating cancer. In one embodiment of this method, the cancer, includes, but is not limited to, lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin’s Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, chronic or acute leukemia, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system (CNS), primary CNS lymphoma, spinal axis tumors, brain stem glioma, pituitary adenoma, or a combination of one or more of the foregoing cancers.

[0363] In one embodiment the method comprises comprising administering to a patient an amount of a compound described herein that is effective in treating said cancer solid tumor. In - 92 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application one preferred embodiment the solid tumor is breast, lung, colon, brain, prostate, stomach, pancreatic, ovarian, skin (melanoma), endocrine, uterine, testicular, and bladder cancer.

[0364] In another embodiment of said method, said cancer is a benign proliferative disease, including, but not limited to, psoriasis, benign prostatic hypertrophy or restenosis.

[0365] Some embodiments relate to a method of treating cancer in a patient which comprises administering to said patient an amount of a compound described herein, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, that is effective in treating cancer in combination with an anti-tumor agent selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, antibodies, cytotoxics, anti -hormones, and anti-androgens.

[0366] Additional embodiments relate to a pharmaceutical composition for treating cancer in a patient, and in particular a human, comprising an amount of a compound described herein, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, that is effective in treating cancer, and a pharmaceutically acceptable carrier. In one embodiment of said composition, the cancer, includes, but not limited to, lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin’s Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, chronic or acute leukemia, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system (CNS), primary CNS lymphoma, spinal axis tumors, brain stem glioma, pituitary adenoma, or a combination of one or more of the foregoing cancers. In another embodiment of said pharmaceutical composition, said abnormal cell growth is a benign proliferative disease, including, but not limited to, psoriasis, benign prostatic hypertrophy or restinosis.

[0367] Further embodiments relate to a method of treating cancer in a patient which comprises administering to said patient an amount of a compound described herein, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, that is effective in treating cancer in combination with another anti-tumor agent selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response - 93 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application modifiers, antibodies, cytotoxics, anti -hormones, and anti-androgens. Some embodiments contemplate a pharmaceutical composition for treating abnormal cell growth wherein the composition includes a compound described herein, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, that is effective in treating abnormal cell growth, and another antitumor agent selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, antibodies, cytotoxics, antihormones, and anti-androgens.

[0368] Yet more embodiments relate to a method of treating a disorder associated with angiogenesis in a patient, including a human, comprising administering to said patient an amount of a compound described herein, as defined above, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, that is effective in treating said disorder in combination with one or more anti-tumor agents listed above. Such disorders include cancerous tumors such as melanoma; ocular disorders such as age- related macular degeneration, presumed ocular histoplasmosis syndrome, and retinal neovascularization from proliferative diabetic retinopathy; rheumatoid arthritis; bone loss disorders such as osteoporosis, Paget’s disease, humoral hypercalcemia of malignancy, hypercalcemia from tumors metastatic to bone, and osteoporosis induced by glucocorticoid treatment; coronary restenosis; and certain microbial infections including those associated with microbial pathogens selected from adenovirus, hantaviruses, Borrelia burgdorferi, Yersinia spp., Bordetella pertussis, and group A Streptococcus.

[0369] Compounds of the disclosure, as well as pharmaceutical compositions comprising them, can be administered to treat any of the described diseases, alone or in combination with a medical therapy. Medical therapies include, for example, surgery and radiotherapy (e.g., gamma-radiation, neutron beam radiotherapy, electron beam radiotherapy, proton therapy, brachytherapy, systemic radioactive isotopes).

[0370] In other aspects, compounds of the disclosure, as well as pharmaceutical compositions comprising them, can be administered to treat any of the described diseases, alone or in combination with one or more other agents.

[0371] In other methods, the compounds of the disclosure, as well as pharmaceutical compositions comprising them, can be administered in combination with agonists of nuclear receptors agents.

[0372] In other methods, the compounds of the disclosure, as well as pharmaceutical compositions comprising them, can be administered in combination with antagonists of nuclear receptors agents.- 94 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0373] In other methods, the compounds of the disclosure, as well as pharmaceutical compositions comprising them, can be administered in combination with an anti -proliferative agent.Combination Therapies

[0374] For treating cancer and other proliferative diseases, the compounds of the invention can be used in combination with chemotherapeutic agents, agonists or antagonists of nuclear receptors, or other anti-proliferative agents. The compounds of the invention can also be used in combination with a medical therapy such as surgery or radiotherapy, e.g., gamma-radiation, neutron beam radiotherapy, electron beam radiotherapy, proton therapy, brachytherapy, and systemic radioactive isotopes. Examples of suitable chemotherapeutic agents include any of: abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol, all -trans retinoic acid, altretamine, anastrozole, arsenic trioxide, asparaginase, azacitidine, bendamustine, bevacizumab, bexarotene, bleomycin, bortezombi, bortezomib, busulfan intravenous, busulfan oral, calusterone, capecitabine, carboplatin, carmustine, cetuximab, chlorambucil, cisplatin, cladribine, clofarabine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, dalteparin sodium, dasatinib, daunorubicin, decitabine, denileukin, denileukin diftitox, dexrazoxane, docetaxel, doxorubicin, dromostanolone propionate, eculizumab, epirubicin, erlotinib, estramustine, etoposide phosphate, etoposide, exemestane, fentanyl citrate, filgrastim, floxuridine, fludarabine, fluorouracil, fulvestrant, gefitinib, gemcitabine, gemtuzumab ozogamicin, goserelin acetate, histrelin acetate, ibritumomab tiuxetan, idarubicin, ifosfamide, imatinib mesylate, interferon alfa 2a, irinotecan, lapatinib ditosylate, lenalidomide, letrozole, leucovorin, leuprolide acetate, levamisole, lomustine, meclorethamine, megestrol acetate, melphalan, mercaptopurine, methotrexate, methoxsalen, mitomycin C, mitotane, mitoxantrone, nandrolone phenpropionate, nelarabine, nofetumomab, oxaliplatin, paclitaxel, pamidronate, panobinostat, panitumumab, pegaspargase, pegfilgrastim, pemetrexed disodium, pentostatin, pipobroman, plicamycin, procarbazine, quinacrine, rasburicase, rituximab, ruxolitinib, sorafenib, streptozocin, sunitinib, sunitinib maleate, tamoxifen, temozolomide, teniposide, testolactone, thalidomide, thioguanine, thiotepa, topotecan, toremifene, tositumomab, trastuzumab, tretinoin, uracil mustard, valrubicin, vinblastine, vincristine, vinorelbine, vorinstat and zoledronate.

[0375] Some embodiments relate to a method of (and to a pharmaceutical composition for) treating cancer in a patient which comprise an amount of a compound described herein, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, in combination with an amount of one or more substances selected from anti-angiogenesis agents, signal transduction - 95 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application inhibitors (e.g., inhibiting the means by which regulatory molecules that govern the fundamental processes of cell growth, differentiation, and survival communicated within the cell), and antiproliferative agents, which amounts are together effective in treating said abnormal cell growth.

[0376] Anti-angiogenesis agents, such as MMP-2 (matrix-metalloprotienase 2) inhibitors, MMP-9 (matrix-metalloprotienase 9) inhibitors, and COX-II (cyclooxygenase II) inhibitors, can be used in conjunction with a compound described herein in the methods and pharmaceutical compositions described herein.

[0377] Tyrosine kinase inhibitors can also be combined with a compound described herein.

[0378] VEGF inhibitors, for example, sutent and axitinib, can also be combined with a compound described herein.

[0379] ErbB2 receptor inhibitors may be administered in combination with a compound described herein. Various other compounds, such as styrene derivatives, have also been shown to possess tyrosine kinase inhibitory properties, and some of tyrosine kinase inhibitors have been identified as erbB2 receptor inhibitors.

[0380] Epidermal growth factor receptor (EGFR) inhibitors may be administered in combination with a compound of the present invention. PI3K inhibitors, such as PI3K alpha or PI3K beta inhibitors, may be administered in combination with a compound of the present invention.

[0381] Mammalian target of rapamycin (mTOR) inhibitors may be administered in combination with a compound of the present invention.

[0382] c-Met inhibitors may be administered in combination with a compound of the present invention.

[0383] CDK inhibitors may be administered in combination with a compound of the present invention.

[0384] MEK inhibitors may be administered in combination with a compound of the present invention.

[0385] PARP inhibitors may be administered in combination with a compound of the present invention.

[0386] JAK inhibitors may be administered in combination with a compound of the present invention.

[0387] An antagonist of a Programmed Death 1 protein (PD-1) may be administered in combination with a compound of the present invention.

[0388] An antagonist of Programmed Death-Ligand 1 (PD-L1) may be administered in combination with a compound of the present invention.- 96 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0389] Other antiproliferative agents that may be used with the compounds described herein include inhibitors of the enzyme farnesyl protein transferase and inhibitors of the receptor tyrosine kinase PDGFr.

[0390] A compound described herein may also be used with other agents useful in treating abnormal cell growth or cancer, including, but not limited to, agents capable of enhancing antitumor immune responses, such as CTLA4 (cytotoxic lymphocyte antigen 4) antibodies, and other agents capable of blocking CTLA4; and anti -proliferative agents such as other farnesyl protein transferase inhibitors, for example the farnesyl protein transferase.

[0391] A compound described herein may be applied as a sole therapy or may involve one or more other anti-tumor substances, for example those selected from, for example, mitotic inhibitors, alkylating agents, anti-metabolites, growth factor inhibitors, cell cycle inhibitors, intercalating antibiotics, enzymes, and anti-hormones.

[0392] The compounds described herein may be used alone or in combination with one or more of a variety of anti-cancer agents or supportive care agents. For example, the compounds described herein may be used with cytotoxic agents. Some embodiments also contemplate the use of the compounds described herein together with hormonal therapy. Further, some embodiments provide a compound described herein alone or in combination with one or more supportive care products, e.g., a product selected from the group consisting of Filgrastim (Neupogen), ondansetron (Zofran), Fragmin, Procrit, Aloxi, Emend, or combinations thereof. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment.

[0393] The compounds described herein may be used with antitumor agents, alkylating agents, antimetabolites, antibiotics, plant-derived antitumor agents, camptothecin derivatives, tyrosine kinase inhibitors, antibodies, interferons, and / or biological response modifiers. In this regard, the following is a non-limiting list of examples of secondary agents that may be used with the compounds described herein.Aspects of the Invention

[0394] In a first aspect of the invention, provided is a compound of Formula (I)ULM - Y - PTM- 97 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application or a pharmaceutically acceptable salt or solvate thereof,wherein Y-PTM is a moiety of Formula IA:R1whereinY is a covalent bond, or chemical moiety that links PTM and ULM;* is a point of attachment to ULM;Ring A is a Ce-Cio membered aryl group or a 5-10 membered heteroaryl group;R1is H or 5-6 membered heteroaryl optionally substituted by methyl;R2is H, Ci-4alk-O-Ci-4alkyl, or -(C(R8)2)n-(5-9 membered heteroaryl) optionally substituted by halogen, C1-C3 alkyl, -CH2OH, or -OH;R3is H or halogen, C1-C4 alkyl, cyclopropyl, haloalkyl, C1-C4 alkoxy, or haloalkoxy;R4is H or halogen, C1-C4 alkyl, cyclopropyl, C1-C4 alkoxy, or -O-cyclopropyl; each R5is independently H, halogen, oxo, -OH, -CN, -NO2, -Ci-Cealkyl, -C2-Cealkenyl, -C2-C6alkynyl, Co-Cialk-aryl, Co-Cialk-heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, -ORa, -SRa, -NRcRd, -NRaRc, -C(O)Rb, -OC(O)Ra, -C(O)ORa, -C(O)NRcRd, -S(O)Rb, -S(O)2NRcRd, -S(O)(=NRb)Rb, -SF5, -P(O)RbRb, -P(O)(ORb)(ORb), -B(ORd)(ORc) or -S(O)2Rb;each Rais independently H, -C(O)Rb, -C(O)ORC, -C(O)NRcRd, -C(=NRb)NRbRc, -C(=NORb)NRbRc, -C(=NCN)NRbRc, -P(ORC)2, -P(O)RcRb, -P(O)ORcORb, -S(O)Rb, -S(O)NRcRd, -S(O)2Rb, -S(O)2NRcRd, SiRb3, -Ci-Cioalkyl, -C1-C10 haloalkyl, -C2-C10 alkenyl, -C2-C10 alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl;each Rb, is independently H, -Ci-Ce alkyl, -Ci-Ce haloalkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl;each Rcor Rdis independently H, -C1-C10 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -OCi-Cealkyl, -O-cycloalkyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl; or- 98 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application Rcand Rd, together with the atom to which they are both attached, form a monocyclic or multicyclic heterocycloalkyl, or a monocyclic or multicyclic heterocyclo-alkenyl group;each R8is independently H, halogen, or C1-C4 alkyl;m is 0, 1, 2, 3, or 4;n is 0 or 1; andULM is- 99 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Applicationwhereinis a point of attachment to Y;each X2 is independently N or CR15; andeach R15is independently H, D, halogen, oxo, -OH, -CN, -NO2, -Ci-Cealkyl, -Ci-Ce haloalkyl, -C2-Cealkenyl, -C2-Cealkynyl, Co-Cialk-aryl, Co-Cialk-heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, -ORa, -SRa, -NRcRd, -NRaRc, -C(O)Rb, -OC(O)Ra, -C(O)ORa, -C(O)NRcRd, -S(O)Rb, -S(O)2NRcRd, -S(O)(=NRb)Rb, -SF5, -P(O)RbRb, -P(O)(ORb)(ORb), -B(ORd)(ORc) or -S(O)2Rb;wherein any of the -Ci-Cealkyl, Ci-Cs alkoxide, -C2-Cealkenyl, -C2-Cealkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, spirocycloalkyl, spiroheterocycloalkyl and spiroheterocycloalkenyl groups in any of R1-R15 and ring A is optionally substituted by 1-6 Rfgroups; andeach Rfis independently H, D, oxo, halogen, Ci-Cs alkoxy, Ci-Cs alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, -OH, -CN, -NO2, -C2-6 alkenyl, -C2-6 alkynyl, Ce-io aryl, C5-12 heteroaryl, C3-8 cycloalkyl, C3-8 cycloalkenyl, C3-8 heterocycloalkyl, C3-8 heterocycloalkenyl, -ORa, -SRa, -NRcRd, -NRaRc, -C(O)Rb, -OC(O)Rb, -C(O)ORb, -C(O)NRcRd, -S(O)Rb, -S(O)2NRcRd, -S(O)(=NRb)Rb, -SF5, -P(O)RbRb, -P(O)RcRd, -P(O)(ORb)(ORb), -B(ORc)(ORd), -S(O)2Rb, -C(O)NRbORb, -S(O)2ORb, -OS(O)2ORb, or -OPO(ORb)(ORb); wherein said Ci-C8alkyl is optionally substituted by 1-6 groups selected from D, halogen, -OH, -CN, -ORa, -SRa, -NRaRd, orNRcRd

[0395] In a second aspect of the invention, provided is a compound of the first aspect, wherein Y is a chemical moiety that links PTM and ULM.

[0396] In a third aspect of the invention, provided is a compound of the second aspect, wherein R1is H.

[0397] In a fourth aspect of the invention, provided is a compound of any one of the preceding aspects, wherein R2is H.

[0398] In a fifth aspect of the invention, provided is a compound of any one of the first through third aspects, wherein R2is -(C(R8)2)n-(5-9 membered heteroaryl) optionally substituted by halogen, C1-C3 alkyl, -CH2OH, or -OH.- 100 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0399] In a sixth aspect of the invention, provided is a compound of the fifth aspect, wherein R2is -(C(R8)2)n-(5-6 membered heteroaryl) optionally substituted by halogen, C1-C3 alkyl, -CH2OH, or -OH.

[0400] In a seventh aspect of the invention, provided is a compound of the sixth aspect, wherein the 5-6 membered heteroaryl is a pyrazole, a pyrrole, a pyridine or a pyridazine.

[0401] In an eighth aspect of the invention, provided is a compound of the sixth aspect, wherein the 5-6 membered heteroaryl is a pyrazole.

[0402] In a ninth aspect of the invention, provided is a compound of any one of the first through third aspects, wherein R2is Ci-4alk-O-Ci-4alkyl.

[0403] In a tenth aspect of the invention, provided is a compound of the ninth aspect, wherein R2is CH2-O-CH3.

[0404] In an eleventh aspect of the invention, provided is a compound of any one of the preceding aspects, wherein n is 0.

[0405] In a twelfth aspect of the invention, provided is a compound of any one of the first through tenth aspects, wherein n is 1.

[0406] In a thirteenth aspect of the invention, provided is a compound of any one of the preceding aspects, wherein R3is H.

[0407] In a fourteenth aspect of the invention, provided is a compound of any one of the first through twelfth aspects, wherein R3is halogen.

[0408] In a fifteenth aspect of the invention, provided is a compound of any one of the first through twelfth aspects, wherein R3is C1-C4 alkyl.

[0409] In a sixteenth aspect of the invention, provided is a compound of any one of the preceding aspects, wherein R4is H.

[0410] In a seventeenth aspect of the invention, provided is a compound of any one of the first through fifteenth aspects, wherein R4is C1-C4 alkyl.

[0411] In an eighteenth aspect of the invention, provided is a compound of any one of the first through fifteenth aspects, wherein R4is C1-C4 alkoxy.

[0412] In a nineteenth aspect of the invention, provided is a compound of the eighteenth aspect, wherein R4is methoxy.

[0413] In a twentieth aspect of the invention, provided is a compound of any one of the preceding aspects, wherein Ring A is Ce-Cio aryl.

[0414] In a twenty first aspect of the invention, provided is a compound of the twentieth aspect, wherein Ring A is phenyl.

[0415] In a twenty second aspect of the invention, provided is a compound of any one of the preceding aspects, wherein each R5is H.- 101 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0416] In a twenty third aspect of the invention, provided is a compound of any one of the first through twenty first aspects, wherein at least one R5is H.

[0417] In a twenty fourth aspect of the invention, provided is a compound of any one of the first through twenty first aspects, wherein each R5 is C1-C4 alkoxy.

[0418] In a twenty fifth aspect of the invention, provided is a compound of any one of the first through twenty first aspects, wherein at least one R5 is C1-C4 alkoxy.

[0419] In a twenty sixth aspect of the invention, provided is a compound of any one of the preceding aspects, wherein m is 0.

[0420] In a twenty seventh aspect of the invention, provided is a compound of any one of the first through twenty fifth aspects, wherein m is 1.

[0421] In a twenty eighth aspect of the invention, provided is a compound of any one of the first through twenty fifth aspects, wherein m is 2.

[0422] In a twenty ninth aspect of the invention, provided is a compound of any one of the first through twenty fifth aspects, wherein m is 3.

[0423] In a thirtieth aspect of the invention, provided is a compound of any one of the first through twenty fifth aspects, wherein m is 4.

[0424] In a thirty first aspect of the invention, provided is a compound of any one of the preceding aspects, wherein each R8is H.

[0425] In a thirty second aspect of the invention, provided is a compound of any one of the preceding aspects, wherein Y is represented by the formula:wherein:q is an integer from 1 to 14;each A is independently selected from the group consisting of CRlaRlb, O, S, SO, SO2, NR1C, SO2NR1C, SONR1C, SO(=NR1C), SO(=NRlc)NRld, CONRlc, NRlcCONRld, NRlcC(O)O, NRlcSO2NRld, CO, CRla=CRlb, C=C, SiRlaRlb, P(O)Rla, P(O)ORla, (CRlaRlb)i-4, -(CRlaRlb)i-4O(CRlaRlb)i-4, -(CRlaRlb)i-4S(CRlaRlb)i-4, -(CRlaRlb)i-4NRlc(CRlaRlb)i-4, NRlcC(=NCN)NRld, NRlcC(=NCN), NRlcC(=CNO2)NRld, 3-11 membered cycloalkyl, optionally substituted with 0-6 Rlaor Rlbgroups, 3-11 membered heterocyclyl optionally substituted with 0-6 Rlaor Rlbgroups, aryl optionally substituted with 0-6 Rlaor Rlbgroups, or heteroaryl optionally substituted with 0-6 Rlaor Rlbgroups,wherein Rla, Rlb, Rlc, Rldand Rleare each independently, -H, -halo, -Ci-Csalkyl, -O-Ci-Csalkyl, -Ci-Cehaloalkyl, -S-Ci-Csalkyl,-NHCi-Csalkyl, -N(Ci-Csalkyl)2, 3-11 membered cycloalkyl, aryl, heteroaryl, 3-11 membered heterocyclyl, -O-(3-ll membered cycloalkyl), -S-- 102 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application (3-11 membered cycloalkyl), NH-(3-11 membered cycloalkyl), N(3-11 membered cycloalkyl)2, N-(3-11 membered cycloalkyl)(Ci-C8alkyl), -OH, -NH2, -SO2Ci-C8alkyl, -SO2-aryl, -SO2-heteroaryl, SO(NH)Ci-C8alkyl, P(O)(OCi-C8alkyl)(Ci-C8alkyl), -P(O)(OCi-C8alkyl)2, -C=C-Ci-C8alkyl, -C=CH, -CH=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=C(Ci-C8alkyl)2, -Si(OH)3, -Si(Ci-C8alkyl)3, -Si(OH)(Ci-C8alkyl)2, -C(O)Ci-C8alkyl, -C(O)OCi-C8alkyl, -CO2H, -CN, -CF3, -CHF2, -CH2F, -NO2, -SF5, -SO2NHC1-C8alkyl, -SO2N(Ci-C8alkyl)2, -SO(NH)NHCi-C8alkyl, -SO(NH)N(Ci-C8alkyl)2, -SONHCi-C8alkyl, -SON(Ci-C8alkyl)2, -CONHCi-C8alkyl, -CON(Ci-C8alkyl)2, -N(Ci-C8alkyl)CONH(Ci-C8alkyl), -N(Ci-C8alkyl)CON(Ci-C8alkyl)2, -NHCONH(Ci-C8alkyl), -NHCON(Ci-C8alkyl)2, -NHCONH2, -N(Ci-C8alkyl)SO2NH(Ci-C8alkyl), -N(Ci-C8alkyl)SO2N(Ci-C8alkyl)2, -NHSO2NH(Ci-C8alkyl), -NHSO2N(Ci-C8alkyl)2, or -NHSO2NH2; and where Rlaor Rlb, each independently may be optionally linked to other groups to form cycloalkyl and / or heterocyclyl moiety, optionally substituted with 0-4 Rlegroups.

[0426] In a thirty third aspect of the invention, provided is a compound of the thirty second aspect, wherein q is an integer from 1 to 5.

[0427] In a thirty fourth aspect of the invention, provided is a compound of any one of the first through thirty first aspects, wherein Y iswherein** is a point of attachment to PTM;Li, L2, and L3are each independently a bond, CRlaRlb, O, S, SO, SO2, NRlc, SO2NR1C, SONR1C, SO(=NR1C), SO(=NRlc)NRld, CONRlc, NRlcCONRld, NRlcC(O)O, NRlcSO2NRld, CO, CRla=CRlb, C=C, SiRlaRlb, P(O)Rla, P(O)ORla, (CRlaRlb)i-4, -(CRlaRlb)i-4O(CRlaRlb)i-4, -(CRlaRlb)i-4S(CRlaRlb)i-4, -(CRlaRlb)i-4NRlc(CRlaRlb)i-4, NRlcC(=NCN)NRld, NRlcC(=NCN), NRlcC(=CNO2)NRld;ring Ai and ring A2 are each independently 3-12 membered cycloalkyl, optionally substituted with 0-6 Rlaor Rlbgroups, 3-12 membered heterocyclyl optionally substituted with 0-6 Rlaor Rlbgroups, aryl optionally substituted with 0-6 Rlaor Rlbgroups, or heteroaryl optionally substituted with 0-6 Rlaor Rlbgroups,wherein Rla, Rlb, Rlc, Rldand Rleare each independently, -H, -halo, -Ci-C8alkyl, -O-Ci-C8alkyl, -Ci-Cehaloalkyl, -S-Ci-C8alkyl,-NHCi-C8alkyl, -N(Ci-C8alkyl)2, 3-11 membered cycloalkyl, aryl, heteroaryl, 3-11 membered heterocyclyl, -O-(3-ll membered cycloalkyl), -S-(3-11 membered cycloalkyl), NH-(3-ll membered cycloalkyl), N(3-ll membered- 103 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application cycloalkyl)2, N-(3-ll membered cycloalkyl)(Ci-C8alkyl), -OH, -NH2, -SH, -SO2Ci-C8alkyl, -SO2-aryl, -SO2-heteroaryl, SO(NH)Ci-C8alkyl, P(O)(OCi-C8alkyl)(Ci-C8alkyl), -P(O)(OCi-C8alkyl)2, -C=C-Ci-C8alkyl, -C=CH, -CH=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=C(Ci-C8alkyl)2, -Si(OH)3, -Si(Ci-C8alkyl)3, -Si(OH)(Ci-C8alkyl)2, -C(O)Ci-C8alkyl, -C(O)OCi-C8alkyl, -CO2H, -CN, -CF3, -CHF2, -CH2F, -NO2, -SF5, -SO2NHC1-C8alkyl, -SO2N(Ci-C8alkyl)2, -SO(NH)NHCi-C8alkyl, -SO(NH)N(Ci-C8alkyl)2, -SONHCi-C8alkyl, -SON(Ci-C8alkyl)2, -CONHCi-C8alkyl, -CON(Ci-C8alkyl)2, -N(Ci-C8alkyl)CONH(Ci-C8alkyl), -N(Ci-C8alkyl)CON(Ci-C8alkyl)2, -NHCONH(Ci-C8alkyl), -NHCON(Ci-C8alkyl)2, -NHCONH2, -N(Ci-C8alkyl)SO2NH(Ci-C8alkyl), -N(Ci-C8alkyl)SO2N(Ci-C8alkyl)2, -NHSO2NH(Ci-C8alkyl), -NHSO2N(Ci-C8alkyl)2, or -NHSO2NH2; and where Rlaor Rlb, each independently may be optionally linked to other groups to form cycloalkyl and / or heterocyclyl moiety, optionally substituted with 0-4 Rlegroups.

[0428] In a thirty fifth aspect of the invention, provided is a compound of any one of the first through thirty first aspects, wherein Y iswherein** is a point of attachment to PTM;Li is a bond, (C(R10)2)P, or CO;L2 is a bond, (C(R10)2)P, or CO;L3is a bond, (C(R10)2)P, or CO;p is 1, 2, 3 or 4;each R10is independently H or C1-C4 alkyl;ring Ai is a 3-7 membered cycloalkyl group, a 4-10-membered heterocycloalkyl group, an aryl group, or a heteroaryl group; andring A2 is a 3-7 membered cycloalkyl group, a 4-12-membered heterocycloalkyl group, an aryl group, or a heteroaryl group.

[0429] In a thirty sixth aspect of the invention, provided is a compound of thirty fifth aspect, wherein L3is a bond.

[0430] In a thirty seventh aspect of the invention, provided is a compound of thirty fifth aspect or the thirty sixth aspect, wherein Li is a bond.

[0431] In a thirty eighth aspect of the invention, provided is a compound of any one of the thirty fifth through thirty seventh aspects, wherein L2 is (C(R10)2)P.- 104 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0432] In a thirty ninth aspect of the invention, provided is a compound of any one of the thirty fifth through thirty eighth aspects, wherein ring Ai is a 4-10-membered heterocycloalkyl group.

[0433] In a fortieth aspect of the invention, provided is a compound of thirty ninth aspect, wherein ring Ai is a piperazine group, a morpholine group, a piperidine group, a pyrrolidine group, an azetidine group or an azabicyclo-alkyl group.

[0434] In a forty first aspect of the invention, provided is a compound of thirty ninth aspect, wherein ring Ai is a piperidine group or pyrrolidine group.

[0435] In a forty second aspect of the invention, provided is a compound of any one of the thirty fifth through forty first aspects, wherein ring A2 is a 4-12-membered heterocycloalkyl group.

[0436] In a forty third aspect of the invention, provided is a compound of the forty second aspect, wherein ring A2 is a piperazine group, a piperidine group, a pyrrolidine group, an azaspiroalkyl group, a diazaspiroalkyl group, or an azabicycloalkyl group.

[0437] In a forty fourth aspect of the invention, provided is a compound of the forty second aspect, wherein ring A2 is a piperazine group, an azaspiroalkyl group, or a diazaspiroalkyl group.

[0438] In a forty fifth aspect of the invention, provided is a compound of the forty second aspect, wherein ring A2 is aryl optionally substituted with 0-6 Rlaor Rlbgroups.

[0439] In a forty sixth aspect of the invention, provided is a compound of the thirty fifth aspect, wherein Y isAi l[-2wherein* is a point of attachment to ULM;** is a point of attachment to PTM;W is CRn orN;U is CRn orN;Rn is H, fluoro, Ci-ealkyl, or Ci-ealkoxide; andeach g, h, j and k is independently 0, 1 or 2.

[0440] In a forty seventh aspect of the invention, provided is a compound of the forty sixth aspect, wherein j and g are each 2.

[0441] In a forty eighth aspect of the invention, provided is a compound of the forty sixth aspect or the forty seventh aspect, wherein k and h are each 1.- 105 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0442] In a forty ninth aspect of the invention, provided is a compound of the forty sixth aspect, wherein j and g are each 1.

[0443] In a fiftieth aspect of the invention, provided is a compound of the forty sixth aspect or the forty seventh aspect, wherein k and h are each 2.

[0444] In a fifty first aspect of the invention, provided is a compound of any one of the forty sixth through fiftieth aspects, wherein W and U are N.

[0445] In a fifty second aspect of the invention, provided is a compound of any one of the forty sixth through fiftieth aspects, wherein W is CRn and U are N.

[0446] In a fifty third aspect of the invention, provided is a compound of any one of the forty sixth through fiftieth aspects, wherein W is N and U is CRn.

[0447] In a fifty fourth aspect of the invention, provided is a compound of any one of thepreceding aspects, wherein Ring A is selected from#and#; wherein■r'JJis a point of attachment to the sulfonamide group and # is a point of attachment to Y.

[0448] In a fifty fifth aspect of the invention, provided is a compound of the fifty fourth aspect, wherein Ring A is selected fromOMe OMe# # # # # #wherein■r'JJis a point of attachment to the sulfonamide group and # is a point of attachment to Y.

[0449] In a fifty sixth aspect of the invention, provided is a compound of the first aspect, wherein Y-PTM is a compound of formula IA-1:- 106 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application(IA-1)or a pharmaceutically acceptable salt thereof.

[0450] In a fifty seventh aspect of the invention, provided is a compound of the first aspect, wherein Y-PTM is a compound of formula IA-2:(IA-2);or a pharmaceutically acceptable salt thereof; wherein* is a point of connection to ULM;L2 is a bond or (C(R10)2)P;p is 1, 2, 3 or 4;each R10is independently H or C1-C4 alkyl;ring Ai is a 3-7 membered cycloalkyl group, a 4-10-membered heterocycloalkyl group, an aryl group, or a heteroaryl group; andring A2 is a 3-7 membered cycloalkyl group, a 4-12-membered heterocycloalkyl group, an aryl group, or a heteroaryl group.

[0451] In a fifty eighth aspect of the invention, provided is a compound of the first aspect, wherein Y-PTM is a compound of formula IA-3:or a pharmaceutically acceptable salt thereof; wherein* is a point of connection to ULM;L2 is a bond or (C(R10)2)P;p is 1, 2, 3 or 4;each R10is independently H or C1-C4 alkyl;- 107 - 105807.00506114896-4870-4897.1105807.005061 - PCT Application ring Ai is a 3-7 membered cycloalkyl group, a 4-10-membered heterocycloalkyl group, an aryl group, or a heteroaryl group;W is CRn orN;U is CRn orN;Rn is H, F, Ci-ealkyl, or Ci-ealkoxide; andeach g, h, j and k is independently 0, 1, 2 or 3.

[0452] In a fifty eighth aspect of the invention, provided is a compound of the fifty eighth aspect, wherein j and g are each 2.

[0453] In a sixtieth aspect of the invention, provided is a compound of the fifty eighth aspect or the fifty ninth aspect, wherein k and h are each 1.

[0454] In a sixth first aspect of the invention, provided is a compound of the fifty eighth aspect, wherein j and g are each 1.

[0455] In a sixty second aspect of the invention, provided is a compound of the fifty eighth aspect or the fifty ninth aspect, wherein k and h are each 2.

[0456] In a sixty third aspect of the invention, provided is a compound of any one of the fifty eighth through sixty second aspects, wherein W and U are N.

[0457] In a sixty fourth aspect of the invention, provided is a compound of any one of the fifty eighth through sixty second aspects, wherein W is CRn and U are N.

[0458] In a sixty fifth aspect of the invention, provided is a compound of any one of the fifty eighth through sixty second aspects, wherein W is N and U is CRn.

[0459] In a sixty sixth aspect of the invention, provided is a compound of any one of the preceding aspects, wherein Y-PTM is a compound of formula IA-4 or formula IA-5:R5R5or a pharmaceutically acceptable salt thereof; wherein* is a point of connection to ULM;- 108 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application L2 is a bond or (C(R10)2)P;p is 1, 2, 3 or 4;each R10is independently H or C1-C4 alkyl;ring Ai is a 3-7 membered cycloalkyl group, a 4-10-membered heterocycloalkyl group, an aryl group, or a heteroaryl group;W is CRn orN;U is CRn or N; andR11 is H, F, Ci-ealkyl, or Ci-ealkoxide.

[0460] In a sixty seventh aspect of the invention, provided is a compound of the sixty sixth aspect, wherein Y-PTM is a compound of formula IA-6 or formula IA-7:R5(IA-6)(IA-7) or a pharmaceutically acceptable salt thereof; wherein* is a point of connection to ULM;W is CRn orN;U is CRn orN; andRn is H, F, Ci-ealkyl, or Ci-ealkoxide;each E is independently CRn orN; andt is 0, 1, 2 or 3.

[0461] In a sixty eighth aspect of the invention, provided is a compound of any one of the fifty sixth through sixty seventh aspects, wherein each R5is independently H, -CN, halogen, Ci-Ce alkyl, Ci-Ce fluoroalkyl, O-Ci-Ce fluoroalkyl, C3-C6 cycloalkyl or Ci-Ce alkoxy.

[0462] In a sixty ninth aspect of the invention, provided is a compound of any one of the preceding aspects, wherein each X2 is CRb.

[0463] In a seventieth aspect of the invention, provided is a compound of any one of the preceding aspects, wherein each X2 is CH.- 109 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0464] In a seventy first aspect of the invention, provided is a compound of any one of the preceding aspects, wherein ULM iswherein is a point of attachment to Y.

[0465] In a seventy second aspect of the invention, provided is a compound of the first aspect, that is:7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(7-(((35)-l-(l- (2,6-dioxopiperidin-3-yl)-3-methyl-l / / -indazol-5-yl)pyrrolidin-3-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)benzenesulfonamide;- 110 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application 7V-(6-((lJ7-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(7-((l-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-17 / -benzo[J]imidazol-5-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)benzenesulfonamide;7V-(6-((lJ7-Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(7-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)pyrrolidin-3-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)benzenesulfonamide;7V-(6-((lJ7-Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-rnethyl-l7 / -pyrrolo[3,2-c']pyridin-6-yl)piperidin-4-yl)rnethyl)-2,7-diazaspiro[3.5]nonan-2-yl)benzenesulfonamide;7V-(6-((lJ7-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(7-((l-(2-(2,6-dioxopiperidin-3-yl)-l-oxo-l,2-dihydroisoquinolin-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2 -methoxybenzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(7-((l-(l-(2,6-dioxopiperidin-S-yl^-methyl-l / Z-indazol-S-y^piperidin-d-y^methyl)^^-diazaspiro[3.5]nonan-2-yl)-2 -methoxybenzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-IT / -indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2 -methoxybenzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(7-((l-(6-(2,6-dioxopiperidin-S-y^-l-methyl-l / Z-indazol-S-y^piperidin-d-y^methyl)^^-diazaspiro[3.5]nonan-2-yl)-2 -methoxybenzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lJH-pyrrolo[2,3- ’]pyridin-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2 -methoxybenzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(7-((l-(3-(2,4-dioxotetrahydropyrimidin-l(277)-yl)-l-methyl-lJH-indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2,4-dimethoxybenzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-S-y^-l-methyl-l / Z-indazol-b-y^piperidin-d-y^methyl)^^-diazaspiro[3.5]nonan-2-yl)-2,6-dimethoxybenzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-4-(7-((l-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-IT / -indazol-5-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)benzenesulfonamide;- Ill - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application 7V-(6-((lZ7-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-4-(7-((l-(2-(2,6-dioxopiperidin-3-yl)-l-oxo-l,2-dihydroisoquinolin-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)benzenesulfonamide;7V-(6-((lJ7-Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-4-(7-((l-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-IT / -indazol-5-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2 -methoxybenzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-4-(7-((l-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-l / / -benzo[J]imidazol-5-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2 -methoxybenzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-4-(4-((l-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-l / / -benzo[J]imidazol-5-yl)piperidin-4-yl)methyl)-3,3-dimethylpiperazin-l-yl)benzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-4-((3a5',6a5)-5-((l-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-17 -benzo[ ]imidazol-5-yl)piperidin-4-yl)methyl)hexahydropyrrolo[3,4-c]pyrrol-2(177)-yl)benzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-4-((3aR,6a5)-5-((l-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-17 -benzo[ ]imidazol-5-yl)piperidin-4-yl)methyl)hexahydropyrrolo[3,4-c]pyrrol-2(177)-yl)-2-methoxybenzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(9-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)-3,9-diazaspiro[5.5]undecan-3-yl)benzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(9-((l-(3-(2,6-dioxopiperidin-S-y^-l-methyl-l / Z-indazol-b-y^piperidin-d-y^methyl)^^-diazaspiro[5.5]undecan-3-yl)benzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-S-y^-l-methyl-l / Z-indazol-b-y^piperidin-d-y^methyl)^^-diazaspiro[3.5]nonan-2-yl)-2-(2, 2, 2-tri fluoroethoxy )benzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-2-chloro-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lJH-indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)benzenesulfonamide;N-(6-((lZ7-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-IT / -indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2 -methoxybenzenesulfonamide;- 112 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application / ' / -(6-((l7 / -Pyrazol-l-yl)methyl)-4-methoxybenzo[t / ]isoxazol-3-yl)-5-chloro-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-IT / -indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2 -methoxybenzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-S-y^-l-methyl-l / Z-indazol-b-y^piperidin-d-y^methyl)^^-diazaspiro[3.5]nonan-2-yl)-2-methoxy-5-methylbenzenesulfonamide; / ' / -(6-((l7 / -pyrazol-l-yl)methyl)-4-methoxybenzo[t / ]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-IT / -indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-(trifluoromethyl)benzenesulfonamide;7V-(6-((lJH-pyrazol-l-yl)methyl)-4-methoxybenzo[t / / isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-IT / -indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2 -fluorobenzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-IT / -indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-5-(7-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-methylbenzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(7-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-methylbenzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-4-(7-((l-(3-(2,6-dioxopiperidin-S-y^-l-methyl-l / Z-indazol-b-y^piperidin-d-y^methyl)^^-diazaspiro[3.5]nonan-2-yl)-2 -methylbenzenesulfonamide;N-(6-(( 1 H-Pyrazol- 1 -yl)methyl)-4-m ethoxyb enzo[d]i soxazol -3 -yl)-4-(7 -(( 1 -(3 -(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-ethylbenzenesulfonamide;N-(6-(( 1 H-Pyrazol- 1 -yl)methyl)-4-m ethoxyb enzo[d]i soxazol -3 -yl)-4-(7 -(( 1 -(3 -(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-(tri fluoromethoxy )benzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lJH-indazol-6-yl)piperidin-4-yl)methyl)-7-azaspiro[3.5]nonan-2-yl)benzenesulfonamide;- 113 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application 7V-(6-((lJ7-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(2-((4-(3-(2,4-di oxotetrahydropyrimidin-1 (2 / 7)-yl)-l -methyl -177-indazol -6-yl Jpiperi din-1 -yl)methyl)-7-azaspiro[3.5]nonan-7-yl)benzenesulfonamide;7V-(6-((lJ7-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(2-((4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-l / 7-indazol-6-yl)piperidin-l-yl)methyl)-7-azaspiro[3.5]nonan-7-yl)benzenesulfonamide;7V-(6-((lJ7-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(2-((4-((l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-l / / -benzo[ ]imidazol-4-yl)ethynyl)piperidin-l-yl)methyl)-7-azaspiro[3.5]nonan-7-yl)benzenesulfonamide;or a pharmaceutically acceptable salt thereof.

[0466] In a seventy third aspect of the invention, provided is a compound of the first aspect, that is:3-(7-((l-(3-(2,6-Dioxopiperidin-3-yl)-l-methyl-l / 7-indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxy-7V-(4-methoxy-6-(methoxyrnethyl)-benzo[ ]isoxazol-3-yl)benzenesulfonamide;3-(7-((l-(3-(2,4-Dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)-piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxy-N-(4-methoxy-6-(methoxymethyl)benzo[d]isoxazol-3-yl)benzenesulfonamide;3-(7-((l-(3-(2,6-Dioxopiperidin-3-yl)-l-methyl-lH-pyrrolo[2,3-b]pyridin-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxy-N-(4-methoxy-6-(methoxy-methyl)benzo[d]isoxazol-3-yl)benzenesulfonamide;3-(2-((l -(3-(2, 6-Dioxopiperi din-3 -yl)-l-methyl-lH-indazol-6-yl)piperi din-4-yl)methyl)-l,2,3,4-tetrahydroisoquinolin-6-yl)-5-fluoro-2,6-dimethoxy-N-(4-methoxy-6-(methoxymethyl)-benzo[d]isoxazol-3-yl)benzenesulfonamide;3-(2-((l-(3-(2,4-Dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)-piperidin-4-yl)methyl)-l,2,3,4-tetrahydroisoquinolin-6-yl)-5-fluoro-2,6-dimethoxy-N-(4-methoxy-6-(methoxymethyl)benzo[d]isoxazol-3-yl)benzenesulfonamide;4'-((4-(3-(2, 6-Dioxopiperi din-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-l-yl)methyl)-5-fluoro-2,4-dimethoxy-N-(4-methoxy-6-(methoxymethyl)benzo[d]isoxazol-3-yl)-3'-methyl-[1,1 '-biphenyl]-3 -sulfonamide;4'-((4-(3-(2,4-Dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperidin-l-yl)methyl)-5-fluoro-2,4-dimethoxy-N-(4-methoxy-6-(methoxymethyl)benzo-[d]isoxazol-3-yl)-3'-methyl-[l,l'-biphenyl]-3-sulfonamide;- 114 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application N-(6-(( IH-Pyrazol- 1 -yl)methyl)-4-methoxybenzo[d]isoxazol-3 -y l)-3 -(7 -(( 1 -(3 -(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;rac-3 -((ci s)-3 -(( 1 -(3 -(2,4-Dioxotetrahy dropyrimidin- 1 (2H)-yl)- 1 -methyl- 1 H-indazol -6-yl)piperidin-4-yl)methyl)-3,7-diazabicyclo[4.2.0]octan-7-yl)-5-fluoro-2,6-dimethoxy-N-(4-methoxy-6-(methoxymethyl)benzo[d]isoxazol-3-yl)benzenesulfonamide;3-((l-(3-(2,6-Dioxopiperidin-3-yl)-l-methyl-lH-pyrrolo[2,3-b]pyridin-6-yl)piperidin-4-yl)methyl)-3,7-diazabicyclo[4.2.0]octan-7-yl)-5-fluoro-2,6-dimethoxy-N-(4-methoxy-6-(methoxymethyl)benzo[d]isoxazol-3-yl)benzenesulfonamide;rac-3 -((ci s)-3 -(( 1 -(3 -(2,4-Dioxotetrahy dropyrimidin- 1 (2H)-yl)- 1 -methyl- 1 H-indazol -6-yl)piperidin-4-yl)methyl)-3,7-diazabicyclo[4.2.0]octan-7-yl)-2 -methoxy -N-(4-methoxy-6-(methoxymethyl)benzo[d]isoxazol-3-yl)-5-(trifluoromethyl)benzenesulfonamide;3-((l-(3-(2,6-Dioxopiperidin-3-yl)-l-methyl-lH-pyrrolo[2,3-b]pyridin-6-yl)piperidin-4-yl)methyl)-3,7-diazabicyclo[4.2.0]octan-7-yl)-2-methoxy-N-(4-methoxy-6-(methoxymethyl)-benzo[d]isoxazol-3-yl)-5-(trifluoromethyl)benzenesulfonamide;7V-(6-((l / 7-pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(6-((l-(3-(2,4-dioxotetrahydropyrimidin-l(2J7)-yl)-l-methyl-l / 7-indazol-6-yl)piperidin-4-yl)methyl)-5,6,7,8-tetrahydro-l,6-naphthyridin-2-yl)-5-fluoro-2,6-dimethoxybenzene-sulfonamide;N-(6-(( 1 H-pyrazol - 1 -yl)methyl)-4-methoxybenzo[d]i soxazol -3 -y 1 ) -3 -(7 -(( 1 -(4-(2, 6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;rac-3-(cis)-N-(6-((lH-pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-((l-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)-piperidin-4-yl)methyl)-3,7-diazabicyclo[4.2.0]octan-7-yl)-5-fluoro-2,6-dimethoxy -benzenesulfonamide;or a pharmaceutically acceptable salt thereof.

[0467] In a seventy fourth aspect of the invention, provided is a compound of any one of the preceding aspects, in the form of a pharmaceutically acceptable salt.

[0468] In a seventy fifth aspect of the invention, provided is a compound of any one of the preceding aspects, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[0469] In a seventy sixth aspect of the invention, provided is a method of treating cancer or solid tumors in a subject in need thereof comprising administering to the subject a compound of any one of the first through seventy fourth aspects or a pharmaceutical composition of the seventy fifth aspect.- 115 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0470] In a seventy seventh aspect of the invention, provided is a method of the seventy sixth aspect, wherein the cancer is selected from the group consisting of lung cancer, mesothelioma, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, hepatic carcinoma, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin’s disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, hematology malignancy, chronic or acute leukemia, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system (CNS), primary CNS lymphoma, spinal axis tumors, glioblastoma, brain stern glioma, pituitary adenoma, and a combination of two or more of the foregoing cancers.

[0471] In a seventy eighth aspect of the invention, provided is a method of the seventy sixth aspect, wherein the solid tumors are selected from the group consisting of breast, lung, colon, brain, prostate, stomach, pancreatic, ovarian, melanoma, endocrine, uterine, testicular, hematologic and bladder.

[0472] In a seventy ninth aspect of the invention, provided is a method of the seventy eighth aspect, wherein the solid tumors are selected from the group consisting of breast, lung, prostate, pancreatic, hematologic and ovarian

[0473] In an eightieth aspect of the invention, provided is a method of the seventy sixth aspect, wherein the cancer is breast cancer.

[0474] In an eighty first aspect of the invention, provided is a method of the eightieth aspect, wherein the breast cancer is ER+ breast cancer.

[0475] In an eighty second aspect of the invention, provided is a method of the eightieth aspect, wherein the breast cancer is ER+ HER2- breast cancer.

[0476] In an eighty third aspect of the invention, provided is a method of the eightieth aspect, wherein the breast cancer is locally advanced or metastatic ER+ HER2- breast cancer.

[0477] In an eighty fourth aspect of the invention, provided is a method of the seventy sixth aspect, wherein the cancer is lung cancer.

[0478] In an eighty fifth aspect of the invention, provided is a method of the eighty fourth aspect, wherein the lung cancer is non-small cell lung cancer.

[0479] In an eighty sixth aspect of the invention, provided is a method of the eighty fourth aspect, wherein the lung cancer is locally advanced or metastatic non-small cell lung cancer - 116 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0480] In an eighty seventh aspect of the invention, provided is a method of the seventy sixth aspect, wherein the cancer is prostate cancer.

[0481] In an eighty eighth aspect of the invention, provided is a method of the eighty seventh aspect, wherein the prostate cancer is castration resistant prostate cancer.

[0482] In an eighty ninth aspect of the invention, provided is a method of the eighty seventh aspect, wherein the prostate cancer is locally advanced or metastatic castration resistant prostate cancer.

[0483] In a ninetieth aspect of the invention, provided is a method of degrading a KAT6 protein comprising contacting the KAT6 protein with a compound of any one of the first through seventy fourth aspects or a pharmaceutical composition of the seventy fifth aspect.

[0484] In a ninety first aspect of the invention, provided is a compound of the first aspect, wherein R2is H or -(C(R8)2)n-(5-9 membered heteroaryl) optionally substituted by halogen, Ci-C3 alkyl, -CH2OH, or -OH.

[0394] Compounds of the invention can be prepared using numerous preparatory reactions known in the literature. The Schemes below provide general guidance in connection with preparing the compounds of the invention. One skilled in the art would understand that the preparations shown in the Schemes can be modified or optimized using general knowledge of organic chemistry to prepare various compounds of the invention. Example synthetic methods for preparing compounds of the invention are provided in the Schemes below.

[0395] The following Examples are provided to illustrate some of the concepts described within this disclosure. While the Examples are considered to provide an embodiment, it should not be considered to limit the more general embodiments described herein.EXAMPLESGeneral Synthetic Procedures

[0396] The compounds of the Invention may be prepared using the general procedures described below. The compounds described herein may be prepared according to the following synthetic schemes and general synthetic procedures.

[0397] Compounds of Formula (I) can be prepared as described in Scheme I. Coupling of optionally protected compounds 1-1 with compounds 1-2 where RG5and RG6are each independently reactive groups such as, but not limited to, halogen (e.g., F, Cl, Br, I), hydroxy, aldehyde, boronic acid, boronate ester, trialkyltin, carboxylic acid, or amine and y is an integer from 0 to 14 using appropriate synthetic methods (such as, but not limited to, S\Ar reaction, Suzuki coupling, Stille coupling, Buchwald-Hartwig reaction, Mitsunobu reaction,- 117 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application Williamson ether synthesis, amide coupling, or reductive amination) can afford compounds 1-3. Reaction of optionally protected 1-4 with compounds 1-5 where RG7and RG8are each independently reactive groups such as, but not limited to, halogen (e.g., F, Cl, Br, I), hydroxy, aldehyde, boronic acid, boronate ester, trialkyltin, carboxylic acid, or amine and z is an integer from 0 to 14 and the sum of y and z is an integer from 1 to 14 using appropriate synthetic methods (such as, but not limited to, S\Ar reaction, Suzuki coupling, Stille coupling, Buchwald-Hartwig reaction, Mitsunobu reaction, Williamson ether synthesis, amide coupling, or reductive amination) can afford compounds 1-6. Coupling of compounds 1-3 and 1-6 using appropriate synthetic methods (such as, but not limited to, S\Ar reaction, Suzuki coupling, Stille coupling, Buchwald-Hartwig reaction, Mitsunobu reaction, Williamson ether synthesis, amide coupling, or reductive amination) can afford compounds 1-7.Scheme I1-6

[0398] Compounds of Formula (I) can be prepared as described in Scheme II. Cleavage of acetals 2-1 where each Rzis independently a Ci-Ce alkyl group or where both Rzcan be taken together with the atoms to which they are both attached form a monocyclic heterocycloalkyl under standard conditions such as in the presence of an acid (e.g., toluenesulfonic acid or trifluoroacetic acid) can afford compounds 2-2. Coupling of compounds 2-3 where Xeis a halogen (e.g., F, Cl, Br, or I) or pseudohalogen (e.g., OMs or OTf) with compounds 2-4 where A2a is 3-11 membered diazaheterocyclyl and P1is an appropriate nitrogen protecting group (e.g., Boc, Cbz, Bn, PMB, or acetyl) under standard S\Ar conditions optionally in the presence of a base (e.g., DIPEA) or under standard Buchwald-Hartwig amination conditions (e.g., in the presence of a palladium catalyst, such as BrettPhos Pd G3, and a base, such as sodium / c / V-butoxide) and subsequent deprotection can afford compounds 2-5. Reaction of compounds 2-2 and amines 2-5 under standard conditions for reductive amination (e.g., in the presence of a reducing agent such as sodium triacetoxy -borohydride or sodium cyanoborohydride and optionally an acid, such as acetic acid) can afford compounds 2-6.- 118 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application Scheme IIReductive amination R1ULM 2-6

[0399] Compounds of Formula (I) can be prepared as described in Scheme III. Coupling of compounds 2-3 where Xeis a halogen (e.g., F, Cl, Br, or I) or pseudohalogen (e.g., OMs or OTf) with compounds 3-1 where A2b is 3-11 membered azaheterocyclyl, P1is an appropriate nitrogen protecting group (e.g., Boc, Cbz, Bn, PMB, or acetyl), and M1is a boronic acid, boronate ester, potassium trifluoroborate, or an appropriately substituted metal, such as Sn(Bu)s, Sn(Me)s, ZnCl, Znl, or ZnBr under standard Suzuki conditions (e.g., in the presence of a palladium catalyst, such as SPhos Pd G2, and a base, such as potassium carbonate) or under standard Stille conditions (e.g., in the presence of a palladium catalyst, such as SPhos Pd G2 or tetrakis(triphenylphosphine)palladium(0)) or under standard Negishi cross-coupling conditions (e.g., in the presence of a palladium catalyst, such as SPhos Pd G2, tetrakis-(triphenylphosphine)palladium(O), or [l,l’-bis(diphenylphosphino)ferrocene]dichloro-- 119 - 105807.00506114896-4870-4897.1105807.005061 - PCT Application palladium(II)) and subsequent deprotection can afford compounds 3-2. Reaction of compounds 2-2 and amines 3-2 under standard conditions for reductive amination (e.g., in the presence of a reducing agent such as sodium triacetoxy -borohydride or sodium cyanoborohydride and optionally an acid, such as acetic acid) can afford compounds 3-3.Scheme III

[0400] Compounds of Formula (I) can be prepared as described in Scheme IV. Coupling of compounds 2-3 where Xeis a halogen (e.g., F, Cl, Br, or I) or pseudohalogen (e.g., OMs or OTf) with compounds 4-1 where A2b is 3-11 membered azaheterocyclyl and P2is an appropriate alcohol protecting group (e.g., TBS, TMS) under standard S\Ar conditions optionally in the presence of a base (e.g., DIPEA) or under standard Buchwald-Hartwig amination conditions (e.g., in the presence of a palladium catalyst, such as BrettPhos Pd G3, and a base, such as sodium / c / V-butoxide) and subsequent deprotection can afford compounds 4-2. Oxidation of alcohols 4-2 under standard conditions such as in the presence of an oxidant (e.g., Dess Martin periodinane, 2-iodoxybenzoic acid, or sulfur tri oxi de pyridine complex) and optionally in the presence of a base (e.g., NaHCCh or EtsN) can afford compounds 4-3. Reaction of compounds 4-3 and amines 4-4 where Aib is 3-11 membered azaheterocyclyl under standard conditions for reductive amination (e.g., in the presence of a reducing agent such as sodium triacetoxy-borohydride or sodium cyanoborohydride and optionally an acid, such as acetic acid) can afford compounds 4-5.Scheme IV- 120 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0401] Compounds of Formula (I) can be prepared as described in Scheme V. Coupling of compounds 2-3 with compounds 5-1 where A2Cis an aryl optionally substituted with 0-6 Rlaor Rlbgroups, or heteroaryl optionally substituted with 0-6 Rlaor Rlbgroups and M1is a boronic acid, boronate ester, potassium trifluoroborate, or an appropriately substituted metal, such as Sn(Bu)s, Sn(Me)s, Znl, ZnCl, or ZnBr under standard Suzuki conditions (e.g., in the presence of a palladium catalyst, such as SPhos Pd G2, and a base, such as potassium carbonate) or under standard Stille conditions (e.g., in the presence of a palladium catalyst, such as SPhos Pd G2 or tetrakis(triphenylphosphine)palladium(0)) or under standard Negishi cross-coupling conditions (e.g., in the presence of a palladium catalyst, such as SPhos Pd G2, tetrakis(triphenylphosphine)palladium(0), or [l,l’-bis(diphenylphosphino)ferrocene]dichloro-palladium(II)) can afford compounds 5-2. Reaction of compounds 5-2 and amines 4-4 where Aib is a 3-12 membered heterocyclyl optionally substituted with 0-6 Rlaor Rlbgroups under standard reductive amination conditions (e.g., in the presence of a reducing agent, such as sodium triacetoxyborohydride or sodium cyanoborohydride, and optionally an acid, such as acetic acid, and optionally a base, such as triethylamine) can afford compounds 5-3.Scheme V

[0402] Intermediates for the synthesis of compound of Formula (I) can be prepared as described in Scheme VI. Coupling of compounds 6-1 where Xais a halogen (e.g., Br or I) or pseudohalogen (e.g., OTf or OMs) with pyridines 6-2, where P3is an appropriate protecting group (e.g., Bn or PMB) and M2is a boronic acid, boronate ester, potassium trifluoroborate, or an appropriately substituted metal, such as Sn(Bu)s, Sn(Me)s, ZnBr, Znl, or ZnCl under standard Suzuki cross-coupling conditions (e.g., in the presence of a palladium catalyst, such as SPhos Pd G2) or standard Stille conditions (e.g., in the presence of a palladium (0) catalyst, such as tetrakis(triphenylphosphine)palladium (0)) or standard Negishi conditions (e.g., in the presence of a palladium catalyst, such as tetrakis(triphenylphosphine) palladium (0) or [1,1’-bis(diphenylphosphino)ferrocene]dichloropalladium(II)), can afford compounds 6-3. Coupling of compounds 6-3 where Xbis a halogen (e.g., F, Cl or Br) or pseudohalogen (e.g., OTf or OMs) with 6-4 where Aiais an optionally protected 3-7 membered cycloalkyl group, a 4-10-membered heterocycloalkyl group, an aryl group, or a heteroaryl group that is optionally- 121 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application substituted with one or more reactive groups such as, but not limited to, halogen (e.g., F, Cl, Br, I), hydroxy, aldehyde, boronic acid, boronate ester, trialkyltin, carboxylic acid, or amine under standard Suzuki (e.g., in the presence of a palladium catalyst, such as SPhos Pd G2) or standard Buchwald-Hartwig cross-coupling (e.g., in the presence of a palladium catalyst, such as BrettPhos Pd G4, and a base, such as sodium / c / 7-butoxide) or standard S\Ar reaction conditions (e.g., in the presence of a base, such as K2CO3, or an acid, such as p-toluenesulfonic acid) can afford compounds 6-5. Compounds 6-5 can be hydrogenated under standard conditions, such as exposure to H2 or D2 gas in the presence of a transition metal catalyst (e.g., palladium on charcoal or platinum(IV) oxide) to afford compounds 6-6.Scheme VIP3OSuzuki6-1

[0403] Intermediates for the synthesis of compounds of Formula (I) can be prepared as described in Scheme VII. Coupling of compounds 7-1 with compounds 7-2, where P4is an appropriate protecting group (e.g., Bn or PMB) under standard Ullmann cross-coupling conditions (e.g., in the presence of a copper catalyst, such as copper acetate, and a ligand, such as tetramethyl phenanthroline) can afford dihydrouracils 7-3. Coupling of 7-3 with 6-4 under standard Suzuki (e.g., in the presence of a palladium catalyst, such as SPhos Pd G2) or standard Buchwald-Hartwig cross-coupling (e.g., in the presence of a palladium catalyst, such as BrettPhos Pd G4, and a base, such as sodium / c / 7-butoxide) or standard S\Ar reaction conditions (e.g., in the presence of a base, such as K2CO3 or an acid, such as / ?-toluenesulfonic acid) can afford compounds 7-5. Compounds 7-5 can be deprotected under standard conditions, such as in the presence of an acid (e.g., TFA) to afford compounds 7-6.Scheme VIIX* XOTQ *2X2'N'X2AUllmann

[0404] Intermediates for the synthesis of compound of Formula (I) can be prepared as described in Scheme VIII. Coupling of compounds 8-1 with pyridines 6-2, under standard Suzuki cross-coupling conditions (e.g., in the presence of a palladium catalyst, such as SPhos Pd G2) or standard Stille conditions (e.g., in the presence of a palladium (0) catalyst, such as - 122 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application tetraki s(tri phenyl phosphi ne)pal 1 adi um (0)) or standard Negishi conditions (e.g., in the presence of a palladium catalyst, such as tetrakis(triphenylphosphine) palladium (0) or [1,1’-bis(diphenylphosphino)ferrocene]dichloropalladium(II)), can afford compounds 8-2. Coupling of compounds 8-2 with 6-4 under standard Suzuki (e.g., in the presence of a palladium catalyst, such as SPhos Pd G2) or standard Buchwald-Hartwig cross-coupling (e.g., in the presence of a palladium catalyst, such as BrettPhos Pd G4, and a base, such as sodium tert-butoxide) or standard S\Ar reaction conditions (e.g., in the presence of a base, such as K2CO3, or an acid, such as p-toluenesulfonic acid) can afford compounds 8-3. Compounds 8-3 can be hydrogenated under standard conditions, such as exposure to H2 or D2 gas in the presence of a transition metal catalyst (e.g., palladium on charcoal or platinum(IV) oxide) to afford compounds 8-4.Scheme VIIIP3O N Suzuki or Buchwald-Hartwig or S^Ar P3O \YSuzuki x2"<xr-x» 6-48-2

[0405] Intermediates for the synthesis of compounds of Formula (I) can be prepared as described in Scheme IX. Coupling of compounds 9-1 with compounds 7-2 under standard Ullmann cross-coupling conditions (e.g., in the presence of a copper catalyst, such as copper acetate, and a ligand, such as tetramethyl phenanthroline) can afford dihydrouracils 9-2.Coupling of 9-2 with 6-4 under standard Suzuki (e.g., in the presence of a palladium catalyst, such as SPhos Pd G2) or standard Buchwald-Hartwig cross-coupling (e.g., in the presence of a palladium catalyst, such as BrettPhos Pd G4, and a base, such as sodium / c / V-butoxide) or standard S\Ar reaction conditions (e.g., in the presence of a base, such as K2CO3 or an acid, such as / ?-toluenesulfonic acid) can afford compounds 9-3. Compounds 9-3 can be deprotected under standard conditions, such as in the presence of an acid (e.g., TFA) to afford compounds 9-4Scheme IXo Suzuki or Buchwald-Hartwig or Sfr|ArXQXM2^x^2x» 6-4

[0406] Intermediates for the synthesis of compounds of Formula (I) can also be prepared as previously described (WO2023019166A1; WO2022195454A1; WO2021053555A1;- 123 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application WO2024255810A1; CN120025316A; WO2017197046A1; CN115557933A;WO2021053555A1; WO2022125790A1; CN120025333A; W02017197051A1; Norris, S., et al. J. Med. Chem. 2023, 66, 16388-16409; Teng, M. et al. J. Med. Chem. 2022, 65, 747-756; Lejava, A., et al. ACS Med. Chem. Lett. 2025, 16, 89-95; Actis, et al. J. Med Chem. 2025, 68, 3591-3611.).Example 1. V-(6-((LH-Pyrazol-l-yl)methyl)-4-methoxybenzo[ |isoxazol-3-yl)-3-(7-(((35)-l-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-lZ7-indazol-5-yl)pyrrolidin-3-yl)methyl)- 2,7-diazaspiro [3.5] nonan-2-yl)benzenesulfonamide

[0407] Step 1. tert-Butyl (R)-3-( (benzyloxy)methyl)pyrrolidine-l -carboxylate

[0408] To a solution of sodium hydride (60% in mineral oil, 159 mg, 3.97 mmol) in THF (5 mL) at 0 °C was added a solution of tert-butyl ( / )-3 -(hydroxymethyl )pyrroli di ne-l-carboxylate (400 mg, 1.99 mmol) in THF (5 mL). The reaction was stirred for 0.5 h at 0 °C. Benzyl bromide (0.350 mL, 2.98 mmol) was added and the reaction was stirred for 2 h at room temperature. The reaction mixture was quenched with sat. NH4CI (aq) and extracted with EtOAc (3 x 15 mL). The combined organic layers were washed with brine, dried over MgSCU, filtered, and concentrated. The crude material was purified by silica gel chromatography (0-25% EtOAc / hexanes) to afford the title compound (192 mg, 0.659 mmol,- 124 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application 33.1%) as a clear, colorless oil. LCMS calc, for C17H26NO3 [M+H]+: m / z= 292.2; Found 292.1.

[0409] Step 2. (R)-3-((Benzyloxy)methyl)pyrrolidine

[0410] To a solution of tert-butyl (A)-3-((benzyloxy)methyl)pyrrolidine-l -carboxylate (659 mg, 2.26 mmol) in 1,4-di oxane (5 mL) was added hydrochloric acid (4N in dioxane, 8.48 mL, 33.9 mmol). The reaction was stirred for 1 h. The reaction mixture was concentrated and carried forward without further purification. LCMS calc, for CnHisNO [M+H]+: m / z= 192.1; Found 192.1.

[0411] Step 3. l-(2,6-bis(Benzyloxy)pyridin-3-yl)-5-bromo-3-methyl-lH-indazole

[0412] A mixture of 2,6-bis(benzyloxy)-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine (1.66 g, 3.98 mmol), 5-bromo-3-methyl-17 / -indazole (700 mg, 3.32 mmol), cesium carbonate (1.30 g, 3.98 mmol), copper(II) acetate (120 mg, 0.663 mmol), and 1,10-phenanthroline (120 mg, 0.663 mmol) in DCE (20 mL) was stirred at 70 °C, open to air, for 16 h.. The reaction mixture was filtered through Celite and the filtrate was concentrated and purified by silica gel chromatography (0-25% EtOAc / hexanes) to afford the title compound (999 mg, 2.00 mmol, 60.2%). LCMS calc, for C27H23BrN3O2 [M+H]+: m / z= 500.1, 502.1; Found 500.0, 501.9.

[0413] Step 4. (R)-5-(3-((Benzyloxy)methyl)pyrrolidin-l-yl)-l-(2,6-bis(benzyloxy)pyridin-3-yl)-3-methyl-lH-indazole- 125 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0414] A solution of l-(2,6-bis(benzyloxy)pyridin-3-yl)-5-bromo-3-methyl-17 / -indazole (200 mg, 0.400 mmol), 2-(dicyclohexylphosphino)-2',4',6'-tri-i-propyl-l,r-biphenyl (38 mg, 0.080 mmol), cesium carbonate (430 mg, 1.32 mmol), (A)-3-((benzyloxy)methyl)pyrrolidine (107 mg, 0.560 mmol), and tris(dibenzylideneacetone)dipalladium(0) (36.6 mg, 0.0400 mmol) in 1,4-di oxane (4 mL) was sparged with nitrogen for 5 min. The reaction was stirred under a nitrogen atmosphere for 16 h at 110 °C. The reaction mixture was cooled to room temperature and diluted with water (10 mL) and MTBE (10 mL). The aqueous layer was extracted with MTBE (3 x 5 mL). The combined organic layers were washed with brine, dried over MgSCL, filtered, and concentrated. The crude material was purified by silica gel chromatography (0-25% EtOAc / hexanes) to afford the title compound (178 mg, 0.291 mmol, 73.0%) as a yellow solid. LCMS calc, for C39H39N4O3 [M+H]+: m / z= 611.3; Found 611.2.

[0415] Step 5. 3-(5-((R)-3-(Hydroxymethyl)pyrrolidin-l-yl)-3-methyl-lH-indazol-l-yl)piperidine-2, 6-dione

[0416] A solution of (A)-5-(3-((benzyloxy)methyl)pyrrolidin-l-yl)-l-(2,6-bis(benzyloxy)-pyri din-3 -yl)-3 -methyl- UT-indazole (400 mg, 0.655 mmol), acetic acid (0.075 mL, 1.3 mmol) and palladium on carbon (10% wt, 139 mg, 0.131 mmol) in methanol (2.5 mL) and THF (2.5 mL) was sparged with hydrogen for 5 min. The reaction was stirred overnight under a hydrogen atmosphere (balloon) then filtered through Celite and concentrated. The crude material was purified by silica gel chromatography (50-100% EtOAc / hexanes then 0-20% MeOHZEtOAc) to afford the title compound (107 mg, 0.313 mmol, 46.0% yield). LCMS calc, for C18H23N4O3 [M+H]+: m / z= 343.2; Found 343.1.

[0417] Step 6. N-( 6-( ( lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(7- ((( 3S)-l-( 1 -(2, 6-dioxopiperidin-3-yl)-3-methyl-lH-indazol-5-yl)pyrrolidin-3-yl)methyl)-2, 7-diazaspiro[ 3.5 ]nonan-2-yl) benzenesulfonamide

[0418] To a solution of 3-(6-((A)-3-(hydroxymethyl)pyrrolidin-l-yl)-l-methyl-17 / -indazol-3-yl)piperidine-2, 6-dione (5.4 mg, 0.016 mmol) and triethylamine (0.020 mL, 0.14 mmol) in DMSO (0.30 mL) was added a solution of sulfurtri oxi de pyridine complex (7.5 mg, 0.047 mmol) in DMSO (0.30 mL). The reaction was stirred for 1 h. A solution of V-(6-(( 177-pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(2,7-diazaspiro[3.5]nonan-2-yl)benzenesulfonamide (which can be prepared as described in WO2023245150A1) (8.0 mg,- 126 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application 0.016 mmol) in MeCN (0.20 mL) and DMSO (0.30 mL) was added followed by acetic acid (0.014 mL, 0.24 mmol). The reaction was stirred for 0.5 h. Sodium triacetoxyborohydride (13 mg, 0.063 mmol) was added and the reaction was stirred for 1 h. The reaction was quenched with water, diluted with MeCN, filtered, and purified by prep-HPLC on a Cl 8 column (21.7-41.7% MeCN / 0.2% TFA (aq)) to afford the title compound (2.3 mg, 0.0022 mmol, 14%) as a white solid. LCMS calc, for C43H49N10O6S [M+H]+: m / z= 833.4; Found 833.2.Example 2. V-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(7-((l- ( 1 -(2.6-dioxopiperidin-3-yl)-3-niethyl-2-oxo-2.3-dihydro- 1 / / -beiizo| |imidazol-5-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)benzenesulfonamideO

[0419] To a solution of l-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-UT-benzo[d]imidazol-5-yl)piperidine-4-carbaldehyde (5.1 mg, 0.014 mmol) andA-(6-((UT-pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(2,7-diazaspiro[3.5]nonan-2-yl)benzenesulfonamide (7.0 mg, 0.014 mmol) in MeCN (0.15 mL) and DMSO (0.60 mL) was added acetic acid (0.012 mL, 0.21 mmol). The reaction was stirred for 0.5 h. Sodium triacetoxyborohydride (12 mg, 0.055 mmol) was added and the reaction was stirred for 1 h. The reaction was quenched with water, diluted with MeCN, filtered, and purified by prep-HPLC on a C18 column (18.1-38.1% MeCN / 0.2% TFA (aq)) to afford the title compound as a TFA salt (5.0 mg, 0.0046 mmol, 33%), a white solid. 'H NMR (400 MHz, DMSO) 6 11.10 (s, 1H), 10.83 (s, 1H), 7.89 (d, J= 2.2 Hz, 1H), 7.51 (d, J= 1.8 Hz, 1H), 7.40 (t, J= 7.9 Hz, 1H), 7.27 (d, J= 7.7 Hz, 1H), 7.12 - 6.93 (m, 3H), 6.84 (s, 1H), 6.76 (s, 2H), 6.67 (dd, J = 8.2, 2.3 Hz, 1H), 6.31 (t, J = 2.1 Hz, 1H), 5.45 (s, 2H), 5.33 (dd, J= 12.9, 5.4 Hz, 1H), 3.87 (s, 3H), 3.75 - 3.67 (m, 6H), 3.55 - 3.41 (m, 4H), 3.33 (s, 3H), 3.14 - 2.81 (m, 5H), 2.78 - 2.58- 127 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application (m, 2H), 2.13 (d, J= 13.8 Hz, 2H), 2.06 - 1.83 (m, 6H), 1.56 - 1.34 (m, 2H). LCMS calc, for C44H51N10O7S [M+H]+: m / z= 863.4; Found 863.4.Example 3. 7V-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J|isoxazol-3-yl)-3-(7-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)pyrrolidin-3-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)benzenesulfonamide

[0421] A solution of l-bromo-4-iodobenzene (1.00 g, 3.53 mmol), pyrrolidin-3-yl-m ethanol (393 mg, 3.89 mmol), copper(I) iodide (135 mg, 0.707 mmol), Z-proline (81.4 mg, 0.707 mmol), and potassium phosphate tribasic (1.50 mg, 7.07 mmol) in DMSO (15 mL) was stirred at 80 °C for 16 h. The reaction was cooled to room temperature and filtered through Celite. The filtrate was diluted with brine (25 mL) and EtOAc (25 mL). The aqueous layer was extracted with EtOAc (3 x 25 mL). The combined organic layers were washed with brine, dried over MgSO4, filtered, and concentrated to afford the title compound (871 mg, 3.40 mmol, 96.2%) as a brown solid. LCMS calc, for CnHisBrNO [M+H]+: m / z= 256.0, 258.0; Found 256.0, 258.0.

[0422] Step 2. (l-(4-(2, 6-Bis(benzyloxy)pyridin-3-yl)phenyl)pyrrolidin-3-yl)methanol- 128 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0423] A solution of 2,6-bis(benzyloxy)-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine (1.87 g, 4.49 mmol), [l-(4-bromophenyl)pyrrolidin-3-yl]methanol (826 mg, 3.22 mmol), cesium carbonate (2.10 g, 6.45 mmol), and [l,l'-bis(diphenylphosphino)ferrocene]-dichloropalladium(II)dichloromethane (0.290 g, 0.355 mmol) in 1,4-dioxane (35 mL) and water (4 mL) was sparged with nitrogen for 10 min then stirred for 16 h at 100 °C. The reaction was cooled to room temperature, filtered, and concentrated onto Celite. The material was purified by silica gel chromatography (0-100% EtOAc / hexanes) to afford the title compound (696 mg, 1.49 mmol, 46.3%) as a tan solid. LCMS calc, for C30H31N2O3 [M+H]+: m / z= 467.2; Found 467.1.

[0424] Step 3. N-( 6-( ( lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(7-( (1-(4-(2, 6-dioxopiperidin-3-yl)phenyl)pyrrolidin-3-yl)methyl) -2, 7-diazaspiro[ 3.5 ] nonan-2-yl) benzenesulfonamide

[0425] The title compound was synthesized according to procedures analogous to Example 1, Steps 5-6. LCMS calc, for C ILnNsOeS [M+H]+: m / z= 779.3; Found 779.1.Example 4. \-(6-(( l / / -I’yr:izol-l-yl)inethyl)-4-inethoxybenzo| |isox:izol-3-yl)-3-(7-(( 1-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lEZ-pyrrolo[3,2-c]pyridin-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro [3.5] nonan-2-yl)benzenesulfonamide

[0426] Step 1. 6-(4-(Dimethoxymethyl)piperidin-l-yl)-l -methyl- IH-pyrrolo [ 3, 2-c]pyridine - 129 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0427] A solution of 6-bromo-l-m ethyl- 17 / -pyrrolo[3,2-c]pyri dine (1.98 g, 9.37 mmol), 4-(dimethoxymethyl)piperidine (2.24 g, 14.1 mmol), potassium tert-butoxide (IN in THF, 2.63 g, 23.4 mmol), RuPhos Pd G3 (CAS 1445085-77-7, 392 mg, 0.468 mmol), and RuPhos (CAS 787618-22-8, 437 mg, 0.937 mmol) in 1,4-dioxane (25 mL) was stirred at 100 °C under a nitrogen atmosphere for 4 h. The mixture was cooled to room temperature, poured into cold water (200 mL), and extracted with EtOAc (100 mL x 3). The combined organic layers were dried over Na2SC>4, filtered, and concentrated. The crude material was purified by silica gel chromatography (0-75% EtOAc / heptanes) to afford the title compound (2.50 g, 8.64 mmol, 92.2%) as a yellow solid. LCMS calc, for C16H24N3O2 [M+H]+: m / z= 290.2; Found 290.5.

[0428] Step 2. 3-(2,6-Bis(benzyloxy)pyridin-3-yl)-6-(4-(dimethoxymethyl)piperidin-l-yl)-l-methyl-lH-pyrrolo[ 3, 2-c ] pyridine

[0429] A solution of 2, 6-bis(benzyloxy)-3 -iodopyridine (3.38 g, 8.10 mmol), 6-(4-(dimethoxymethyl)piperidin-l-yl)-l-methyl-17 / -pyrrolo[3,2-c]pyridine (1.88 g, 6.48 mmol), palladium(II) acetate (0.146 g, 0.648 mmol), potassium carbonate (2.69 g, 19.5 mmol), tetrabutylammonium bromide (0.418 g, 1.30 mmol), and triphenylphosphine (0.170 g, 0.648 mmol) in DMSO (18 mL) was stirred at 120 °C for 18 h. The reaction was cooled to room temperature, diluted with EtOAc (250 mL), washed with water (75 mL) and brine (75 mL), dried over Na2SO4, filtered, and concentrated. The crude material was purified by silica gel chromatography (0-50% EtOAc / heptanes) to afford the title compound (3.00 g, 5.18 mmol, 79.8%) as a yellow solid. LCMS calc, for C35H39N4O4 [M+H]+: m / z= 579.3; Found 579.6.

[0430] Step 3. 3-(6-(4-(Dimethoxymethyl)piperidin- l-yl)-l -methyl- lH-pyrrolo[ 3,2-c ]pyridin-3-yl)piperidine-2, 6-dione- 130 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application°\

[0431] The title compound was synthesized according to procedures analogous to Example 1, Step 5. LCMS calc, for C21H29N4O4 [M+H]+: m / z= 401.2; Found 401.4.

[0432] Step 4. l-( 3-(2, 6-Dioxopiperidin-3-yl)-l -methyl- lH-pyrrolo[ 3, 2-c ]pyridin-6-yl)piperidine-4-carbaldehyde

[0433] To a solution of 3 -(6-(4-(dimethoxymethyl)piperi din- l-yl)-l -methyl- UT-pyrrolo- [3, 2-c]pyri din-3 -yl)piperidine-2, 6-dione (20.0 mg, 0.0499 mmol) in DCM (0.45 mL) and Acetone (0.18 mL) was added trifluoroacetic acid (0.153 mL, 2.00 mmol). The reaction was stirred for 2 h. The mixture was neutralized with NaHCCh then diluted with water and 3: 1 CHCI3 / IPA. The aqueous layer was exacted with 3:1 CHCI3 / IPA (3 x 10 mL). The combined organic layers were washed with brine, dried over MgSCL, filtered, and concentrated to afford the title compound (28.0 mg, 0.0790 mmol, >99%). LCMS calc, for C19H23N4O3 [M+H]+: m / z= 355.2; Found 355.1.

[0434] Step 5. N-( 6-( ( lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(7-( (1- (3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-pyrrolo[3,2-c]pyridin-6-yl)piperidin-4-yl)methyl)-2, 7 -diazaspiro [ 3.5 ]nonan-2-yl) benzenesulfonamide

[0435] The title compound was synthesized according to procedures analogous to Example 2. ‘HNMR (400 MHz, DMSO-tL) 6 11.03 (s, 1H), 9.26 (s, 1H), 8.60 (s, 1H), 7.89 (d, J= 2.3 Hz, 1H), 7.51 (d, J= 1.8 Hz, 1H), 7.40 (t, J= 7.9 Hz, 1H), 7.27 (d, J= 7.1 Hz, 2H), 7.01 -6.93 (m, 1H), 6.84 (s, 1H), 6.76 (s, 1H), 6.68 (dd, J= 8.0, 2.3 Hz, 1H), 6.62 (s, 1H), 6.31 (t, J = 2.1 Hz, 1H), 5.45 (s, 2H), 4.39 (dd, J= 12.4, 4.6 Hz, 1H), 4.11 - 3.94 (m, 2H), 3.87 (s, 4H), 3.74 (d, J= 9.8 Hz, 5H), 3.66 (s, 2H), 3.51 (d, J= 12.3 Hz, 3H), 3.19 - 2.92 (m, 5H), 2.84 -- 131 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application 2.59 (m, 2H), 2.27 - 2.08 (m, 4H), 2.07 - 1.83 (m, 4H), 1.48 - 1.30 (m, 2H). LCMS calc, for C44H51N10O6S [M+H]+: m / z= 847.4; Found 847.2.Example 5. 7V-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(7-((l-(2-(2,6-dioxopiperidin-3-yl)-l-oxo-l,2-dihydroisoquinolin-6-yl)piperidin-4-yl)methyl)- 2,7-diazaspiro [3.5] nonan-2-yl)-2-methoxybenzenesulfonamide

[0436] The title compound was synthesized according to procedures analogous to Example 2, using A-(6-((U / -pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-2-methoxy-3-(2,7-diazaspiro[3.5]nonan-2-yl)benzenesulfonamide (which can be prepared as described in WO2023245150A1) and l-(2-(2,6-dioxopiperidin-3-yl)-l-oxo-l,2-dihydroisoquinolin-6-yl)piperidine-4-carbaldehyde (which can be prepared as described in WO2022099117A1).JH NMR (400 MHz, DMSO-tL) 6 11.01 (s, 1H), 10.56 (s, 1H), 7.99 (d, J= 9.0 Hz, 1H), 7.89 (d, J= 2.3 Hz, 1H), 7.51 (d, J= 1.8 Hz, 1H), 7.27 (d, J= 7.5 Hz, 1H), 7.25 - 7.12 (m, 3H), 6.98 (d, J= 2.4 Hz, 1H), 6.86 (s, 1H), 6.83 - 6.75 (m, 2H), 6.47 (d, J= 7.5 Hz, 1H), 6.31 (t, J= 2.1 Hz, 1H), 5.45 (s, 2H), 4.00 (d, J= 12.7 Hz, 2H), 3.81 (s, 3H), 3.69 (d, J= 3.4 Hz, 5H), 3.61 (s, 2H), 3.55 - 3.40 (m, 4H), 3.15 - 2.76 (m, 6H), 2.73 - 2.55 (m, 2H), 2.11 (d, J= 13.4 Hz, 3H), 2.05 - 1.89 (m, 3H), 1.82 (d, J= 12.6 Hz, 2H), 1.30 (q, J= 12.4 Hz, 2H). LCMS calc, for C46H52N9O8S [M+H]+: m / z= 890.4; Found 890.2.Example 6. 7V-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(7-((l-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-lH-indazol-5-yl)piperidin-4-yl)methyl)-2,7-diazaspiro [3.5] nonan-2-yl)-2-methoxybenzenesulfonamide- 132 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0437] Step 1. 3-(5-(4-(Dimethoxymethyl)piperidin-l-yl)-3-methyl-lH-indazol-l-yl)piperidine-2, 6-dioneO

[0438] The title compound was synthesized according to procedures analogous to Example 1, Steps 4-5, using 4-(dimethoxymethyl)piperidine. LCMS calc, for C21H29N4O4 [M+H]+: m / z= 401.2; Found 401.1.

[0439] Step 2. l-(l-(2,6-Dioxopiperidin-3-yl)-3-methyl-lH-indazol-5-yl)piperidine-4-carbaldehydeN, N

[0440] The title compound was synthesized according to procedures analogous to Example 4, Step 4. LCMS calc, for C19H23N4O3 [M+H]+: m / z= 355.2; Found 355.0.- 133 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0441] Step 3. N-( 6-( ( lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(7-( (1-(l-(2, 6-dioxopiperidin-3-yl)-3-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)-2, 7-diazaspiro[ 3.5 ]nonan-2-yl)-2-methoxybenzenesulfonamide

[0442] The title compound was synthesized according to procedures analogous to Example 2.JH NMR (400 MHz, DMSO-tL ) 6 11.06 (s, 1H), 10.56 (s, 1H), 7.89 (d, J= 2.3 Hz, 1H), 7.51 (d, J= 1.9 Hz, 1H), 7.22 (dd, = 8.0, 1.6 Hz, 1H), 7.16 (t, J = 7.9 Hz, 1H), 6.86 (s, 1H), 6.83 - 6.73 (m, 2H), 6.31 (t, J= 2.1 Hz, 1H), 5.78 - 5.64 (m, 1H), 5.46 (s, 2H), 3.81 (s, 4H), 3.76 - 3.65 (m, 8H), 3.62 (s, 3H), 3.50 (d, J= 12.0 Hz, 3H), 3.19 - 2.64 (m, 8H), 2.49 - 2.43 (m, 3H), 2.32 - 2.05 (m, 4H), 2.03 - 1.86 (m, 4H), 1.61 - 1.42 (m, 2H). LCMS calc, for C45H53NIO07S [M+H]+: m / z= 877.4; Found 877.2.Example 7. 7V-(6-((lEZ-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro [3.5] nonan-2-yl)-2-methoxybenzenesulfonamide

[0443] The title compound was synthesized according to procedures analogous to Example 2, using l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-U / -indazol-6-yl)piperidine-4-carbaldehyde (which can be prepared as described in W020240399901 A2). 'H NMR (400 MHz, DMSO-d6) 6 10.87 (s, 1H), 10.56 (s, 1H), 7.89 (d, J= 2.3 Hz, 1H), 7.58 - 7.45 (m, 2H), 7.21 (dd, J = 8.0, 1.6 Hz, 1H), 7.15 (t, J= 7.9 Hz, 1H), 6.91 (d, J = 40.6 Hz, 3H), 6.82 - 6.74 (m, 2H), 6.31 (t, J= 2.1 Hz, 1H), 5.46 (s, 2H), 4.27 (dd, J= 9.4, 5.1 Hz, 1H), 3.90 (s, 3H), 3.81 (s, 6H), 3.70 (d, J= 4.2 Hz, 6H), 3.61 (s, 2H), 3.49 (d, J= 12.1 Hz, 2H), 3.12 - 2.92 (m, 3H), 2.91 - 2.76 (m, 2H), 2.71 - 2.57 (m, 2H), 2.36 - 2.26 (m, 1H), 2.22 - 1.77 (m, 7H), 1.48 - 1.29 (m, 2H). LCMS calc, for C45H53N10O7S [M+H]+: m / z= 877.4; Found 877.2.- 134 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application Example 8. 7V-(6-((LH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J|isoxazol-3-yl)-3-(7-((l-(6-(2,6-dioxopiperidin-3-yl)-l-methyl-LH-indazol-3-yl)piperidin-4-yl)methyl)-2,7-diazaspiro [3.5] nonan-2-yl)-2-methoxybenzenesulfonamideN-N

[0444] Step 1. 6-Bromo-3-(4-(dimethoxymethyl)piperidin-l-yl)-l-methyl-lH-indazoleOMe

[0445] To a solution of 6-bromo-3-iodo-l-methyl-17 / -indazole (4.00 g, 11.9 mmol) and 4-(dimethoxymethyl)piperidine (1.89 g, 11.9 mmol) in DMSO (32 mL) was added potassium carbonate (3.28 g, 23.7 mmol), Z-proline (547 mg, 4.75 mmol) and copper(I) iodide (452 mg, 2.37 mmol). The reaction mixture was stirred at 80 °C for 16 h. The reaction was cooled to room temperature, quenched with water, and stirred for 30 minutes. The aqueous phase was extracted with EtOAc (x 3). The combined organic layers were dried over ISfeSC, filtered, and concentrated. The crude material was purified by silica gel chromatography (0-30% EtOAc / heptanes) to afford the title compound (1.49 g, 4.05 mmol, 34.1%). LCMS calc, for C16H23N3O2 [M+H]+: m / z= 368.1, 370.1; Found 368.4, 370.4.

[0446] Step 2. 6-(2,6-Bis(benzyloxy)pyridin-3-yl)-3-(4-(dimethoxymethyl)piperidin-l-yl)-l-methyl-lH-indazole- 135 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0447] A solution of 6-bromo-3-(4-(dimethoxymethyl)piperidin-l-yl)-l-methyl-lH-indazole (1.49 g, 4.05 mmol), 2,6-bis(benzyloxy)-3-(4,4,5,5-tetramethyl-l,3,2-dioxa-borolan-2-yl)pyridine (2.53 g, 6.07 mmol), potassium phosphate tribasic (2.58 g, 12.1 mmol), and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane (0.331 g, 0.405 mmol)in 1,4-dioxane (30 mL) and water (7.5 mL) was sparged with nitrogen for 10 minutes, then stirred at 100 °C for 4 h. The reaction mixture was cooled to room temperature and poured into water then extracted with EtOAc (3 x). The combined organic layers were dried over Na2SC>4, filtered, and concentrated. The crude material was purified by silica gel chromatography (0-30% EtOAc / heptanes) to afford the title compound (2.20 g, 3.80 mmol, 94.0%). LCMS calc, for C35H39N4O4 [M+H]+: m / z= 579.3; Found 579.6.

[0448] Step 3. 3-(3-(4-(Dimethoxymethyl)piperidin-l-yl)-l -methyl- lH-indazol-6-yl)piperidine-2, 6-dione

[0449] The title compound was synthesized according to procedures analogous to Example 1, Step 5. LCMS calc, for C21H29N4O4 [M+H]+: m / z= 401.2; Found 401.5.

[0450] Step 4. l-(6-(2,6-Dioxopiperidin-3-yl)-l -methyl- lH-indazol-3-yl)piperidine-4-carbaldehyde- 136 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0451] The title compound was synthesized according to procedures analogous to Example 4, Step 4. LCMS calc, for C19H23N4O3 [M+H]+: m / z= 355.2; Found 355.1.

[0452] Step 5. N-( 6-( ( lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(7-( 1-( 6-(2, 6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-3-yl)piperidin-4-yl)methyl)-2, 7-diazaspiro[ 3.5 ]nonan-2-yl)-2-methoxybenzenesulfonamide

[0453] The title compound was synthesized according to procedures analogous to Example 2. ‘HNMR (400 MHz, DMSO-d6) 6 10.88 (s, 1H), 10.55 (s, 1H), 7.89 (d, J = 2.3 Hz, 1H), 7.69 (d, J = 8.5 Hz, 1H), 7.51 (d, J = 1.8 Hz, 1H), 7.32 (s, 1H), 7.21 (dd, J = 7.9, 1.6 Hz, 1H), 7.15 (t, J = 7.9 Hz, 1H), 6.92 - 6.82 (m, 2H), 6.83 - 6.74 (m, 2H), 6.31 (t, J = 2.1 Hz, 1H), 5.46 (s, 2H), 3.96 (dd, J = 11.8, 4.9 Hz, 1H), 3.89 (d, J = 12.3 Hz, 2H), 3.81 (d, J = 3.6 Hz, 6H), 3.70 (d, J = 4.1 Hz, 6H), 3.61 (s, 2H), 3.49 (d, J = 12.1 Hz, 2H), 3.13 - 2.93 (m, 4H), 2.86 (t, J= 12.0 Hz, 2H), 2.72 (ddd, J= 17.0, 12.0, 5.1 Hz, 1H), 2.38 - 2.22 (m, 1H), 2.16 -1.76 (m, 8H), 1.51 - 1.36 (m, 2H). LCMS calc, for C45H53NIO07S [M+H]+: m / z= 877.4; Found 877.2.Example 9. 7V-(6-((lEZ-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lEZ-pyrrolo[2,3-6]pyi'idin-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-methoxybenzenesulfonamide- 137 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0454] Step 1. 3-(2,6-Bis(benzyloxy)pyridin-3-yl)-6-chloro-l-methyl-lH-pyrrolo[2,3-b] pyridine

[0455] The title compound was synthesized according to procedures analogous to Example 8, Step 2. LCMS calc, for C27H23CIN3O2 [M+H]+: m / z= 456.1; Found 456.4.

[0456] Step 2. 3-(2,6-Bis(benzyloxy)pyridin-3-yl)-6-(4-(dimethoxymethyl)piperidin-l-yl)-l-methyl-lH-pyrrolo[ 2, 3-b ] pyridine

[0457] The title compound was synthesized according to procedures analogous to Example 4, Step 1. LCMS calc, for C35H39N4O4 [M+H]+: m / z= 579.3; Found 579.7.

[0458] Step 3. 3-(6-(4-(Dimethoxymethyl)piperidin-l-yl)-l -methyl- IH-pyrrolo [2,3-b ]pyridin-3-yl)piperidine-2, 6-dione°\

[0459] The title compound was synthesized according to procedures analogous to Example 1, Step 5. LCMS calc, for C21H29N4O4 [M+H]+: m / z= 401.2; Found 401.5.

[0460] Step 4. l-(3-(2,6-Dioxopiperidin-3-yl)-l-methyl-lH-pyrrolo[2,3-b]pyridin-6-yl)piperidine-4-carbaldehyde- 138 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0461] The title compound was synthesized according to procedures analogous to Example 4, Step 4. LCMS calc, for C19H23N4O3 [M+H]+: m / z= 355.2; Found 355.1.

[0462] Step 5. N-( 6-( ( lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(7-( (1-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-pyrrolo[2, 3-b]pyridin-6-yl)piperidin-4-yl)methyl)-2, 7 -diazaspiro [ 3.5 ]nonan-2-yl)-2-methoxybenzene sulfonamide

[0463] The title compound was synthesized according to procedures analogous to Example 2. LCMS calc, for C45H53NIO07S [M+H]+: m / z= 877.4; Found 877.9.Example 10. V-(6-((lEZ-Pyrazol-l-yl)methyl)-4-methoxybenzo[< / ]isoxazol-3-yl)-3-(7-((l-(3-(2,4-dioxotetrahydropyrimidin-l(2ET)-yl)-l-methyl-lZ7-indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2,6-dimethoxybenzenesulfonamide

[0464] The title compound was synthesized according to procedures analogous to Example 2, using N-(6-((lH-pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-2,6-dimethoxy-3-(2,7-diazaspiro[3.5]nonan-2-yl)benzenesulfonamide (which can be prepared as described in WO2023245150A1) and l-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperidine-4-carbaldehyde (which can be prepared as described in WO2023249970A1). 'H NMR (400 MHz, DMSO-d6) 6 10.52 (s, 1H), 9.60 (s, 1H), 7.89 (d, J = 2.2 Hz, 1H), 7.50 (d, J = 1.8 Hz, 1H), 7.46 (d, J = 9.0 Hz, 1H), 6.98 - 6.91 (m, 1H), 6.89 - 6.82 (m, 3H), 6.79 (s,- 139 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application 1H), 6.71 (d, J = 9.1 Hz, 1H), 6.31 (t, J = 2.1 Hz, 1H), 5.45 (s, 2H), 3.96 - 3.83 (m, 9H), 3.69 (d, J = 3.1 Hz, 7H), 3.64 (s, 2H), 3.55 (s, 2H), 3.48 (d, J = 12.3 Hz, 2H), 3.10 - 2.91 (m, 4H), 2.86 -2.71 (m, 4H), 2.15 -2.01 (m, 3H), 1.95 (t, J= 12.9 Hz, 2H), 1.84 (d, J = 12.6 Hz, 2H), 1.37 (q, J = 11.4 Hz, 2H). LCMS calc, for C45H54NIIO8S [M+H]+: m / z= 908.4; Found 908.2.Example 11. V-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[< / ]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lEZ-indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro [3.5] nonan-2-yl)-2,6-dim ethoxybenzenesulfonamideO

[0465] The title compound was synthesized according to procedures analogous to Example 2, using 1 -(3 -(2,6-dioxopiperidin-3 -yl)- 1 -methyl- 1 H-indazol -6-yl)piperidine-4-carbaldehyde (which can be prepared as described in W02024039901A2). LCMS calc, for C46H55N10O8S [M+H]+: m / z= 907.4; Found 907.2.Example 12. V-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[< / ]isoxazol-3-yl)-4-(7-((l-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-lH-indazol-5-yl)piperidin-4-yl)methyl)-2,7-diazaspiro [3.5] nonan-2-yl)benzenesulfonamide

[0466] Step 1. N-( 6-( ( lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-4-bromobenzenesulfonamide- 140 - 105807.00506114896-4870-4897.1105807.005061 - PCT Application

[0467] To a solution of 6-((lH-pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-amine (which can be prepared as described in WO2023245150A1) (50.0 mg, 0.205 mmol) and 4-bromobenzenesulfonyl chloride (131 mg, 0.512 mmol) in THF (1.0 mL) was added potassium tert-butoxide (184 mg, 1.64 mmol). The reaction was stirred for 1 h then diluted with IN HC1 (aq) and EtOAc. The layers were separated, and the aqueous layer was extracted with EtOAc (3 x). The combined organic layers were washed with brine, dried over MgSO4, filtered, and concentrated. The crude material was purified by silica gel chromatography (0-10% MeOH / DCM) to afford the title compound (53.4 mg, 0.115 mmol, 56.3%) as a white solid. LCMS calc, for Ci8Hi6BrN4O4S [M+H]+: m / z= 463.0, 465.0; Found 462.9, 464.9.

[0468] Step 2. N-( 6-( ( lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-4-(2, 7-diazaspiro[ 3.5 ]nonan-2-yl) benzenesulfonamide

[0469] To a nitrogen-sparged solution of N-(6-((lH-pyrazol-l-yl)methyl)-4-methoxybenzo-[d]isoxazol-3-yl)-4-bromobenzenesulfonamide (53.4 mg, 0.115 mmol), tert-butyl 2,7-diazaspiro[3.5]nonane-7-carboxylate (31.3 mg, 0.138 mmol), and sodium tert-butoxide (55.4 mg, 0.576 mmol) in 1,4-dioxane (1.15 mL) was added BrettPhos Pd G3 (CAS 1470372-59-8, 8.36 mg, 0.00922 mmol). The reaction was stirred for 1 h at 100 °C, under a nitrogen atmosphere. The reaction mixture was cooled to room temperature and concentrated.Trifluoroacetic acid (0.5 mL) was added to the residue, and the reaction was stirred for 1 h. The reaction mixture was concentrated then purified by silica gel chromatography (0-25% MeOH / DCM) to afford the title compound (47.0 mg, 0.0920 mmol, 80.0%) as a white solid. C25H29N6O4S [M+H]+: m / z= 509.2; Found 509.0.

[0470] Step 3. N-( 6-( ( lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-4-(7-( (1-(l-(2, 6-dioxopiperidin-3-yl)-3-methyl-lH-indazol-5-yl)piperidin-4-yl)methyl)-2, 7-diazaspiro[ 3.5 ]nonan-2-yl) benzenesulfonamide

[0471] The title compound was synthesized according to procedures analogous to Example 2, using 1 -( 1 -(2,6-dioxopiperidin-3 -y l)-3 -methyl- 1 H-indazol -5-yl)piperidine-4-carbaldehyde (from Example 6, Step 2). LCMS calc, for C44H51N10O6S [M+H]+: m / z= 847.4; Found 847.2.- 141 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application Example 13. V-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[< / ]isoxazol-3-yl)-4-(7-((l-(2-(2,6-dioxopiperidin-3-yl)-l-oxo-l,2-dihydroisoquinolin-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro [3.5] nonan-2-yl)benzenesulfonamide

[0472] The title compound was synthesized according to procedures analogous to Example 2, using l-(2-(2,6-dioxopiperidin-3-yl)-l-oxo-l,2-dihydroisoquinolin-6-yl)piperidine-4-carbaldehyde (which can be prepared as described in W02022099117A1).JH NMR (400 MHz, DMSO-de) 8 11.01 (s, 1H), 10.42 (s, 1H), 7.99 (d, J = 9.0 Hz, 1H), 7.88 (d, J = 2.3 Hz, 1H), 7.78 (d, J = 8.8 Hz, 2H), 7.50 (d, J = 1.8 Hz, 1H), 7.27 (d, J = 7.5 Hz, 1H), 7.20 (dd, J = 9.3, 2.4 Hz, 1H), 6.98 (d, J = 2.4 Hz, 1H), 6.81 (s, 1H), 6.74 (s, 1H), 6.54 - 6.44 (m, 3H), 6.31 (t, J = 2.1 Hz, 1H), 5.44 (s, 2H), 4.00 (d, J = 12.7 Hz, 2H), 3.88 (s, 3H), 3.78 (s, 2H), 3.71 (s, 2H), 3.48 (d, J = 12.0 Hz, 2H), 3.09 - 2.77 (m, 7H), 2.63 (t, J = 18.0 Hz, 3H), 2.11 (d, J = 13.7 Hz, 3H), 2.05 - 1.90 (m, 3H), 1.82 (d, J = 12.6 Hz, 2H), 1.29 (q, J = 11.8 Hz, 2H). LCMS calc, for C45H50N9O7S [M+H]+: m / z= 860.4; Found 860.2.Example 14. V-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[< / ]isoxazol-3-yl)-4-(7-((l-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-lH-indazol-5-yl)piperidin-4-yl)methyl)-2,7-diazaspiro [3.5] nonan-2-yl)-2-methoxybenzenesulfonamide- 142 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0473] Step 1. N-( 6-( ( lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-2-methoxy-4-(2, 7-diazaspiro[ 3.5 ]nonan-2-yl) benzenesulfonamide

[0474] The title compound was synthesized according to procedures analogous to Example 12, Steps 1-2, using 4-bromo-2 -methoxybenzenesulfonyl chloride. LCMS calc, for C26H31N6O5S [M+H]+: m / z= 539.2; Found 539.1.

[0475] Step 2. N-( 6-( ( lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-4-(7-( (1-(l-(2, 6-dioxopiperidin-3-yl)-3-methyl-lH-indazol-5-yl)piperidin-4-yl)methyl)-2, 7-diazaspiro[ 3.5 ]nonan-2-yl)-2-methoxybenzenesulfonamide

[0476] The title compound was synthesized according to procedures analogous to Example 2, using 1 -( 1 -(2,6-dioxopiperidin-3 -y l)-3 -methyl- 1 H-indazol -5-yl)piperidine-4-carbaldehyde (from Example 6, Step 2). LCMS calc, for C45H53N10O7S [M+H]+: m / z= 877.4; Found 877.1.Example 15. N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-4-(7-((l-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-5-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-methoxybenzene-sulfonamide- 143 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application o o

[0477] The title compound was synthesized according to procedures analogous to Example 2, using l-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-5-yl)piperidine-4-carbaldehyde (which can be prepared as described in WO2022236058A1). LCMS calc, for C45H53N10O8S [M+H]+: m / z= 893.4; Found 893.2.Example 16. V-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[< / ]isoxazol-3-yl)-4-(4-((l- ( 1 -(2.6-dioxopiperidiii-3-yl)-3-niethyl-2-oxo-2.3-dihydro- 1 / / -beiizo| |iniidazol-5-yl)piperidin-4-yl)methyl)-3,3-dimethylpiperazin-l-yl)benzenesulfonamide

[0478] Step 1. N-( 6-( ( lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-4-( 3, 3-dimethylpiperazin-l-yl)benzenesulfonamide- 144 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0479] The title compound was synthesized according to procedures analogous to Example 12, Step 2, using tert-butyl 2,2-dimethylpiperazine-l -carboxylate. LCMS calc, for C24H29N6O4S [M+H]+: m / z= 497.2; Found 497.1.

[0480] Step 2. N-( 6-( ( lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-4-( 4-( (1-(l-(2, 6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2, 3-dihydro-lH-benzo[d]imidazol-5-yl)piperidin-4-yl)methyl)-3,3-dimethylpiperazin-l-yl)benzenesulfonamide

[0481] The title compound was synthesized according to procedures analogous to Example 2, using l-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-5-yl)piperidine-4-carbaldehyde (which can be prepared as described in WO2022236058A1). LCMS calc, for C43H5INIO07S [M+H]+: m / z= 851.4; Found 851.2.Example 17. V-(6-((lEZ-Pyrazol-l-yl)methyl)-4-methoxybenzo[< / ]isoxazol-3-yl)-4-((3U. S.6<7. S)- -(( l-( l-(2.6-dioxopiperidiii-3-yl)-3-niethyl-2-oxo-2.3-dihydro-l / / -benzo [ ] imidazol-5-yl)piperidin-4-yl)methyl)hexahydropyrrolo [3, 4-c] pyrrol-2(lEZ)-yl)benzenesulfonamide

[0482] Step 1. N-( 6-( ( lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-4- ( ( 3aS, 6aS)-hexahydropyrrolo[ 3, 4-c ]pyrrol-2( lH)-yl)benzenesulfonamide

[0483] The title compound was synthesized according to procedures analogous to Example 12, Step 2, using tert-butyl (3a / ,6a / )-hexahydropyrrolo[3,4-c]pyrrole-2(l / 7)-carboxylate- 145 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application (relative stereochemistry, CAS 1818847-81-2). LCMS calc, for C24H27N6O4S [M+H]+: m / z= 495.2; Found 495.0.

[0484] Step 2. N-( 6-( ( lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-4- ( ( 3aS, 6aS)-5-( (l-(l-(2, 6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2, 3-dihydro-lH-benzo[d]imidazol-5-yl)piperidin-4-yl)methyl)hexahydropyrrolo[3, 4-c]pyrrol-2( 1H)~ yl) benzenesulfonamide

[0485] The title compound was synthesized according to procedures analogous to Example 2, using l-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-17 / -benzo[ ]imidazol-5-yl)piperidine-4-carbaldehyde (which can be prepared as described in WO2022236058A1). LCMS calc, for C43H49N10O7S [M+H]+: m / z= 849.4; Found 849.2.Example 18. V-(6-((lZ / -Pyrazol-l-yl)methyl)-4-methoxybenzo[< / ]isoxazol-3-yl)-4-((3a7?,6a»y)-5-((l-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-lH-benzo [ ] imidazol-5-yl)piperidin-4-yl)methyl)hexahydropyrrolo [3,4-c] pyrrol-2(lEZ)-yl)-2-methoxybenzenesulfonamide

[0486] Step 1. N-( 6-( ( lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-4- ( ( 3aR, 6aS)-hexahydropyrrolo[ 3, 4-c ]pyrrol-2( lH)-yl)-2-methoxybenzenesulfonamide

[0487] The title compound was synthesized according to procedures analogous to Example 12, Step 2, using tert-butyl (3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrole-2(177)-carboxylate and A-(6-((17 / -pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-4-bromo-2-methoxybenzenesulfonamide. LCMS calc, for C25H29N6O5S [M+H]+: m / z= 525.2; Found 525.1.- 146 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0488] Step 2. N-( 6-( ( lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-4- ( ( 3aR, 6aS)-5-( (l-(l-(2, 6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2, 3-dihydro-lH-benzo[ d]-imidazol-5-yl)piperidin-4-yl)methyl)hexahydropyrrolo[ 3, 4-c ]pyrrol-2( lH)-yl)-2-methoxybenzenesulfonamide

[0489] The title compound was synthesized according to procedures analogous to Example 2, using l-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-lJ / -benzo-[J]imidazol-5-yl)piperidine-4-carbaldehyde (which can be prepared as described in WO2022236058A1). LCMS calc, for C44H51N10O S [M+H]+: m / z= 879.4; Found 879.2.Example 19. \-(6-(( l / / -I’yr:izol-l-yl)inethyl)-4-inethoxybenzo| |isox:izol-3-yl)-3-(9-(( 1-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)-3,9-diazaspiro[5.5]-undecan-3-yl)benzenesulfonamide

[0490] Step 1. N-( 6-( ( lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-( 3, 9-diazaspiro [ 5.5 ]undecan-3-yl) benzenesulfonamide

[0491] The title compound was synthesized according to procedures analogous to Example 12, Step 2 using 7V-(6-((lJ / -pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-bromobenzenesulfonamide (which can be prepared as described in WO2023245150A1) and- 147 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application tert-butyl 3,9-diazaspiro[5.5]-undecane-3-carboxylate. LCMS calc, for C27H33N6O4S [M+H]+: m / z= 537.2; Found 537.4.

[0492] Step 2. N-( 6-( ( lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(9-( (1-(4-(2, 6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl) -3, 9-diazaspiro[ 5.5 ]undecan-3-yl) benzenesulfonamide

[0493] The title compound was synthesized according to procedures analogous to Example 2, using l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidine-4-carbaldehyde (which can be prepared as described in W02021219070A1). LCMS calc, for C44H53N8O6S [M+H]+: m / z= 821.4; Found 821.7.Example 20. V-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[< / ]isoxazol-3-yl)-3-(9-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lEZ-indazol-6-yl)piperidin-4-yl)methyl)-3,9-diazaspiro [5.5] undecan-3-yl)benzenesulfonamide

[0494] The title compound was synthesized according to procedures analogous to Example 2, using A-(6-((U / -pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(3,9-diazaspiro[5.5]undecan-3-yl)benzenesulfonamide (from Example 19, Step 1) and l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-U / -indazol-6-yl)piperidine-4-carbaldehyde (which can be prepared as described in W02024039901A2). LCMS calc, for C46H55N10O6S [M+H]+: m / z= 875.4; Found 875.8.Example 21. 7V-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lEZ-indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-(2,2,2-trifluoroethoxy)benzenesulfonamide- 148 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0495] Step 1: 1, 3-Dibromo-2-( 2, 2, 2-trifluoroethoxy) benzene

[0496] A mixture of 2,6-dibromophenol (1.00 g, 3.97 mmol), A, -di methyl formamide (10.0 mL), potassium carbonate (16.50 g, 11.90 mmol), and l,l,l-trifluoro-2 -iodoethane (1.8 mL, 12.00 mmol) were stirred at 100 °C for 5 hours. After cooling to room temperature, the mixture was diluted with water (30 mL) and hexanes (30 mL). The phases were separated, and the aqueous phase was extracted with hexanes (20 mL). The combined organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated. The crude material was purified by silica gel chromatography (hexanes) to afford the title compound (840 mg, 63% yield) as white crystalline solid. 'HNMR (400 MHz, CDC13) 67.56 (d, J= 8.1 Hz, 2H), 6.97 (t, J= 8.0 Hz, 1H), 4.43 (q, J= 8.2 Hz, 2H).19F NMR (376 MHz, CDCI3) 6 -74.0.

[0497] Step 2: Benzyl(3-bromo-2-(2,2,2-trifluoroethoxy)phenyl)sulfane

[0498] A mixture of phenylmethanethiol (115 pL, 0.98 mmol), A, A-diisopropylethyl-amine (0.33 mL, 1.90 mmol), l,3-dibromo-2-(2,2,2-trifhioroethoxy)benzene (313.0 mg, 0.94 mmol), and 1,4-dioxane (8 mL) was sparged with nitrogen for 5 minutes. Tris(di-benzylideneacetone)dipalladium(O) (42.9 mg, 0.05 mmol) and 9,9-dimethyl-4,5-bis(di-phenylphosphino)xanthene (54.2 mg, 0.09 mmol) were added. The mixture was purged with nitrogen for 5 minutes, and then stirred at 100 °C for 4 hours. After cooling to room temperature, the mixture was passed through a pad of silica gel (10 g) eluting with ethyl acetate (50 mL) and concentrated. The crude material was purified by silica gel chromatography (0-15% dichloromethane / hexanes) to afford the title compound (140 mg, 40% yield) as clear oil.XH NMR (400 MHz, CDCI3) 87.44 (dd, J= 8.1, 1.5 Hz, 1H), 7.34 -- 149 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application 7.20 (m, 6H), 6.97 (t, J= 7.9 Hz, 1H), 4.40 (q, J= 8.4 Hz, 2H), 4.15 (s, 2H).19F NMR (376 MHz, CDCI3) 8 -74.0.

[0499] Step 3: 3-Bromo-2-(2,2,2-trifluoroethoxy)benzenesulfonyl chloride

[0500] To a mixture of benzyl(3-bromo-2-(2,2,2-trifluoroethoxy)phenyl)sulfane (132.0 mg, 0.35 mmol), water (0.5 mL), and acetic acid (2.5 mL) was added 1 -chloropyrrolidine-2, 5-dione (186.9 mg, 1.4 mmol). The mixture was stirred for 90 min, diluted with ethyl acetate (20 mL), and quenched with brine (10 mL). The phases were separated, and the aqueous phase was extracted with ethyl acetate (10 mL). The combined organic phases were dried over anhydrous magnesium sulfate, filtered, and concentrated. The crude material was purified by silica gel chromatography (0-30% ethyl acetate / hexanes) to afford the title compound (124.0 mg, 100% yield) as colorless oil.XH NMR (400 MHz, CDC13) 68.03 - 7.98 (m, 2H), 7.34 (t, J = 8.1 Hz, 1H), 4.67 (q, J= 7.9 Hz, 2H).19F NMR (376 MHz, CDCI3) 6 -73.8.

[0501] Step 4: N-( 6-( lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-bromo- 2-(2, 2, 2-trifluoroethoxy) benzenesulfonamide

[0502] To a mixture of 6-((U / -pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-amine (48.0 mg, 0.20 mmol) and 3-bromo-2-(2, 2, 2-trifluoroethoxy )benzenesulfonyl chloride (125.1 mg, 0.35 mmol) in tetrahydrofuran (1 mL) was added potassium tert-butoxide (0.69 mL, 0.69 mmol, 1.0 M in tetrahydrofuran) drop wise. The mixture was stirred for 15 minutes. The mixture was next diluted with brine (10 mL) and extracted with ethyl acetate (2 x 30 mL). The combined organic phases were dried over anhydrous magnesium sulfate, filtered, and concentrated. The crude material was purified by silica gel chromatography (0-5% methanol / dichloromethane) to afford the title compound (99.0 mg, 90% yield) as pale yellow solid. LCMS calc, for C2oHi7BrF3N405S [M+H]+: m / z = 561.0; Found: 560.7.

[0503] Step 5: tert-Butyl 2-( 3-(N-( 6-( ( lH-pyrazol-l-yl)methyl) -4-methoxybenzo-[ d]isoxazol-3 -yl) sulfamoyl) -2 -(2, 2, 2-trifluoroethoxy)phenyl)-2, 7-diazaspiro[ 3.5 ] nonane- 7 -carboxylate- 150 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0504] A nitrogen sparged mixture of tert-butyl 2-azaspiro[3.5]nonane-7-carboxylate hydrochloride (64.6 mg, 0.25 mmol), sodium tert-butoxide (84.7 mg, 0.88 mmol),pyrazol-l-yl)methyl)-4-methoxybenzo[t / ]isoxazol-3-yl)-3-bromo-2-(2,2,2-tri fluoroethoxy)-benzenesulfonamide (99.0 mg, 0.18 mmol), and BrettPhos Pd G4 (24.4 mg, 0.03 mmol) in 1,4-di oxane (2 mL) was stirred at 100 °C for 1 hour. After cooling to room temperature, the mixture was diluted with dichloromethane, passed through a pad of Celite (10 g), and concentrated. The crude material was purified by silica gel chromatography (0 -6% methanol / dichloromethane) to afford the title compound as pale-yellow viscous oil. LCMS calc, for C32H38F3N6O7S [M+H]+: m / z = 707.2; Found: 707.0.

[0505] Step 6: N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(2, 7-diazaspiro[ 3.5 ]nonan-2-yl)-2-( 2, 2, 2-trifluoroethoxy) benzenesulfonamide

[0506] A mixture of tert-butyl 2-(3-(A-(6-((l / 7-pyrazol-l-yl)methyl)-4-methoxybenzo-[d]isoxazol-3-yl)sulfamoyl)-2-(2,2,2-trifluoroethoxy)phenyl)-2,7-diazaspiro[3.5]nonane-7-carboxylate (40.0 mg, 0.06 mmol), dichloromethane (1.0 mL), and 2,2,2-trifluoroacetic acid (220 pL, 2.83 mmol) was stirred for 20 minutes. The crude mixture was concentrated, diluted with acetonitrile (5 mL), and purified by preparative (Waters CSH Cl 8, 5 pm particle size, 30x100 mm) HPLC (26.2-46.2% CH3CN in H2O with 0.2% TFA in 5 minutes) to afford the title compound as a TFA salt (24.3 mg, 60% yield), a white solid. LCMS calc, for C27H30F3N6O5S [M+H]+: m / z = 607.2; Found: 607.0.

[0507] Step 7: N-( 6-( f lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(7-( (1-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)-2, 7-diazaspiro[ 3.5 ]nonan-2-yl)-2-( 2, 2, 2-trijluoroethoxy) benzenesulfonamide- 151 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application

[0508] To a mixture of l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-U / -indazol-6-yl)-piperidine-4-carbaldehyde (7.5 mg, 0.02 mmol) and A-(6-((lJ / -pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(2, 7-diazaspiro[3.5]nonan-2-yl)-2-(2, 2, 2 -tri fluoroethoxy )benzenesulfonamide (8.0 mg, 0.01 mmol) in DMSO (1 mL) was added N, N-diisopropylethylamine (13.8 pL, 0.08 mmol) and acetic acid (2.3 pL, 0.04 mmol). The mixture was stirred for 10 minutes. Next, sodium triacetoxyborohydride (14.0 mg, 0.07 mmol) was added and the mixture was stirred for 2 hours. The crude mixture was diluted with DMSO, filtered through a 0.2 um PTFE syringe filter, and purified by preparative (Waters CSH C18, 5 pm particle size, 30x100 mm) HPLC (24.6-44.6% CH3CN in H2O with 0.2% TFA in 5 minutes) to afford the title compound as a TFA salt (9.5 mg, 68% yield), a white solid. LCMS calc, for C46H52F3N10O7S [M+H]+: m / z = 945.4; Found: 945.2.Example 22. 7V-(6-((lEZ-Pyrazol-l-yl)methyl)-4-methoxybenzo[< / ]isoxazol-3-yl)-2-chloro- 3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)- 2,7-diazaspiro [3.5] nonan-2-yl)benzenesulfonamide

[0509] The title compound was synthesized by procedures analogous to that described in Example 21, Steps 2-7. LCMS calc, for C44H50CIN10O6S [M+H]+: m / z =881.3; Found: 881.3.Example 23. \-(6-(( l / / -Pyrazol-l-yl)methyl)-4-methoxybenzo| |isox:izol-3-yl)-3-(7-(( 1-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lEZ-indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2-methoxybenzenesulfonamide

[0510] The title compound was synthesized by procedures analogous to that described in Example 21, Steps 2-7. LCMS calc, for C45H52FN10O7S [M+H]+: m / z =895.4; Found: 895.2.- 152 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application Example 24. 7V-(6-((lEZ-Pyrazol-l-yl)methyl)-4-methoxybenzo[< / ]isoxazol-3-yl)-5-chloro- 3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)- 2,7-diazaspiro [3.5] nonan-2-yl)-2-methoxybenzenesulfonamide

[0511] The title compound was synthesized by procedures analogous to that described in Example 21, Step 2-7. LCMS calc, for C45H52CIN10O7S [M+H]+: m / z =911.3; Found: 911.2.Example 25. 7V-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-methoxy-5-methylbenzenesulfonamide

[0512] The title compound was synthesized by procedures analogous to that described in Example 21, Steps 2-7. LCMS calc, for C46H55N10O7S [M+H]+: m / z =891.4; Found: 891.2.Example 26. 7V-(6-((lEZ-pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-(trifluoromethyl)benzenesulfonamide

[0513] The title compound was synthesized by procedures analogous to that described in 21, Seps 2-7. LCMS calc, for C45H50F3N10O6S [M+H]+: m / z =915.4; Found: 915.2.- 153 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application Example 27. 7V-(6-((lH-pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro [3.5] nonan-2-yl)-2-fluorobenzenesulfonamide

[0514] The title compound was synthesized by procedures analogous to that described in Example 21, Steps 2-7. LCMS calc, for C44H50FN10O6S [M+H]+: m / z =865.4; Found: 865.2.Example 28. V-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[< / ]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lZ7-indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide

[0515] Step 1: Benzyl(3-fluoro-2,6-dimethoxyphenyl)sulfanePh

[0516] A solution of l-fluoro-2,4-dimethoxybenzene (570 mg, 3.65 mmol) in THF (20 mL) was purged with nitrogen for 5 minutes at 0 °C. The mixture was stirred at 0 °C for 5 minutes then w-butyllithium (1.90 mL, 4.75 mmol, 2.5 M in hexane) was added drop wise. The mixture was stirred at 0 °C for 1 hour. A solution of dibenzyl disulfide (1.03 g, 4.20 mmol) in THF (1 mL) was added drop wise. The ice bath was removed, and the mixture was allowed to warm to room temperature while stirring for 20 min. The reaction mixture was quenched with brine (20 mL) and extracted with ethyl acetate (2 x 20 mL). The combined organic phases were dried over MgSCU, filtered, and concentrated. The crude material was purified by silica gel chromatography (0-70% DCM / hexanes) to afford the title compound (0.76 g, 74% yield) as colorless oil. *HNMR (400 MHz, CDC13) 87.27 - 7.15 (m, 5H), 7.01 (dd, J= 10.6, 9.1 Hz,- 154 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application 1H), 6.55 (dd, J= 9.1, 3.9 Hz, 1H), 4.07 (s, 2H), 3.84 (s, 3H), 3.71 (s, 3H).19F NMR (376 MHz, CDC13) 6 -138.2

[0517] Step 2: 3 -Chloro-5-fluoro-2, 6-dimethoxybenzenesulfonyl chloride

[0518] To a solution of benzyl(3-fluoro-2,6-dimethoxyphenyl)sulfane (580 mg, 2.08 mmol) in water (2 mL) and acetic acid (10 mL) was added 1 -chloropyrrolidine-2, 5-dione (1.11 g, 8.34 mmol). The mixture was stirred at room temperature for 2.5 hour...

Claims

105807.005061 - PCT Application What is claimed:

1. A compound of F ormula (I):ULM - Y - PTMor a pharmaceutically acceptable salt or solvate thereof,wherein Y-PTM is a moiety of Formula IA:R1whereinY is a covalent bond, or chemical moiety that links PTM and ULM;* is a point of attachment to ULM;Ring A is a Ce-Cio membered aryl group or a 5-10 membered heteroaryl group;R1is H or 5-6 membered heteroaryl optionally substituted by methyl;R2is H, Ci-4alk-O-Ci-4alkyl, or -(C(R8)2)n-(5-9 membered heteroaryl) optionally substituted by halogen, C1-C3 alkyl, -CH2OH, or -OH;R3is H, halogen, C1-C4 alkyl, cyclopropyl, haloalkyl, C1-C4 alkoxy, orhaloalkoxy;R4is H, halogen, C1-C4 alkyl, cyclopropyl, C1-C4 alkoxy, or -O-cyclopropyl;each R5is independently H, halogen, oxo, -OH, -CN, -NO2, -Ci-Cealkyl, -C2-C6alkenyl, -C2-Cealkynyl, Co-Cialk-aryl, Co-Cialk-heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, -ORa, -SRa, -NRcRd, -NRaRc, -C(O)Rb, -OC(O)Ra, -C(O)ORa, -C(O)NRcRd, -S(O)Rb, -S(O)2NRcRd, -S(O)(=NRb)Rb, -SF5, -P(O)RbRb, -P(O)(ORb)(ORb), -B(ORd)(ORc), or -S(O)2Rb;each Rais independently H, -C(O)Rb, -C(O)ORC, -C(O)NRcRd, -C(=NRb)NRbRc, -C(=NORb)NRbRc, -C(=NCN)NRbRc, -P(ORC)2, -P(O)RcRb, -P(O)ORcORb, -S(O)Rb, -S(O)NRcRd, -S(O)2Rb, -S(O)2NRcRd, SiR\ -Ci-Cioalkyl, -C1-C10 haloalkyl, -C2-C10 alkenyl, -C2-C10 alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl;each Rbis independently H, -Ci-Ce alkyl, -Ci-Ce haloalkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl;- 266 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application each Rcor Rdis independently H, -C1-C10 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -OCi- Cealkyl, -O-cycloalkyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl; orRcand Rd, together with the atom to which they are both attached, form a monocyclic or multicyclic heterocycloalkyl, or a monocyclic or multicyclic heterocyclo-alkenyl group;each R8is independently H, halogen, or C1-C4 alkyl;m is 0, 1, 2, 3, or 4;n is 0 or 1; andULM is- 267 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Applicationis a point of attachment to Y;each X2 is independently N or CR15; andeach R15is independently H, D, halogen, oxo, -OH, -CN, -NO2, -Ci-Cealkyl, -Ci-Ce haloalkyl, -C2-Cealkenyl, -C2-Cealkynyl, Co-Cialk-aryl, Co-Cialk-heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, -ORa, -SRa, -NRcRd, -NRaRc, -C(O)Rb, -- 268 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application OC(O)Ra, -C(O)ORa, -C(O)NRcRd, -S(O)Rb, -S(O)2NRcRd, -S(O)(=NRb)Rb, -SF5, -P(O)RbRb, -P(O)(ORb)(ORb), -B(ORd)(ORc) or -S(O)2Rb;wherein any of the -Ci-Cealkyl, Ci-Cs alkoxide, -C2-Cealkenyl, -C2-Cealkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, spirocycloalkyl, spiroheterocycloalkyl and spiroheterocycloalkenyl groups in any of R1-R5, Rs, Ris.and ring A is optionally substituted by 1-6 Rfgroups; andeach Rfis independently D, oxo, halogen, Ci-Cs alkoxy, Ci-Cs alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, -OH, -CN, -NO2, -C2-6 alkenyl, -C2-6 alkynyl, Ce-io aryl, C5-12 heteroaryl, C3-8 cycloalkyl, C3-8 cycloalkenyl, C3-8 heterocycloalkyl, C3-8 heterocycloalkenyl, -ORa, -SRa, -NRcRd, -NRaRc, -C(O)Rb, -OC(O)Rb, -C(O)ORb, -C(O)NRcRd, -S(O)Rb, -S(O)2NRcRd, -S(O)(=NRb)Rb, -SF5, -P(O)RbRb, -P(O)RcRd, -P(O)(ORb)(ORb), -B(ORc)(ORd), -S(O)2Rb, -C(O)NRbORb, -S(O)2ORb, -OS(O)2ORb, or -OPO(ORb)(ORb); wherein said Ci-Cs alkyl is optionally substituted by 1-6 groups selected from D, halogen, -OH, -CN, -ORa, -SRa, -NRaRd, or NRcRd.

2. The compound according to claim 1, wherein Y is a chemical moiety that links PTM and ULM.

3. The compound according to claim 1 or claim 2, wherein R1is H.

4. The compound according to any one of the preceding claims, wherein R2is H.

5. The compound according to any one of claims 1-3, wherein R2is -(C(R8)2)n-(5-9 membered heteroaryl) optionally substituted by halogen, C1-C3 alkyl, -CH2OH, or -OH.

6. The compound according to claim 5, wherein R2is -(C(R8)2)n-(5-6 membered heteroaryl) optionally substituted by halogen, C1-C3 alkyl, -CH2OH, or -OH.

7. The compound according to claim 6, wherein the 5-6 membered heteroaryl is a pyrazole, a pyrrole, a pyridine or a pyridazine.

8. The compound according to claim 6, wherein the 5-6 membered heteroaryl is a pyrazole.

9. The compound according to any one of the preceding claims, wherein n is 0.

10. The compound according to any one of claims 1-8, wherein n is 1.- 269 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application11 The compound according to any one of the preceding claims, wherein each R8is H.

12. The compound according to any one of claims 1-3, wherein R2is Ci-4alk-O-Ci-4alkyl.

13. The compound according to claim 12, wherein R2is CH2-O-CH3.

14. The compound according to any one of the preceding claims, wherein R3is H.

15. The compound according to any one of claims 1-13, wherein R3is halogen.

16. The compound according to any one of claims 1-13, wherein R3is C1-C4 alkyl.

17. The compound according to any one of the preceding claims, wherein R4is H.

18. The compound according to any one of claims 1-16, wherein R4is C1-C4 alkyl.

19. The compound according to any one of claims 1-16, wherein R4is C1-C4 alkoxy.

20. The compound according to claim 19, wherein R4is methoxy.

21. The compound according to any one of the preceding claims, wherein Ring A is Ce-Cio aryl.

22. The compound according to claim 21, wherein Ring A is phenyl.

23. The compound according to any one of the preceding claims, wherein each R5is H.

24. The compound according to any one of claims 1-22, wherein at least one R5is H.

25. The compound according to any one of claims 1-22, wherein each R5 is C1-C4 alkoxy.

26. The compound according to any one of claims 1-22, wherein at least one R5 is C1-C4 alkoxy.- 270 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application27. The compound according to any one of claims 1-22, wherein at least one Rs is halogen.

28. The compound according to any one of claims 1-22, wherein at least one Rs is halogen and at least one Rs is C1-C4 alkoxy.

29. The compound according to any one of claims 1-22, wherein one Rs is halogen and two Rs are C1-C4 alkoxy.

30. The compound according to any one of claims 1-22, wherein one Rs is F and two Rs are OCH3.

31. The compound according to any one of claims 1 -22, wherein m is 0.

32. The compound according to any one of claims 1-27, wherein m is 1.

33. The compound according to any one of claims 1-28, wherein m is 2.

34. The compound according to any one of claims 1-30, wherein m is 3.

35. The compound according to any one of claims 1-28, wherein m is 4.

36. The compound according to any one of the preceding claims, wherein Y is represented by the formula:wherein:q is an integer from 1 to 14;each A is independently selected from the group consisting of CRlaRlb, O, S, SO, SO2, NR1C, SO2NR1C, SONR1C, SO(=NR1C), SO(=NRlc)NRld, CONRlc, NRlcCONRld, NRlcC(O)O, NRlcSO2NRld, CO, CRla=CRlb, C=C, SiRlaRlb, P(O)Rla, P(O)ORla, (CRlaRlb)i-4, -(CRlaRlb)i-4O(CRlaRlb)i-4, -(CRlaRlb)i-4S(CRlaRlb)i-4, -(CRlaRlb)i-4NRlc(CRlaRlb)i-4, NRlcC(=NCN)NRld, NRlcC(=NCN), NRlcC(=CNO2)NRld, 3-11 membered cycloalkyl, optionally substituted with 0-6 Rlaor Rlbgroups, 3-11 membered heterocyclyl optionally substituted with 0-6 Rlaor Rlbgroups,- 271 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application aryl optionally substituted with 0-6 Rlaor Rlbgroups, or heteroaryl optionally substituted with 0-6 Rlaor Rlbgroups,wherein Rla, Rlb, Rlc, Rldand Rleare each independently, -H, -halo, -Ci-Csalkyl, -O-Ci-Csalkyl, -Ci-Cehaloalkyl, -S-Ci-C8alkyl,-NHCi-C8alkyl, -N(Ci-Csalkyl)2, 3-11 membered cycloalkyl, aryl, heteroaryl, 3-11 membered heterocyclyl, -O-(3-ll membered cycloalkyl), -S-(3-11 membered cycloalkyl), NH-(3-ll membered cycloalkyl), N(3-ll membered cycloalkyl)2, N-(3-11 membered cycloalkyl)(Ci-C8alkyl), -OH, -NH2, -SO2Ci-C8alkyl, -SO2-aryl, -SO2-heteroaryl, SO(NH)Ci-C8alkyl, P(O)(OCi-C8alkyl)(Ci-C8alkyl), -P(O)(OCi-C8alkyl)2, -C=C-Ci-Csalkyl, -C=CH, -CH=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=C(Ci-C8alkyl)2, -Si(OH)3, -Si(Ci-C8alkyl)3, -Si(OH)(Ci-C8alkyl)2, -C(O)Ci-C8alkyl, -C(O)OCi-Csalkyl, -CO2H, -CN, -CF3, -CHF2, -CH2F, -NO2, -SF5, -SO2NHCi-C8alkyl, -SO2N(Ci-C8alkyl)2, -SO(NH)NHCi-C8alkyl, -SO(NH)N(Ci-C8alkyl)2, -SONHCi-C8alkyl, -SON(Ci-C8alkyl)2, -CONHCi-Csalkyl, -CON(Ci-C8alkyl)2, -N(Ci-C8alkyl)CONH(Ci-C8alkyl), -N(Ci-C8alkyl)CON(Ci-C8alkyl)2, -NHCONH(Ci-C8alkyl), -NHCON(Ci-C8alkyl)2, -NHCONH2, -N(Ci-C8alkyl)SO2NH(Ci-C8alkyl), -N(Ci-C8alkyl)SO2N(Ci-C8alkyl)2, -NHSO2NH(Ci-C8alkyl), -NHSO2N(Ci-C8alkyl)2, or -NHSO2NH2; and where Rlaor Rlb, each independently may be optionally linked to other groups to form cycloalkyl and / or heterocyclyl moiety, optionally substituted with 0-4 Rlegroups.

37. The compound according to claim 36, wherein q is an integer from 1 to 5.

38. The compound according to any one of claims 1-35, wherein Y is* _ ^k**■1 I-2 I-3wherein** is a point of attachment to PTM;Li, L2, and L3are each independently a bond, CRlaRlb, O, S, SO, SO2, NRlc, SO2NRlc, SONR1C, SO(=NRlc), SO(=NRlc)NRld, CONRlc, NRlcCONRld, NRlcC(O)O, NRlcSO2NRld, CO, CRla=CRlb, C=C, SiRlaRlb, P(O)Rla, P(O)ORla, (CRlaRlb)i-4, -(CRlaRlb)i-4O(CRlaRlb)i-4, -(CRlaRlb)i-4S(CRlaRlb)i-4, -(CRlaRlb)i-4NRlc(CRlaRlb)i-4, NRlcC(=NCN)NRld, NRlcC(=NCN), NRlcC(=CNO2)NRld;ring Ai and ring A2 are each independently 3-12 membered cycloalkyl, optionally substituted with 1-6 Rlaor Rlbgroups; 3-12 membered heterocyclyl optionally substituted with 1-6 Rlaor Rlbgroups; aryl optionally substituted with 1-6 Rlaor Rlbgroups; or heteroaryl optionally substituted with 1-6 Rlaor Rlbgroups;- 272 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application wherein Rla, Rlb, Rlc, Rldand Rleare each independently, -H, -halo, -Ci-Csalkyl, -O-Ci-Csalkyl, -Ci-Cehaloalkyl, -S-Ci-C8alkyl,-NHCi-C8alkyl, -N(Ci-Csalkyl)2, 3-11 membered cycloalkyl, aryl, heteroaryl, 3-11 membered heterocyclyl, -O-(3-ll membered cycloalkyl), -S-(3-11 membered cycloalkyl), NH-(3-ll membered cycloalkyl), N(3-ll membered cycloalkyl)2, N-(3-11 membered cycloalkyl)(Ci-C8alkyl), -OH, -NH2, -SH, -SO2Ci-C8alkyl, -SO2-aryl, -SO2-heteroaryl, SO(NH)Ci-C8alkyl, P(O)(OCi-C8alkyl)(Ci-C8alkyl), -P(O)(OCi-C8alkyl)2, -C=C-Ci-Csalkyl, -C=CH, -CH=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=C(Ci-C8alkyl)2, -Si(OH)3, -Si(Ci-C8alkyl)3, -Si(OH)(Ci-C8alkyl)2, -C(O)Ci-C8alkyl, -C(O)OCi-Csalkyl, -CO2H, -CN, -CF3, -CHF2, -CH2F, -NO2, -SF5, -SO2NHCi-C8alkyl, -SO2N(Ci-C8alkyl)2, -SO(NH)NHCi-C8alkyl, -SO(NH)N(Ci-C8alkyl)2, -SONHCi-C8alkyl, -SON(Ci-C8alkyl)2, -CONHCi-Csalkyl, -CON(Ci-C8alkyl)2, -N(Ci-C8alkyl)CONH(Ci-C8alkyl), -N(Ci-C8alkyl)CON(Ci-C8alkyl)2, -NHCONH(Ci-C8alkyl), -NHCON(Ci-C8alkyl)2, -NHCONH2, -N(Ci-C8alkyl)SO2NH(Ci-C8alkyl), -N(Ci-C8alkyl)SO2N(Ci-C8alkyl)2, -NHSO2NH(Ci-C8alkyl), -NHSO2N(Ci-C8alkyl)2, or -NHSO2NH2; and where Rlaor Rlb, each independently may be optionally linked to other groups to form cycloalkyl and / or heterocyclyl moiety, optionally substituted with 0-4 Rlegroups.

39. The compound according to any one of claims 1-35, wherein Y is* ^k**■1 I-2 I-3wherein* is a point of attachment to ULM** is a point of attachment to PTM;Li is a bond, (C(R10)2)P, or CO;L2 is a bond, (C(R10)2)P, or CO;L3 is a bond, (C(R10)2)P, or CO;p is 1, 2, 3 or 4;each R10is independently H or C1-C4 alkyl;ring Ai is a 3-7 membered cycloalkyl group, a 4-10-membered heterocycloalkyl group, an aryl group, or a heteroaryl group; andring A2 is a 3-7 membered cycloalkyl group, a 4-12-membered heterocycloalkyl group, an aryl group, or a heteroaryl group;wherein ring Ai and ring A2 are optionally substituted with 1-6 Rlaor Rlbgroups.

40. The compound according to claim 39, wherein L3 is a bond.- 273 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application41. The compound according to claim 39 or claim 40, wherein Li is a bond.

42. The compound according to any one of claims 39-41, wherein L2 is (C(R10)2)P.

43. The compound according to any one of claims 39-42, wherein ring Ai is a 4-10-membered heterocycloalkyl group.

44. The compound according to claim 43, wherein ring Ai is a piperazine group, a morpholine group, a piperidine group, a pyrrolidine group, an azetidine group or an azabicycloalkyl group.

45. The compound according to claim 44, wherein ring Ai is a piperidine group or pyrrolidine group.

46. The compound according to any one of claims 39-45, wherein ring A2 is a 4-12-membered heterocycloalkyl group.

47. The compound according to claim 46, wherein ring A2 is a piperazine group, a piperidine group, a pyrrolidine group, an azaspiroalkyl group, a diazaspiroalkyl group, or an azabicycloalkyl group.

48. The compound according to claim 47, wherein ring A2 is a piperazine group, an azaspiroalkyl group, or a diazaspiroalkyl group.

49. The compound according to claim 39, wherein ring A2 is aryl optionally substituted with 1-6 Rlaor Rlbgroups.

50. The compound according to claim 39, wherein Y isA1 1 W1-2wherein is a point of attachment to ULM;* is a point of attachment to PTM;- 274 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application W is CRn orN;Uis CRn orN;Rn is H, fluoro, Ci-ealkyl, or Ci-ealkoxide; andeach g, h, j and k is independently 0, 1 or 2.

51. The compound according to claim 50, wherein j and g are each 2.

52. The compound according to claim 50 or claim 51, wherein k and h are each 1.

53. The compound according to claim 50, wherein j and g are each 1.

54. The compound according to claim 50 or claim 51, wherein k and h are each 2.

55. The compound according to any one of claims 50-54, wherein W and U are N.

56. The compound according to any one of claims 50-54, wherein W is CRn and U are N.

57. The compound according to any one of claims 50-54, wherein W is N and U is CRn.

58. The compound according to claim 39, wherein Y iswherein* is a point of attachment to ULM;** is a point of attachment to PTM;each E is independently CRn orN;Rn is H, F, Ci-ealkyl, or Ci-ealkoxide; andt is 0, 1, 2 or 3.

59. The compound according to claim 58, wherein t is 1.

60. The compound according to claim 58, wherein t is 0.- 275 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application 61. The compound according to any one of claims 58-60, wherein each E is N.

62. The compound according to any one of claims 58-60, wherein one E is CRn and the other E isN.

63. The compound according to any one of claims 50-62, wherein L2 is -CH2-.

64. The compound according to any one of claims 50-63, wherein Li is a bond.

65. The compound according to any one of claims 36-39, wherein Y iswherein * is a point of attachment to ULM and ** is a point of attachment to PTM.

66. The compound according to claim 65, wherein Y iswherein is a point of attachment to ULM and ** is a point of attachment to PTM.

67. The compound according to claim 65, wherein Yis wherein * is a point of attachment to ULM and ** is a point of attachment to PTM.- 276 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application68. The compound according to claim 65, wherein Y iswherein * is a point of attachment to ULM and ** is a point of attachment to PTM.ft69. The compound according to claim 65, wherein Yis wherein * is a point of attachment to ULM and ** is a point of attachment to PTM.*70. The compound according to claim 65, wherein Yis wherein * is a point of attachment to ULM and ** is a point of attachment to PTM.* 71. The compound according to claim 65, wherein Yis wherein is a point of attachment to ULM and ** is a point of attachment to PTM.ft*72. The compound according to claim 65, wherein Yis; wherein * is a point of attachment to ULM and ** is a point of attachment to PTM.

73. The compound according to any one of the preceding claims, wherein Ring A iswhereinis a point of attachment to the sulfonamide group and # is a point of attachment to Y.- 277 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application74. The compound according to claim 73, wherein Ring A isOMe OMewhereinis a point of attachment to the sulfonamide group and # is a point of attachment to Y.

75. The compound according to claim 74, wherein Ring A isOMe; whereinis a point of attachment to the sulfonamide group and # is a point of attachment to Y.

76. The compound according to claim 74, wherein Ring A isis a point of attachment to the sulfonamide group and # is a point of attachment to Y.

77. The compound according to claim 74, wherein Ring A is#; whereinis a point of attachment to the sulfonamide group and # is a point of attachment to Y.

78. The compound according to claim 74, wherein Ring A is- 278 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application#\ whereinis a point of attachment to the sulfonamide group and # is a point of attachment to Y.

79. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Y-PTM has the formula IA-1:R2(IA-1).

80. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Y-PTM has the formula IA-2:(IA-2);; wherein* is a point of connection to ULM;L2 is a bond or (C(R10)2)P;p is 1, 2, 3 or 4;each R10is independently H or C1-C4 alkyl;ring Ai is a 3-7 membered cycloalkyl group, a 4-10-membered heterocycloalkyl group, an aryl group, or a heteroaryl group; andring A2 is a 3-7 membered cycloalkyl group, a 4-12-membered heterocycloalkyl group, an aryl group, or a heteroaryl group.

81. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Y-PTM has the formula IA-3:- 279 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application; wherein* is a point of connection to ULM;L2 is a bond or (C(R10)2)P;p is 1, 2, 3 or 4;each R10is independently H or C1-C4 alkyl;ring Ai is a 3-7 membered cycloalkyl group, a 4-10-membered heterocycloalkyl group, an aryl group, or a heteroaryl group;W is CRn orN;U is CRn orN;Rn is H, F, Ci-ealkyl, or Ci-ealkoxide; andeach g, h, j and k is independently 0, 1, 2 or 3.

82. The compound according to claim 81, wherein j and g are each 2.

83. The compound according to claim 81 or claim 82, wherein k and h are each 1.

84. The compound according to claim 81, wherein j and g are each 1.

85. The compound according to claim 81 or claim 82, wherein k and h are each 2.

86. The compound according to any one of claims 81-85, wherein W and U are N.

87. The compound according to any one of claims 81-85, wherein W is CRn and U are N.

88. The compound according to any one of claims 81-85, wherein W is N and U is CRn.

89. The compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein Y-PTM has formula IA-4 or formula IA-5:- 280 - 105807.005061\4896-4870-4897.1105807.005061 - PCT ApplicationR5(IA-5); wherein* is a point of connection to ULM;L2 is a bond or (C(R10)2)P;p is 1, 2, 3 or 4;each R10is independently H or C1-C4 alkyl;ring Ai is a 3-7 membered cycloalkyl group, a 4-10-membered heterocycloalkyl group, an aryl group, or a heteroaryl group;W is CRn orN;U is CRn or N; andR11 is H, F, Ci-ealkyl, or Ci-ealkoxide.

90. The compound of any one of claims 38-42, 50-57, 80-89, wherein ring Ai is:whereinis a point of attachment to L2 and * is a point of attachment to ULM.

91. The compound according to claim 89, or a pharmaceutically acceptable salt thereof, wherein Y-PTM has formula IA-6 or formula IA-7:- 281 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application R5(IA-6)(IA-7); wherein* is a point of connection to ULM;W is CRn orN;U is CRn or N; andRn is H, F, Ci-ealkyl, or Ci-ealkoxide;each E is independently CRn or N; andt is 0, 1, 2 or 3.

92. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Y-PTM has formula IA-8:; wherein* is a point of connection to ULM;L2 is a bond or (C(R10)2)P;p is 1, 2, 3 or 4;each R10is independently H or C1-C4 alkyl;ring A2 is a 3-7 membered cycloalkyl group, a 4-10-membered heterocycloalkyl group, an aryl group, or a heteroaryl group;each E is independently CRn or N;R11 is H, F, Ci-ealkyl, or Ci-ealkoxide; and- 282 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application t is 0, 1, 2 or 3.

93. The compound according to claim 92, wherein t is 1.

94. The compound according to claim 92, wherein t is 0.

95. The compound according to any one of claims 91-94, wherein each E is N.

96. The compound according to any one of claims 91-94, wherein one E is CRn and the other E isN.

97. The compound according to any one of claims 91-96, or a pharmaceutically acceptable salt thereof, wherein Y-PTM has formula IA-9:; wherein* is a point of connection to ULM;L2 is a bond or (C(R10)2)P;p is 1, 2, 3 or 4;each R10is independently H or C1-C4 alkyl;ring A2 is a 3-7 membered cycloalkyl group, a 4-10-membered heterocycloalkyl group, an aryl group, or a heteroaryl group;each E is independently CRn or N; andR11 is H, F, Ci-ealkyl, or Ci-ealkoxide.

98. The compound according to any one of claims 38-45, 58-64, 80, and 92-97, wherein ring A2 is selected from:- 283 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Applicationis a point of attachment to PLM and * is a point of attachment to L2.

99. The compound according to any one of claims 79-98, wherein each R5is independently H, -CN, halogen, Ci-Ce alkyl, Ci-Ce fluoroalkyl, O-Ci-Ce fluoroalkyl, C3-C6 cycloalkyl or Ci-Ce alkoxy.

100. The compound according to claim 99, wherein each R5is Ci-Ce alkoxy or halogen.

101. The compound according to any one of claims 99-100, wherein two R5are OCH3 and one R5is F.

102. The compound according to any one of claims 79-101, wherein R4is C1-C4 alkoxy.- 284 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application 103. The compound according to any one of claims 79-102, wherein R4is OCH3.

104. The compound according to any one of claims 79-103, wherein R2is -(C(R8)2)n-(5-9 membered heteroaryl).

105. The compound according to any one of claims 79-104, wherein R2is106. The compound according to any one of the preceding claims, wherein ULM is107. The compound according to any one of the preceding claims, wherein each X2 is CRb.

108. The compound according to any one of the preceding claims, wherein each X2 is CH.

109. The compound according to any one of the preceding claims, wherein ULM is- 285 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application- 286 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application110. The compound according to any one of the preceding claims, wherein ULM iswherein is a point of attachment to Y.wherein is a point of attachment to Y.- 287 - 105807.005061\4896-4870-4897.1105807.005061 - PCT ApplicationIwherein is a point of attachment to Y.

113. The compound according to claim 110, wherein ULM is wherein is a point of attachment to Y.wherein is a point of attachment to Y.

115. The compound according to claim 110, wherein ULM is wherein is a point of attachment to Y.- 288 - 105807.005061\4896-4870-4897.1105807.005061 - PCT ApplicationIwherein is a point of attachment to Y.

117. The compound according to claim 1 that is:7V-(6-((17 / -Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(7-(((35)-l-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-lJ / -indazol-5-yl)pyrrolidin-3-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)benzenesulfonamide;7V-(6-((17 / -Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(7-((l-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-17 / -benzo[ ]imidazol-5-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)benzenesulfonamide;7V-(6-((17 / -Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(7-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)pyrrolidin-3-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)benzenesulfonamide;7V-(6-((17 / -Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-17 / -pyrrolo[3,2-c]pyridin-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)benzenesulfonamide;7V-(6-((17 / -Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(7-((l-(2-(2,6-dioxopiperidin-3-yl)-l-oxo-l,2-dihydroisoquinolin-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2 -methoxybenzenesulfonamide;7V-(6-((17 / -Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(7-((l-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-17 / -indazol-5-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2 -methoxybenzenesulfonamide;7V-(6-((17 / -Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-17 / -indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2 -methoxybenzenesulfonamide;7V-(6-((17 / -Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(7-((l-(6-(2,6-dioxopiperidin-3-yl)-l-methyl-17 / -indazol-3-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2 -methoxybenzenesulfonamide;- 289 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application 7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-l7 / -pyrrolo[2,3- / i]pyridin-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2 -methoxybenzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(7-((l-(3-(2,4-dioxotetrahydropyrimidin-l(277)-yl)-l-methyl-lJH-indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2,4-dimethoxybenzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-IT / -indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2,6-dimethoxybenzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-4-(7-((l-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-IT / -indazol-5-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)benzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-4-(7-((l-(2-(2,6-dioxopiperidin-3-yl)-l-oxo-l,2-dihydroisoquinolin-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)benzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-4-(7-((l-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-IT / -indazol-5-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2 -methoxybenzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-4-(7-((l-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3- ihydro-17 -benzo[ ]imidazol-5-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2 -methoxybenzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-4-(4-((l-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3- ihydro-17 -benzo[ ]imidazol-5-yl)piperidin-4-yl)methyl)-3,3-dimethylpiperazin-l-yl)benzenesulfonamide;A-(6-((IT / -Pyrazol-l-yl)methyl)-4-methoxybenzo[t / ]isoxazol-3-yl)-4-((3aA',6aA')-5-((l-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3- ihydro-17 -benzo[ ]imidazol-5-yl)piperidin-4-yl)methyl)hexahydropyrrolo[3,4-c]pyrrol-2(177)-yl)benzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-4-((3aR,6a5)-5-((l-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3- ihydro-17 -benzo[ ]imidazol-5-yl)piperidin-4-yl)methyl)hexahy dropyrrolo[3,4-c]pyrrol -2(1 J7)-yl)-2 -methoxybenzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(9-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)-3,9-diazaspiro[5.5]undecan-3-yl)benzenesulfonamide;- 290 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application 7V-(6-((lZ7-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(9-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-IT / -indazol-6-yl)piperidin-4-yl)methyl)-3,9-diazaspiro[5.5]undecan-3-yl)benzenesulfonamide;7V-(6-((lJ7-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-rnethyl-l / / -indazol-6-yl)piperidin-4-yl)rnethyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-(2,2,2-trifluoroethoxy)benzenesulfonamide;7V-(6-((177-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-2-chloro-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-IT / -indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)benzenesulfonamide;N-(6-((lJ7-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-rnethyl-l7 / -indazol-6-yl)piperidin-4-yl)rnethyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2 -methoxybenzenesulfonamide;7V-(6-((lZ7-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-5-chloro-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lJH-indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2 -methoxybenzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-IT / -indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-methoxy-5-methylbenzenesulfonamide;7V-(6-((l / 7-pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-IT / -indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-(trifluoromethyl)benzenesulfonamide;7V-(6-((lJH-pyrazol-l-yl)methyl)-4-methoxybenzo[t / / isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-IT / -indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2 -fluorobenzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-IT / -indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-5-(7-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-methylbenzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(7-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-methylbenzenesulfonamide;- 291 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application 7V-(6-((lJ / -Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-4-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-IT / -indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan- 2-yl)-2 -methylbenzenesulfonamide;N-(6-(( 1 H-Pyrazol- 1 -yl)methyl)-4-m ethoxyb enzo[d]i soxazol -3 -yl)-4-(7 -(( 1 -(3 -(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-ethylbenzenesulfonamide;N-(6-(( 1 H-Pyrazol- 1 -yl)methyl)-4-m ethoxyb enzo[d]i soxazol -3 -yl)-4-(7 -(( 1 -(3 -(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-(tri fluoromethoxy )benzenesulfonamide;7V-(6-((17 / -Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-17 / -indazol-6-yl)piperidin-4-yl)methyl)-7-azaspiro[3.5]nonan-2-yl)benzenesulfonamide;7V-(6-((17 / -Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(2-((4-(3-(2,4-dioxotetrahydropyrimidin-l(2J7)-yl)-l-methyl-17 / -indazol-6-yl)piperidin-l-yl)methyl)-7-azaspiro[3.5]nonan-7-yl)benzenesulfonamide;7V-(6-((17 / -Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(2-((4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-17 / -indazol-6-yl)piperidin-l-yl)methyl)-7-azaspiro[3.5]nonan-7-yl)benzenesulfonamide;7V-(6-((17 / -Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(2-((4-((l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-17 / -benzo[J]imidazol-4-yl)ethynyl)piperidin-l-yl)methyl)-7-azaspiro[3.5]nonan-7-yl)benzenesulfonamide;or a pharmaceutically acceptable salt thereof.

118. The compound according to claim 1 that is:3-(7-((l-(3-(2,6-Dioxopiperidin-3-yl)-l-methyl-17 / -indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxy-7V-(4-methoxy-6-(methoxymethyl)-benzo[d]isoxazol-3-yl)benzenesulfonamide;3-(7-((l-(3-(2,4-Dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)-piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxy-N-(4-methoxy-6-(methoxymethyl)benzo[d]isoxazol-3-yl)benzenesulfonamide;3-(7-((l-(3-(2,6-Dioxopiperidin-3-yl)-l-methyl-lH-pyrrolo[2,3-b]pyridin-6-yl)piperidin- 4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxy-N-(4-methoxy-6-(methoxy-methyl)benzo[d]isoxazol-3-yl)benzenesulfonamide;- 292 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application 3-(2-((l -(3-(2, 6-Dioxopiperi din-3 -yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)-l,2,3,4-tetrahydroisoquinolin-6-yl)-5-fluoro-2,6-dimethoxy-N-(4-methoxy-6-(methoxymethyl)-benzo[d]isoxazol-3-yl)benzenesulfonamide;3-(2-((l-(3-(2,4-Dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)-piperidin-4-yl)methyl)-l,2,3,4-tetrahydroisoquinolin-6-yl)-5-fluoro-2,6-dimethoxy-N-(4-methoxy-6-(methoxymethyl)benzo[d]isoxazol-3-yl)benzenesulfonamide;4'-((4-(3-(2, 6-Dioxopiperi din-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-l-yl)methyl)-5-fluoro-2,4-dimethoxy-N-(4-methoxy-6-(methoxymethyl)benzo[d]isoxazol-3-yl)-3'-methyl-[l,r-biphenyl]-3-sulfonamide;4'-((4-(3-(2,4-Dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperidin-l-yl)methyl)-5-fluoro-2,4-dimethoxy-N-(4-m ethoxy -6-(methoxymethyl)benzo-[d]isoxazol -3 -yl)-3 '-methyl-[ 1, 1 '-biphenyl]-3 -sulfonamide;N-(6-(( IH-Pyrazol- 1 -yl)methyl)-4-methoxybenzo[d]isoxazol-3 -y l)-3 -(7 -(( 1 -(3 -(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;rac-3 -((ci s)-3 -(( 1 -(3 -(2,4-Dioxotetrahy dropyrimidin- 1 (2H)-yl)- 1 -methyl- 1 H-indazol -6-yl)piperidin-4-yl)methyl)-3,7-diazabicyclo[4.2.0]octan-7-yl)-5-fluoro-2,6-dimethoxy-N-(4-methoxy-6-(methoxymethyl)benzo[d]isoxazol-3-yl)benzenesulfonamide;3-((l-(3-(2,6-Dioxopiperidin-3-yl)-l-methyl-lH-pyrrolo[2,3-b]pyridin-6-yl)piperidin-4-yl)methyl)-3,7-diazabicyclo[4.2.0]octan-7-yl)-5-fluoro-2,6-dimethoxy-N-(4-methoxy-6-(methoxymethyl)benzo[d]isoxazol-3-yl)benzenesulfonamide;rac-3 -((ci s)-3 -(( 1 -(3 -(2,4-Dioxotetrahy dropyrimidin- 1 (2H)-yl)- 1 -methyl- 1 H-indazol -6-yl)piperidin-4-yl)methyl)-3,7-diazabicyclo[4.2.0]octan-7-yl)-2 -methoxy -N-(4-methoxy-6-(methoxymethyl)benzo[d]isoxazol-3-yl)-5-(trifluoromethyl)benzenesulfonamide;3-((l-(3-(2,6-Dioxopiperidin-3-yl)-l-methyl-lH-pyrrolo[2,3-b]pyridin-6-yl)piperidin-4-yl)methyl)-3,7-diazabicyclo[4.2.0]octan-7-yl)-2 -methoxy -N-(4-methoxy-6-(methoxymethyl)-benzo[d]isoxazol-3-yl)-5-(trifluoromethyl)benzenesulfonamide;7V-(6-((lJH-pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(6-((l-(3-(2,4-dioxotetrahydropyrimidin-l(277)-yl)-l-methyl-lJH-indazol-6-yl)piperidin-4-yl)methyl)-5,6,7,8-tetrahydro-l,6-naphthyridin-2-yl)-5-fluoro-2,6-dimethoxybenzene-sulfonamide;N-(6-(( 1 H-pyrazol - 1 -yl)methyl)-4-methoxybenzo[d]i soxazol -3 -y 1 ) -3 -(7 -(( 1 -(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;- 293 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application rac-3-(cis)-N-(6-((lH-pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-((l-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)-piperidin-4-yl)methyl)-3,7-diazabicyclo[4.2.0]octan-7-yl)-5-fluoro-2,6-dimethoxy -benzenesulfonamide;or a pharmaceutically acceptable salt thereof.

119. The compound according to claim 1 that is:7V-(6-((17 / -Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(7-((4-(3-(2,4-dioxotetrahydropyrimidin-l(2J7)-yl)-l-methyl-17 / -indazol-6-yl)piperazin-l-yl)methyl)-2-azaspiro[3.5]nonan-2-yl)benzenesulfonamide;7V-(6-((17 / -Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(7-((4-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-l-yl)methyl)-2-azaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;N-(6-(( 1 H-Pyrazol- 1 -yl)methyl)-4-m ethoxyb enzo[d]i soxazol -3 -y 1 ) -3 -(7 -(( 1 -(3 -(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)benzenesulfonamide;N-(6-(( IH-Pyrazol- 1 -yl)methyl)-4-methoxybenzo[d]isoxazol-3 -y l)-3 -(7 -(( 1 -(3 -(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-pyrazolo[3,4-b]pyridin-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2,6-dimethoxybenzenesulfonamide;N-(6-(( 1 H-Pyrazol- 1 -yl)methyl)-4-m ethoxyb enzo[d]i soxazol -3 -y 1 ) -3 -(7 -(( 1 -(3 -(2,6-dioxopiperidin-3-yl)-l-methyl-lH-pyrazolo[3,4-b]pyridin-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;N-(6-(( IH-Pyrazol- 1 -yl)methyl)-4-methoxybenzo[d]isoxazol-3 -y l)-3 -(7 -(( 1 -(3 -(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-7-fluoro-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(4-((7-(3-(2,4-dioxotetrahy dropyrimidin- 1 (2H)-yl)- 1 -methyl - 1 H-indazol -6-yl) -7 -azaspiro[3.5 ]nonan-2-yl)methyl)piperazin-l-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(6-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)-5,6,7,8-tetrahydro-l,6-naphthyridin-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-4'-((4-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperidin-l-yl)methyl)-2,4-dimethoxy-3'-methyl-[l, T-biphenyl]-3-sulfonamide;- 294 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-4'-((4-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperidin-l-yl)methyl)-2,2',4-trimethoxy-[ 1, 1 '-biphenyl]-3 -sulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-4'-((4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-pyrrolo[2,3-b]pyridin-6-yl)piperidin-l-yl)methyl)-2,3',4-trimethoxy-[ 1, 1 '-biphenyl]-3 -sulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-4'-((4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-l-yl)methyl)-2,4-dimethoxy-3'-(trifluoromethoxy)-[ 1, 1 '-biphenyl]-3 -sulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-4'-((4-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperidin-l-yl)methyl)-2'-fluoro-2,4-dimethoxy-[ 1, 1 '-biphenyl]-3 -sulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-4'-((4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-l-yl)methyl)-3'-fluoro-2,4-dimethoxy-[1,1 '-biphenyl]-3 -sulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-4'-((4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-l-yl)methyl)-2',5'-difluoro-2,4-dimethoxy-[ 1, 1 '-biphenyl]-3 -sulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-4'-((4-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperidin-l-yl)methyl)-2,4-dimethoxy-3'-(trifluoromethyl)-[l,r-biphenyl]-3-sulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-4'-((4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-l-yl)methyl)-2,4-dimethoxy-2'-(trifluoromethyl)-[ 1, 1 '-biphenyl]-3 -sulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-2'-cyano-4'-((4-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperidin-l-yl)methyl)-2,4-dimethoxy-[ 1, 1 '-biphenyl]-3 -sulfonamide;N-(6-(( 1 H-Pyrazol- 1 -yl)methyl)-4-m ethoxyb enzo[d]i soxazol -3 -y 1 ) -3 -(5 -((4-(3 -(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-l-yl)methyl)thiophen-3-yl)-2,6-dimethoxybenzenesulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(2-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)-l,2,3,4-tetrahydro-isoquinolin-6-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;- 295 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(2-((l-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)-isoindolin-5-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(2-((l-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)-l,2,3,4-tetrahydroisoquinolin-6-yl)-6-fluoro-2 -methoxybenzenesulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(2-((l-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol -6-yl)piperidin-4-yl)methyl)-l, 2,3,4-tetrahydroisoquinolin-7-yl)-2-methoxy-5-(trifluoromethyl)benzenesulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-5-(tert-butyl)-3-(6-((l-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)-5, 6, 7, 8-tetrahydro-l,6-naphthyridin-2-yl)-2 -methoxybenzenesulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(2-((4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-l-yl)methyl)pyrimidin-5-yl)-2,6-dimethoxybenzenesulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(6-((4-(3-(2,6-di oxopiperi din-3 -yl)-l -m ethyl-lH-indazol-6-yl)piperi din-l-yl)methyl)-2-methylpyri din-3 -yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-4'-(4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidine-l-carbonyl)-2,4-dimethoxy-[l,r-biphenyl]-3-sulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(l-((l-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)-piperidin-4-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(4-((4-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperidin-l-yl)methyl)cyclo-hexyl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(3-((l-(3-(2,6-dioxopiperidin-S-y^-l-methyl-l / Z-indazol-b-y^piperidin-d-y^methy^-S-azaspirofS. SJ-undecan-9-yl)-2,6-dimethoxybenzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-((l-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lJH-pyrrolo[2,3-Z>]pyridin-6-yl)piperidin-4-yl)methyl)piperidin-4-yl)methyl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;- 296 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-4'-((4-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperidin-l-yl)methyl)-2,4-dimethoxy-[ 1, 1 '-biphenyl]-3 -sulfonamide;7V-(6-((l / 7-Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-4'-((4-(3-(2,4-dioxotetrahydropyrimidin-l(2J7)-yl)-l-methyl-l / 7-indazol-6-yl)piperazin-l-yl)methyl)-5-fluoro-2,4-dimethoxy-2'-(trifluoromethyl)-[ 1, 1 '-biphenyl]-3 -sulfonamide;7V-(6-((l / 7-Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-4'-((3-(3-(2,6-dioxopiperidin-S-y^-l-methyl-l / f-indazol-b-y^pyrrolidin-l-y^methy^-S-fluoro^d-dimethoxy-2'-(trifluoromethyl)-[ 1, 1 '-biphenyl]-3 -sulfonamide;rac-N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-((3a,7a)-5-((l-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)octahydro-2H-pyrrolo[3,4-c]pyridin-2-yl)-5-fluoro-2,6-dimethoxy-benzenesulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-((4aR,8aR)-6-((l-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)octahydro-2,6-naphthyridin-2(lH)-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-((3aR,6aR)-5-((l-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-ethyl-lH-indazol-6-yl)piperidin-4-yl)methyl)hexahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)-2,6-dimethoxybenzenesulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(ll-((l-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)-3,l 1-diazadispiro[5.1.58.16]tetradecan-3-yl)-2,6-dimethoxybenzenesulfonamide;N-(6-(( IH-Pyrazol- 1 -yl)methyl)-4-methoxybenzo[d]isoxazol-3 -y l)-3 -(7 -(( 1 -(3 -(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-ethyl-lH-indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;N-(6-(( 1 H-Pyrazol- 1 -yl)methyl)-4-m ethoxyb enzo[d]i soxazol -3 -y 1 ) -3 -(7 -(( 1 -(4-(2,6-dioxopiperidin-3-yl)-2-methylphenyl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;N-(6-(( 1 H-Pyrazol- 1 -yl)methyl)-4-m ethoxyb enzo[d]i soxazol -3 -y 1 ) -3 -(7 -(( 1 -(4-(2, 6-dioxopiperidin-3-yl)-3-fluorophenyl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-methoxybenzenesulfonamide;N-(6-(( 1 H-Pyrazol- 1 -yl)methyl)-4-m ethoxyb enzo[d]i soxazol -3 -y 1 ) -3 -(7 -(( 1 -(4-(2,6-dioxopiperidin-3-yl)-3,5-difluorophenyl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-methoxybenzenesulfonamide;- 297 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(7-(2-(l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)ethyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;N-(6-(( 1 H-Pyrazol- 1 -yl)methyl)-4-m ethoxyb enzo[d]i soxazol -3 -y 1 ) -3 -(7 -(((3 S ) - 1 -( 1 -(2, 6 -dioxopiperidin-3-yl)-3-methyl-lH-indazol-5-yl)pyrrolidin-3-yl)methyl)-2,7-diazaspiro- [3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;N-(6-(( 1 H-Pyrazol- 1 -yl)methyl)-4-m ethoxyb enzo[d]i soxazol -3 -y 1 ) -3 -(7 -(((3 S)-l-(4-(2,6-dioxopiperidin-3-yl)phenyl)pyrrolidin-3-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(7-(((3R,4S)-l-(4-(2,6-dioxopiperidin-3-yl)phenyl)-3-fluoropiperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;N-(6-(( IH-Pyrazol- 1 -yl)methyl)-4-methoxybenzo[d]isoxazol-3 -y l)-3 -(7 -(( 1 -(3 -(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-pyrrolo[2,3-b]pyridin-6-yl)-4-fluoro-piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2 -methoxybenzenesulfonamide;3-[7-[[4-[4-(2,6-Dioxopiperidin-3-yl)phenyl]piperazin-l-yl]methyl]-2-azaspiro- [3.5]nonan-2-yl]-5-fluoro-2-methoxy-N-[4-methoxy-6-(pyrazol-l-ylmethyl)-l,2-benzoxazol-3-yl]benzenesulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-((lS,6S)-3-((l-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)-3,7-diazabicyclo[4.2.0]octan-7-yl)-2-methoxy-6-methylbenzenesulfonamide;N-(6-(( 1 H-Pyrazol- 1 -yl)methyl)-4-m ethoxyb enzo[d]i soxazol -3 -y 1 ) -3 -(7 -(( 1 -(3 -(2,6-dioxopiperidin-3-yl)-5-fluoro-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-((3R)-3-((4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-l-yl)methyl)piperidin-l-yl)-2,6-dimethoxybenzenesulfonamide;3-[6-[[4-[3-(2,6-Dioxopiperidin-3-yl)-l-methylindazol-6-yl]piperidin-l-yl]methyl]-2-pyridinyl]-2,6-dimethoxy-N-[4-methoxy-6-(pyrazol-l-ylmethyl)-l,2-benzoxazol-3-yl]benzenesulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(4-((4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-l-yl)methyl)pyridin-2-yl)-2,6-dimethoxybenzenesulfonamide;- 298 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(8-((l-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)-8-azabicyclo[3.2.1]octan-3-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;N-(6-(( 1 H-Pyrazol- 1 -yl)methyl)-4-m ethoxyb enzo[d]i soxazol -3 -y 1 ) -3 -(7 -(( 1 -(2-(2, 6-dioxopiperidin-3-yl)-l-methyl-lH-pyrrolo[2,3-b]pyridin-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2 -methoxybenzenesulfonamide;N-(6-(( 1 H-Pyrazol- 1 -yl)methyl)-4-m ethoxyb enzo[d]i soxazol -3 -y 1 ) -3 -(7 -(( 1 -(2-(2, 6-dioxopiperidin-3-yl)-l-methyl-lH-pyrrolo[2,3-b]pyridin-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;N-(6-(( 1 H-Pyrazol- 1 -yl)methyl)-4-m ethoxyb enzo[d]i soxazol -3 -y 1 ) -3 -(7 -(( l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;4-(4-((2-(3-(N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)sulfamoyl)-5-fluoro-2,4-dimethoxyphenyl)-2,7-diazaspiro[3.5]nonan-7-yl)methyl)-piperidin-l-yl)-N-(2,6-dioxopiperidin-3-yl)benzamide;(R)-N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(7-((l-(4-(2,6-dioxopiperidin-3-yl-3, 4,4,5, 5-d5)phenyl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]-nonan-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;(7?)-7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(7-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;(5)-7V-(6-((l#-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(7-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(6-((l-(3-(2,6-dioxopiperidin-3-yl)-l-(methyl-d3)-l 7-pyrrolo[2,3-Z>]pyridin-6-yl)piperidin-4-yl)methyl)-5,6,7,8-tetrahydro-1, 6-naphthyridin-2-yl)-5-fluoro-2,6-dimethoxybenzene-sulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(6-((l-(3-(2,4-dioxotetrahydropyrimidin-l(2J7)-yl)-l-(methyl-t / 3)-1 -indazol-6-yl)piperidin-4-yl)methyl)-5,6,7,8-tetrahydro-l,6-naphthyridin-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;7V-(6-((lJH-Pyrazol-l-yl)methyl)-4-methoxybenzo[J]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-(2,2,2-trifluoroethyl)-lJH-indazol-6-yl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]wowaw-2-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;- 299 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application A-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(2-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-4-yl)methyl)-2,8-diazaspiro[4.5]decan-8-yl)-5-fluoro-2,6-dimethoxybenzenesulfonamide;A-(6-((17 / -Pyrazol-l-yl)methyl)-4-methoxybenzo[ ]isoxazol-3-yl)-3-(7-((l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-l / / -indazol-6-yl)piperidin-4-yl)methyl)-5,6,7,8-tetrahydro-imidazo[l,2-a]pyrazin-3-yl)-2,6-dimethoxybenzenesulfonamide;N-(6-((lH-Pyrazol-l-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-3-(7-(3-(2,6-dioxo-piperidin-3-yl)-l-methyl-lH-indazol-6-yl)-2,7-diazaspiro[3.5]nonan-2-yl)-2 -methoxybenzenesulfonamide;or a pharmaceutically acceptable salt thereof.

120. The compound of any one of the preceding claims, in the form of a pharmaceutically acceptable salt.

121. A pharmaceutical composition comprising a compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

122. A method of treating cancer or solid tumors in a subject in need thereof comprising administering to the subject a compound of any one of claims 1-120 or a pharmaceutical composition of claim 121.

123. The method of claim 122, wherein the cancer is selected from the group consisting of lung cancer, mesothelioma, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, hepatic carcinoma, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carci noma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin’s disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, hematology malignancy, chronic or acute leukemia, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system (CNS),- 300 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application primary CNS lymphoma, spinal axis tumors, glioblastoma, brain stem glioma, pituitary adenoma, and a combination of two or more of the foregoing cancers.

124. The method of claim 122, wherein the solid tumors are selected from the group consisting of breast, lung, colon, brain, prostate, stomach, pancreatic, ovarian, melanoma, endocrine, uterine, testicular, hematologic and bladder.

125. The method of claim 122, wherein the solid tumors are selected from the group consisting of breast, lung, prostate, pancreatic, hematologic and ovarian.

126. The method of claim 122, wherein the cancer is breast cancer.

127. The method of claim 125, wherein the breast cancer is ER+ breast cancer.

128. The method of claim 126, wherein the breast cancer is ER+ HER2- breast cancer.

129. The method of claim 126, wherein the breast cancer is locally advanced or metastatic ER+ HER2- breast cancer.

130. The method of claim 122, wherein the cancer is lung cancer.

131. The method of claim 130, wherein the lung cancer is non-small cell lung cancer132. The method of claim 130, wherein the lung cancer is locally advanced or metastatic non- small cell lung cancer.

133. The method of claim 122, wherein the cancer is prostate cancer.

134. The method of claim 133, wherein the prostate cancer is castration resistant prostate cancer.

135. The method of claim 133, wherein the prostate cancer is locally advanced or metastatic castration resistant prostate cancer.- 301 - 105807.005061\4896-4870-4897.1105807.005061 - PCT Application 136. A method of degrading a KAT6 protein comprising contacting the KAT6 protein with a compound of any one of claims 1-120 or a pharmaceutical composition of claim 121.- 302 - 105807.005061\4896-4870-4897.1

Images